This bibliography shows the most interesting papers selected from pmc PubMedCentral which were newly included in covid026P
It is available online and for download at http://www.kidney.de/write/PMCmedVIP_covid026P.html
Skewed: Nephrology, Rheumatology, Immunology, Cell Biology, Research Methods. on-topic and educational Clinical Medicine.
The full table of all monthly collections is: at house-of-papers.com
PMC searches were done at moremed.org

{{tp|p=33623472|t=2021. Corona-Cov-2 (COVID-19) and ginseng: Comparison of possible use in COVID-19 and influenza.|pdf=|usr=}}
{{tp|p=33657907|t=2021. A cross-sectional study of physical activity behaviour and associations with wellbeing during the UK coronavirus lockdown.|pdf=|usr=}}
{{tp|p=33640005|t=2021. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.|pdf=|usr=}}
{{tp|p=33563499|t=2021. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.|pdf=|usr=}}
{{tp|p=33816085|t=2021. Appropriate use of essential oils and their components in the management of upper respiratory tract symptoms in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33774141|t=2021. Rapid decrease of SARS-CoV-2 circulation in a large Italian hospital six weeks after the start of the immunization program.|pdf=|usr=}}
{{tp|p=33547169|t=2021. IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study.|pdf=|usr=}}
{{tp|p=33763494|t=2021. Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19.|pdf=|usr=}}
{{tp|p=33745918|t=2021. IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression.|pdf=|usr=}}
{{tp|p=33549625|t=2021. Early clinical experience with imatinib in COVID-19: Searching for a dual effect.|pdf=|usr=}}
{{tp|p=33716109|t=2021. Short durations of corticosteroids for hospitalised COVID-19 patients are associated with a high readmission rate.|pdf=|usr=}}
{{tp|p=33582204|t=2021. Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study.|pdf=|usr=}}
{{tp|p=33577902|t=2021. Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study.|pdf=|usr=}}
{{tp|p=33639176|t=2021. In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy.|pdf=|usr=}}
{{tp|p=33678548|t=2021. Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33676844|t=2021. A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19.|pdf=|usr=}}
{{tp|p=33690202|t=2021. The influence of vitamin-C intake on blood glucose measurements in COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33715012|t=2021. Comment on: Nature and Dimensions of the Systemic Hyper-inflammation and Its Attenuation by Convalescent Plasma in Severe COVID-19.|pdf=|usr=}}
{{tp|p=33585890|t=2021. A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in Coronavirus Disease 2019 Patients With Regular Intravenous Immunoglobulin Therapy.|pdf=|usr=}}
{{tp|p=33725725|t=2021. Rapidly Increasing SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced from Plasma Collected During the 2020 Pandemic.|pdf=|usr=}}
{{tp|p=33535239|t=2021. Lessons From Bacille Calmette-Guerin for SARS-CoV-2 Vaccine Candidates.|pdf=|usr=}}
{{tp|p=33647555|t=2021. The find of COVID-19 vaccine: Challenges and opportunities.|pdf=|usr=}}
{{tp|p=33647553|t=2021. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.|pdf=|usr=}}
{{tp|p=33751982|t=2021. COVID-19 infection, inception and immunity: Observations and recommendations in the light of vitamin D?|pdf=|usr=}}
{{tp|p=33743371|t=2021. Combating COVID-19: The role of drug repurposing and medicinal plants.|pdf=|usr=}}
{{tp|p=33776469|t=2021. Evaluation of Adjunctive Photobiomodulation (PBMT) for COVID-19 Pneumonia via Clinical Status and Pulmonary Severity Indices in a Preliminary Trial.|pdf=|usr=}}
{{tp|p=33758527|t=2021. Coronil, a Tri-Herbal Formulation, Attenuates Spike-Protein-Mediated SARS-CoV-2 Viral Entry into Human Alveolar Epithelial Cells and Pro-Inflammatory Cytokines Production by Inhibiting Spike Protein-ACE-2 Interaction.|pdf=|usr=}}
{{tp|p=33679136|t=2021. The Implications of Zinc Therapy in Combating the COVID-19 Global Pandemic.|pdf=|usr=}}
{{tp|p=33574690|t=2021. Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19.|pdf=|usr=}}
{{tp|p=33583756|t=2021. Early therapeutic interventions of traditional Chinese medicine in COVID-19 patients: A retrospective cohort study.|pdf=|usr=}}
{{tp|p=33547011|t=2021. Impact of the COVID-19 pandemic on intention to use traditional Chinese medicine: A cross-sectional study based on the theory of planned behavior.|pdf=|usr=}}
{{tp|p=33663244|t=2021. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS.|pdf=|usr=}}
{{tp|p=33634528|t=2021. Inhibition of SARS-CoV-2 replication using calcineurin inhibitors: are concentrations required clinically achievable?|pdf=|usr=}}
{{tp|p=33648905|t=2021. Safety of New mRNA Vaccines Against COVID-19 in Severely Allergic Patients.|pdf=|usr=}}
{{tp|p=33574015|t=2021. Delving Into COVID-19 Vaccination-Induced Anaphylaxis: Are mRNA Vaccines Safe in Mast Cell Disorders?|pdf=|usr=}}
{{tp|p=33558797|t=2021. Combined docking methods and molecular dynamics to identify effective antiviral 2, 5-diaminobenzophenonederivatives against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33531790|t=2021. Enhanced production of camptothecin by immobilized callus of Ophiorrhiza mungos and a bioinformatic insight into its potential antiviral effect against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33686812|t=2021. Estimating Baseline Incidence of Conditions Potentially Associated with Vaccine Adverse Events: a Call for Surveillance System Using the Korean National Health Insurance Claims Data.|pdf=|usr=}}
{{tp|p=33783147|t=2021. COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.|pdf=|usr=}}
{{tp|p=33754512|t=2021. Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study.|pdf=|usr=}}
{{tp|p=33559409|t=2021. What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021.|pdf=|usr=}}
{{tp|p=33627186|t=2021. The use of integrative therapy based on Yoga and Ayurveda in the treatment of a high-risk case of COVID-19/SARS-CoV-2 with multiple comorbidities: a case report.|pdf=|usr=}}
{{tp|p=33755450|t=2021. Direct Observation of Protonation State Modulation in SARS-CoV-2 Main Protease upon Inhibitor Binding with Neutron Crystallography.|pdf=|usr=}}
{{tp|p=33560998|t=2021. Artificial Intelligence-Aided Precision Medicine for COVID-19: Strategic Areas of Research and Development.|pdf=|usr=}}
{{tp|p=33638553|t=2021. Interaction effects between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and steroid or antiviral therapies in COVID-19: A population-based study.|pdf=|usr=}}
{{tp|p=33629384|t=2021. A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in hospitalized COVID-19 patients.|pdf=|usr=}}
{{tp|p=33620107|t=2021. Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=33590901|t=2021. Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19.|pdf=|usr=}}
{{tp|p=33590886|t=2021. Comment on Hadadi et al., Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects? J. Med. Virol. 2020; 92:915-918.|pdf=|usr=}}
{{tp|p=33580518|t=2021. Three salvianolic acids inhibit 2019-nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2.|pdf=|usr=}}
{{tp|p=33527424|t=2021. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.|pdf=|usr=}}
{{tp|p=33666253|t=2021. In vitro activity of itraconazole against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33666250|t=2021. Efficacy of corticosteroid in patients with COVID-19: A multi-center retrospective study and meta-analysis.|pdf=|usr=}}
{{tp|p=33666244|t=2021. Is a single dose of mRNA vaccine sufficient for COVID-19 survivors?|pdf=|usr=}}
{{tp|p=33666241|t=2021. Vitamin D axis status and the severity of COVID-19.|pdf=|usr=}}
{{tp|p=33656189|t=2021. Letter to Editor in response to the article "Vitamin D insufficiency as a potential culprit in critical COVID-19 patients".|pdf=|usr=}}
{{tp|p=33580540|t=2021. Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity.|pdf=|usr=}}
{{tp|p=33527314|t=2021. Raloxifene as a treatment option for viral infections.|pdf=|usr=}}
{{tp|p=33746189|t=2021. Clinical Effect of Traditional Chinese Medicine Shenhuang Granule in Critically Ill Patients with COVID-19: A Single-Centered, Retrospective, Observational Study.|pdf=|usr=}}
{{tp|p=33632620|t=2021. Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients?|pdf=|usr=}}
{{tp|p=33623736|t=2020. COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors.|pdf=|usr=}}
{{tp|p=33623735|t=2020. Hydroxychloroquine Toxicity Management: A Literature Review in COVID-19 Era.|pdf=|usr=}}
{{tp|p=33775667|t=2021. Engineered Ultra-High Affinity Synthetic Antibodies for SARS-CoV-2 Neutralization and Detection.|pdf=|usr=}}
{{tp|p=33753053|t=2021. Platforms for Personalized Polytherapeutics Discovery in COVID-19.|pdf=|usr=}}
{{tp|p=33693723|t=2021. What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology.|pdf=|usr=}}
{{tp|p=33556646|t=2021. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.|pdf=|usr=}}
{{tp|p=33684603|t=2021. Ensemble-based screening of natural products and FDA-approved drugs identified potent inhibitors of SARS-CoV-2 that work with two distinct mechanisms.|pdf=|usr=}}
{{tp|p=33647752|t=2021. Pinpointing the potential hits for hindering interaction of SARS-CoV-2 S-protein with ACE2 from the pool of antiviral phytochemicals utilizing molecular docking and molecular dynamics (MD) simulations.|pdf=|usr=}}
{{tp|p=33612899|t=2021. Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach.|pdf=|usr=}}
{{tp|p=33753950|t=2021. Binding and drug displacement study of colchicine and bovine serum albumin in presence of azithromycin using multispectroscopic techniques and molecular dynamic simulation.|pdf=|usr=}}
{{tp|p=33641023|t=2021. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M(pro)) of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33583954|t=2021. Computational search for drug repurposing to identify potential inhibitors against SARS-COV-2 using Molecular Docking, QTAIM and IQA methods in viral Spike protein - Human ACE2 interface.|pdf=|usr=}}
{{tp|p=33526951|t=2021. 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol as potential antiviral SARS-CoV-2 candidate: Synthesis, crystal structure, Hirshfeld surface analysis, DFT and molecular docking studies.|pdf=|usr=}}
{{tp|p=33612858|t=2021. "Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL(pro) and PL(pro)."|pdf=|usr=}}
{{tp|p=33603214|t=2021. Ensuring continued progress for development of COVID-19 therapeutics in children.|pdf=|usr=}}
{{tp|p=33680575|t=2021. DisCoVering potential candidates of RNAi-based therapy for COVID-19 using computational methods.|pdf=|usr=}}
{{tp|p=33615115|t=2021. Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalization.|pdf=|usr=}}
{{tp|p=33676968|t=2021. Antiviral peptides against Coronaviridae family: A review.|pdf=|usr=}}
{{tp|p=33816211|t=2021. Hydroxychloroquine in the prophylaxis of COVID 19: A survey of safety on the healthcare workers in India.|pdf=|usr=}}
{{tp|p=33660201|t=2021. Nanoparticle-Mediated Cytoplasmic Delivery of Messenger RNA Vaccines: Challenges and Future Perspectives.|pdf=|usr=}}
{{tp|p=33668390|t=2021. Evaluation of the Antiviral Activity of Sitagliptin-Glatiramer Acetate Nano-Conjugates against SARS-CoV-2 Virus.|pdf=|usr=}}
{{tp|p=33572332|t=2021. Conjugation of Mannans to Enhance the Potency of Liposome Nanoparticles for the Delivery of RNA Vaccines.|pdf=|usr=}}
{{tp|p=33562240|t=2021. Therapeutic Potential of Mesenchymal Stem Cells and Their Products in Lung Diseases-Intravenous Administration versus Inhalation.|pdf=|usr=}}
{{tp|p=33652894|t=2021. Repurposing of Sitagliptin- Melittin Optimized Nanoformula against SARS-CoV-2: Antiviral Screening and Molecular Docking Studies.|pdf=|usr=}}
{{tp|p=33668969|t=2021. Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities.|pdf=|usr=}}
{{tp|p=33688154|t=2021. WTP for COVID-19 vaccine in Chile.|pdf=|usr=}}
{{tp|p=33564224|t=2021. COVID-19 vaccination predicted to be cost effective in USA.|pdf=|usr=}}
{{tp|p=33759544|t=2021. Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33542445|t=2021. Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs.|pdf=|usr=}}
{{tp|p=33779964|t=2021. The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis.|pdf=|usr=}}
{{tp|p=33666864|t=2021. Perspectives on glucocorticoid treatment for COVID-19: a systematic review.|pdf=|usr=}}
{{tp|p=33625686|t=2021. Evaluation of effects of chronic nasal steroid use on rhinological symptoms of COVID-19 with SNOT-22 questionnaire.|pdf=|usr=}}
{{tp|p=33608850|t=2021. In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33604795|t=2021. Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33781873|t=2021. Understanding the heart-brain axis response in COVID-19 patients: A suggestive perspective for therapeutic development.|pdf=|usr=}}
{{tp|p=33710753|t=2021. Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33687995|t=2021. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.|pdf=|usr=}}
{{tp|p=33662449|t=2021. SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin.|pdf=|usr=}}
{{tp|p=33601001|t=2021. A systematic review of photodynamic therapy as an antiviral treatment: Potential guidance for dealing with SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33564274|t=2021. Quantum mechanical studies of the adsorption of Remdesivir, as an effective drug for treatment of COVID-19, on the surface of pristine, COOH-functionalized and S-, Si- and Al- doped carbon nanotubes.|pdf=|usr=}}
{{tp|p=33580917|t=2021. Breastfeeding importance and its therapeutic potential against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33527774|t=2021. Lingonberry polyphenols: Potential SARS-CoV-2 inhibitors as nutraceutical tools?|pdf=|usr=}}
{{tp|p=33685739|t=2021. Out-patient physiotherapy service delivery post COVID-19: opportunity for a re-set and a new normal?|pdf=|usr=}}
{{tp|p=33637412|t=2021. Effect and safety of Chinese herbal medicine granules in patients with severe coronavirus disease 2019 in Wuhan, China: a retrospective, single-center study with propensity score matching.|pdf=|usr=}}
{{tp|p=33593628|t=2021. Toxicity as prime selection criterion among SARS-active herbal medications.|pdf=|usr=}}
{{tp|p=33596494|t=2021. Randomized placebo-controlled pilot clinical trial on the efficacy of ayurvedic treatment regime on COVID-19 positive patients.|pdf=|usr=}}
{{tp|p=33587321|t=2021. Oroxylin A is a severe acute respiratory syndrome coronavirus 2-spiked pseudotyped virus blocker obtained from Radix Scutellariae using angiotensin-converting enzyme II/cell membrane chromatography.|pdf=|usr=}}
{{tp|p=33564969|t=2021. Glucocorticoid use in patients with adrenal insufficiency following administration of the COVID-19 vaccine: a pituitary society statement.|pdf=|usr=}}
{{tp|p=33673316|t=2021. COVID-19 Crisis: How Can Plant Biotechnology Help?|pdf=|usr=}}
{{tp|p=33647008|t=2021. Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action.|pdf=|usr=}}
{{tp|p=33544720|t=2021. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.|pdf=|usr=}}
{{tp|p=33657114|t=2021. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.|pdf=|usr=}}

{{tp|p=33620862|t=2021. COVID (SARS-COV-2) Vaccine|pdf=|usr=}}
{{tp|p=33666876|t=2021. Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients with COVID-19.|pdf=|usr=}}
{{tp|p=33685335|t=2021. In silico identification of novel SARS-COV-2 2'-O-methyltransferase (nsp16) inhibitors: structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches.|pdf=|usr=}}
{{tp|p=33641565|t=2021. Exposure of human intestinal epithelial cells and primary human hepatocytes to trypsin-like serine protease inhibitors with potential antiviral effect.|pdf=|usr=}}
{{tp|p=33605108|t=2021. The Role of Convalescent Plasma and Tocilizumab in the Management of COVID-19 Infection: A Cohort of 110 Patients from a Tertiary Care Hospital in Oman.|pdf=|usr=}}
{{tp|p=33605118|t=2021. A Case Series of Severe Hospitalized COVID-19 Patients Treated with Tocilizumab and Glucocorticoids: A Report from Saudi Arabian Hospital.|pdf=|usr=}}
{{tp|p=33631276|t=2021. Evaluating the Traditional Chinese Medicine (TCM) Officially Recommended in China for COVID-19 Using Ontology-Based Side-Effect Prediction Framework (OSPF) and Deep Learning.|pdf=|usr=}}
{{tp|p=33716085|t=2021. Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants.|pdf=|usr=}}
{{tp|p=33529638|t=2021. Efficacy and safety assessment of severe COVID-19 patients with Chinese medicine: A retrospective case series study at early stage of the COVID-19 epidemic in Wuhan, China.|pdf=|usr=}}
{{tp|p=33587756|t=2021. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics.|pdf=|usr=}}
{{tp|p=33752263|t=2021. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.|pdf=|usr=}}
{{tp|p=33650226|t=2021. Insights into Sars-CoV-2 vaccination in patients with chronic plaque psoriasis on systemic treatments.|pdf=|usr=}}
{{tp|p=33787349|t=2021. Licorice: A Potential Herb in Overcoming SARS-CoV-2 Infections.|pdf=|usr=}}
{{tp|p=33554423|t=2021. Role of vitamin D in COVID-19 infections and deaths.|pdf=|usr=}}
{{tp|p=33786534|t=2021. News About the Extracellular Vesicles from Mesenchymal Stem Cells: Functions, Therapy and Protection from COVID-19.|pdf=|usr=}}
{{tp|p=33772438|t=2021. Chronotherapy in COVID-19 Disease.|pdf=|usr=}}
{{tp|p=33711156|t=2021. Impact of systemic corticosteroids on mortality in older adults with critical COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=33678903|t=2021. Inhibitory efficacy of RNA virus drugs against SARS-CoV-2 proteins: An extensive study.|pdf=|usr=}}
{{tp|p=33814612|t=2021. Unmasking of crucial structural fragments for coronavirus protease inhibitors and its implications in COVID-19 drug discovery.|pdf=|usr=}}
{{tp|p=33758509|t=2021. Corticosteroids Use in Pregnant Women with COVID-19: Recommendations from Available Evidence.|pdf=|usr=}}
{{tp|p=33544324|t=2021. A Role for Extracellular Vesicles in SARS-CoV-2 Therapeutics and Prevention.|pdf=|usr=}}
{{tp|p=33534108|t=2021. Repurposing of Tetracyclines for COVID-19 Neurological and Neuropsychiatric Manifestations: A Valid Option to Control SARS-CoV-2-Associated Neuroinflammation?|pdf=|usr=}}
{{tp|p=33721079|t=2021. Neurology and vaccinations: considerations in the context of COVID-19/SARS-COV-2.|pdf=|usr=}}
{{tp|p=33537898|t=2021. Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19.|pdf=|usr=}}
{{tp|p=33638680|t=2021. Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab.|pdf=|usr=}}
{{tp|p=33611630|t=2021. Bell's palsy following COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=33692301|t=2021. Physical compatibility of nafamostat with analgesics, sedatives, and muscle relaxants for coronavirus disease treatment.|pdf=|usr=}}
{{tp|p=33693698|t=2021. Risk of Malnutrition Is Common in Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Cross-sectional Study.|pdf=|usr=}}
{{tp|p=33575730|t=2021. Malnutrition Prolongs the Hospitalization of Patients with COVID-19 Infection: A Clinical Epidemiological Analysis.|pdf=|usr=}}
{{tp|p=33643836|t=2021. Virucidal activity of oral care products against SARS-CoV-2 in vitro.|pdf=|usr=}}
{{tp|p=33527524|t=2021. Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns.|pdf=|usr=}}
{{tp|p=33716511|t=2021. Recommendations and Guidance for Steroid Injection Therapy and COVID-19 Vaccine Administration from the American Society of Pain and Neuroscience (ASPN).|pdf=|usr=}}
{{tp|p=33649442|t=2021. Previous viral symptoms and individual mothers influenced the leveled duration of human milk antibodies cross-reactive to S1 and S2 subunits from SARS-CoV-2, HCoV-229E, and HCoV-OC43.|pdf=|usr=}}
{{tp|p=33578937|t=2021. Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea.|pdf=|usr=}}
{{tp|p=33782640|t=2021. The potential of miRNA-based therapeutics in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection: a review.|pdf=|usr=}}
{{tp|p=33552628|t=2021. Accurate and sensitive determination of hydroxychloroquine sulfate used on COVID-19 patients in human urine, serum and saliva samples by GC-MS.|pdf=|usr=}}
{{tp|p=33549875|t=2021. Vitamin C supplementation is necessary for patients with coronavirus disease: An ultra-high-performance liquid chromatography-tandem mass spectrometry finding.|pdf=|usr=}}
{{tp|p=33548872|t=2021. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum.|pdf=|usr=}}
{{tp|p=33688448|t=2021. Potential therapeutic and pharmacological strategies for SARS-CoV2.|pdf=|usr=}}
{{tp|p=33793885|t=2021. Propolis antiviral and immunomodulatory activity: a review and perspectives for COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33684397|t=2021. Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33657325|t=2021. An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33577324|t=2021. Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19.|pdf=|usr=}}
{{tp|p=33776343|t=2021. Structure-based inhibitor screening of natural products against NSP15 of SARS-CoV-2 revealed thymopentin and oleuropein as potent inhibitors.|pdf=|usr=}}
{{tp|p=33667055|t=2021. Elevated clozapine levels and toxic effects after SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=33703870|t=2021. COVID-19 infection causes a reduction in neutrophil counts in patients taking clozapine.|pdf=|usr=}}
{{tp|p=33589559|t=2021. Rethinking Physical Activity Promotion During the COVID-19 Pandemic: Focus on a 24-hour Day.|pdf=|usr=}}
{{tp|p=33775882|t=2021. Physical activity and its relationship with COVID-19 cases and deaths: Analysis of U.S. counties.|pdf=|usr=}}
{{tp|p=33775818|t=2021. Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies.|pdf=|usr=}}
{{tp|p=33569200|t=2021. Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials.|pdf=|usr=}}
{{tp|p=33615209|t=2021. Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients.|pdf=|usr=}}
{{tp|p=33789686|t=2021. Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis.|pdf=|usr=}}
{{tp|p=33635318|t=2021. What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective.|pdf=|usr=}}
{{tp|p=33620081|t=2021. 'Blue toes' following vaccination with the BNT162b2 mRNA COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33663198|t=2021. Can we use mesenchymal stem cell transplantation for COVID-19 patients in puerperium period?|pdf=|usr=}}
{{tp|p=33573494|t=2021. The evolving use of hyperbaric oxygen therapy during the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33748377|t=2021. "COVID arm": A reaction to the Moderna vaccine.|pdf=|usr=}}
{{tp|p=33782672|t=2021. Regression of Coronary Aneurysms With Intravenous Immunoglobulins and Steroids for COVID-19 Adult Multisystem Inflammatory Syndrome.|pdf=|usr=}}
{{tp|p=33760094|t=2021. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.|pdf=|usr=}}
{{tp|p=33739433|t=2021. Association of Vitamin D Levels, Race/Ethnicity, and Clinical Characteristics With COVID-19 Test Results.|pdf=|usr=}}
{{tp|p=33774074|t=2021. The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33639316|t=2021. Multi-targeting approach for nsp3, nsp9, nsp12 and nsp15 proteins of SARS-CoV-2 by Diosmin as illustrated by molecular docking and molecular dynamics simulation methodologies.|pdf=|usr=}}
{{tp|p=33729874|t=2021. Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.|pdf=|usr=}}
{{tp|p=33744495|t=2021. COVID-19 Vaccine Decisions: Considering the Choices and Opportunities.|pdf=|usr=}}
{{tp|p=33776146|t=2021. Green micellar solvent-free HPLC and spectrofluorimetric determination of favipiravir as one of COVID-19 antiviral regimens.|pdf=|usr=}}
{{tp|p=33572117|t=2021. Fluoxetine Can Inhibit SARS-CoV-2 In Vitro.|pdf=|usr=}}
{{tp|p=33668694|t=2021. Antiviral Activity of Vacuolar ATPase Blocker Diphyllin against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33688701|t=2021. Statin therapy is associated with less ICU admissions in COVID-19 patients. A preliminary analysis of the current observations.|pdf=|usr=}}
{{tp|p=33709676|t=2021. The administration of S. salivarius K12 to children may reduce the rate of SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33661860|t=2021. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine - United States, February 2021.|pdf=|usr=}}
{{tp|p=33793460|t=2021. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.|pdf=|usr=}}
{{tp|p=33551490|t=2021. COVID-19 Convalescent Plasma: from donation to treatment - A Systematic Review & Single Center Experience.|pdf=|usr=}}
{{tp|p=33750821|t=2021. Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33785743|t=2021. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.|pdf=|usr=}}
{{tp|p=33658497|t=2021. Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques.|pdf=|usr=}}
{{tp|p=33654090|t=2021. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques.|pdf=|usr=}}
{{tp|p=33741945|t=2021. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.|pdf=|usr=}}
{{tp|p=33741941|t=2021. Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33731724|t=2021. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies.|pdf=|usr=}}
{{tp|p=33707427|t=2021. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.|pdf=|usr=}}
{{tp|p=33649323|t=2021. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates.|pdf=|usr=}}
{{tp|p=33558541|t=2021. Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide.|pdf=|usr=}}
{{tp|p=33547300|t=2021. Efficacy and tolerability of bevacizumab in patients with severe Covid-19.|pdf=|usr=}}
{{tp|p=33536425|t=2021. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33637713|t=2021. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19.|pdf=|usr=}}
{{tp|p=33531496|t=2021. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors.|pdf=|usr=}}
{{tp|p=33589624|t=2021. Causal network models of SARS-CoV-2 expression and aging to identify candidates for drug repurposing.|pdf=|usr=}}
{{tp|p=33568665|t=2021. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19.|pdf=|usr=}}
{{tp|p=33542537|t=2021. COVID-19 vaccines: acting on the evidence.|pdf=|usr=}}
{{tp|p=33785883|t=2021. Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD.|pdf=|usr=}}
{{tp|p=33564149|t=2021. Targeting autoantibodies in COVID-19.|pdf=|usr=}}
{{tp|p=33674759|t=2021. COVID-19 vaccines: modes of immune activation and future challenges.|pdf=|usr=}}
{{tp|p=33658707|t=2021. Are COVID-19 vaccines safe in pregnancy?|pdf=|usr=}}
{{tp|p=33558753|t=2021. COVID-19 vaccines and kidney disease.|pdf=|usr=}}
{{tp|p=33587164|t=2021. Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies.|pdf=|usr=}}
{{tp|p=33640181|t=2021. Consenso multidisciplinar sobre la valoracion y el tratamiento nutricional y dietetico en pacientes con enfermedad renal cronica e infeccion por SARS-CoV-2. Consenso de nutricion en enfermedad renal cronica e infeccion por SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33693778|t=2021. Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases.|pdf=|usr=}}
{{tp|p=33786291|t=2021. In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.|pdf=|usr=}}
{{tp|p=33585155|t=2021. Exploring the active constituents of Oroxylum indicum in intervention of novel coronavirus (COVID-19) based on molecular docking method.|pdf=|usr=}}
{{tp|p=33527083|t=2021. To stress or not to stress: Brain-behavior-immune interaction may weaken or promote the immune response to SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33555604|t=2021. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.|pdf=|usr=}}
{{tp|p=33411196|t=2021. Acupuncture helps to regain the consciousness of a COVID-19 patient complicated with hypoxic-ischemic encephalopathy: a case report.|pdf=|usr=}}
{{tp|p=33760858|t=2021. Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study.|pdf=|usr=}}
{{tp|p=33750975|t=2021. DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice.|pdf=|usr=}}
{{tp|p=33735271|t=2021. A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing.|pdf=|usr=}}
{{tp|p=33730088|t=2021. COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients.|pdf=|usr=}}
{{tp|p=33730022|t=2021. Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein.|pdf=|usr=}}
{{tp|p=33725021|t=2021. Knowledge of medical professionals, their practices, and their attitudes toward traditional Chinese medicine for the prevention and treatment of coronavirus disease 2019: A survey in Sichuan, China.|pdf=|usr=}}
{{tp|p=33667247|t=2021. Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma.|pdf=|usr=}}
{{tp|p=33674391|t=2021. COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.|pdf=|usr=}}
{{tp|p=33658349|t=2021. Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain.|pdf=|usr=}}
{{tp|p=33622961|t=2021. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL(pro) inhibitor PF-00835231 as a potential new treatment for COVID-19.|pdf=|usr=}}

{{tp|p=33551489|t=2021. Magnesium and Vitamin D Deficiency as a Potential Cause of Immune Dysfunction, Cytokine Storm and Disseminated Intravascular Coagulation in covid-19 patients.|pdf=|usr=}}
{{tp|p=33551236|t=2021. The need for precision nutrition, genetic variation and resolution in Covid-19 patients.|pdf=|usr=}}
{{tp|p=33620659|t=2021. Glucose-6-phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID-19 era: a mini review.|pdf=|usr=}}
{{tp|p=33625681|t=2021. Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19.|pdf=|usr=}}
{{tp|p=33722265|t=2021. Clinical and immunological effects of mRNA vaccines in malignant diseases.|pdf=|usr=}}
{{tp|p=33632261|t=2021. mRNA vaccine for cancer immunotherapy.|pdf=|usr=}}
{{tp|p=33593376|t=2021. mRNA vaccine: a potential therapeutic strategy.|pdf=|usr=}}
{{tp|p=33631104|t=2021. Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication.|pdf=|usr=}}
{{tp|p=33604809|t=2021. Role of vitamin D in treating COVID-19-associated coagulopathy: problems and perspectives.|pdf=|usr=}}
{{tp|p=33587232|t=2021. Therapeutic opportunities of edible antiviral plants for COVID-19.|pdf=|usr=}}
{{tp|p=33675510|t=2021. Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery.|pdf=|usr=}}
{{tp|p=33786727|t=2021. Pharmacoinformatics-based identification of transmembrane protease serine-2 inhibitors from Morus Alba as SARS-CoV-2 cell entry inhibitors.|pdf=|usr=}}
{{tp|p=33765239|t=2021. In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase.|pdf=|usr=}}
{{tp|p=33582935|t=2021. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.|pdf=|usr=}}
{{tp|p=33571463|t=2021. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=33723514|t=2021. In vitro characterization of engineered red blood cells as viral traps against HIV-1 and SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33573318|t=2021. COVID-19 Prophylaxis Efforts Based on Natural Antiviral Plant Extracts and Their Compounds.|pdf=|usr=}}
{{tp|p=33573088|t=2021. In Silico Study of Polyunsaturated Fatty Acids as Potential SARS-CoV-2 Spike Protein Closed Conformation Stabilizers: Epidemiological and Computational Approaches.|pdf=|usr=}}
{{tp|p=33525415|t=2021. Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism.|pdf=|usr=}}
{{tp|p=33525411|t=2021. Computational Determination of Potential Multiprotein Targeting Natural Compounds for Rational Drug Design Against SARS-COV-2.|pdf=|usr=}}
{{tp|p=33530467|t=2021. Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets.|pdf=|usr=}}
{{tp|p=33562030|t=2021. Therapeutic Potential of Resveratrol in COVID-19-Associated Hemostatic Disorders.|pdf=|usr=}}
{{tp|p=33557115|t=2021. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease.|pdf=|usr=}}
{{tp|p=33669054|t=2021. Propolis, Bee Honey, and Their Components Protect against Coronavirus Disease 2019 (COVID-19): A Review of In Silico, In Vitro, and Clinical Studies.|pdf=|usr=}}
{{tp|p=33668085|t=2021. EGCG, a Green Tea Catechin, as a Potential Therapeutic Agent for Symptomatic and Asymptomatic SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33672163|t=2021. Therapeutic Intervention of COVID-19 by Natural Products: A Population-Specific Survey Directed Approach.|pdf=|usr=}}
{{tp|p=33672721|t=2021. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.|pdf=|usr=}}
{{tp|p=33669720|t=2021. In Silico Screening of the DrugBank Database to Search for Possible Drugs against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33668428|t=2021. Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses.|pdf=|usr=}}
{{tp|p=33578831|t=2021. Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors.|pdf=|usr=}}
{{tp|p=33590551|t=2021. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis.|pdf=|usr=}}
{{tp|p=33556628|t=2021. FN3-based monobodies selective for the receptor binding domain of the SARS-CoV-2 spike protein.|pdf=|usr=}}
{{tp|p=33657299|t=2021. Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.|pdf=|usr=}}
{{tp|p=33631066|t=2021. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.|pdf=|usr=}}
{{tp|p=33631065|t=2021. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.|pdf=|usr=}}
{{tp|p=33631064|t=2021. Interleukin-6 Receptor Inhibition in Covid-19 - Cooling the Inflammatory Soup.|pdf=|usr=}}
{{tp|p=33626250|t=2021. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.|pdf=|usr=}}
{{tp|p=33657292|t=2021. Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33815564|t=2021. Role of nanotechnology behind the success of mRNA vaccines for COVID-19.|pdf=|usr=}}
{{tp|p=33758593|t=2021. Engineering a self-navigated MnARK nanovaccine for inducing potent protective immunity against novel coronavirus.|pdf=|usr=}}
{{tp|p=33753982|t=2021. 2D MXenes with antiviral and immunomodulatory properties: A pilot study against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33753282|t=2021. Cerium oxide nanoparticle delivery of microRNA-146a for local treatment of acute lung injury.|pdf=|usr=}}
{{tp|p=33662593|t=2021. Synthesis and immunogenicity assessment of a gold nanoparticle conjugate for the delivery of a peptide from SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33815808|t=2021. Computational insights of phytochemical-driven disruption of RNA-dependent RNA polymerase-mediated replication of coronavirus: a strategic treatment plan against coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=33580031|t=2020. Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure.|pdf=|usr=}}
{{tp|p=33785745|t=2021. Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters.|pdf=|usr=}}
{{tp|p=33767200|t=2021. The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization.|pdf=|usr=}}
{{tp|p=33741993|t=2021. Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease.|pdf=|usr=}}
{{tp|p=33741992|t=2021. Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2.|pdf=|usr=}}
{{tp|p=33619260|t=2021. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates.|pdf=|usr=}}
{{tp|p=33526776|t=2021. Piglet immunization with a spike subunit vaccine enhances disease by porcine epidemic diarrhea virus.|pdf=|usr=}}
{{tp|p=33580085|t=2020. Universal coronavirus vaccines: the time to start is now.|pdf=|usr=}}
{{tp|p=33580049|t=2020. Certainty of success: three critical parameters in coronavirus vaccine development.|pdf=|usr=}}
{{tp|p=33580061|t=2020. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines.|pdf=|usr=}}
{{tp|p=33580080|t=2020. Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens.|pdf=|usr=}}
{{tp|p=33580058|t=2020. Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic.|pdf=|usr=}}
{{tp|p=33580068|t=2020. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.|pdf=|usr=}}
{{tp|p=33580044|t=2020. COVID-19 vaccines: breaking record times to first-in-human trials.|pdf=|usr=}}
{{tp|p=33549288|t=2021. Herbal Medication to Enhance or Modulate Viral Infections.|pdf=|usr=}}
{{tp|p=33667020|t=2021. Nutrition Support in Patients With Acute Respiratory Distress Syndrome COVID-19.|pdf=|usr=}}
{{tp|p=33651909|t=2021. Early Enteral Nutrition in Mechanically Ventilated Patients With COVID-19 Infection.|pdf=|usr=}}
{{tp|p=33549452|t=2021. Excessive vitamin B12 and poor outcome in COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=33549427|t=2021. Nutrition and the Covid-19 pandemic: Three factors with high impact on community health.|pdf=|usr=}}
{{tp|p=33592454|t=2021. Probiotics: A potential immunomodulator in COVID-19 infection management.|pdf=|usr=}}
{{tp|p=33570583|t=2021. Nutritional perspectives for the prevention and mitigation of COVID-19.|pdf=|usr=}}
{{tp|p=33573173|t=2021. Phytonutrient and Nutraceutical Action against COVID-19: Current Review of Characteristics and Benefits.|pdf=|usr=}}
{{tp|p=33573169|t=2021. Micronutrients, Phytochemicals and Mediterranean Diet: A Potential Protective Role against COVID-19 through Modulation of PAF Actions and Metabolism.|pdf=|usr=}}
{{tp|p=33525447|t=2021. Vitamin D Supplementation to Prevent COVID-19 Infections and Deaths-Accumulating Evidence from Epidemiological and Intervention Studies Calls for Immediate Action.|pdf=|usr=}}
{{tp|p=33572045|t=2021. Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33557013|t=2021. Diagnostic and Pharmacological Potency of Creatine in Post-Viral Fatigue Syndrome.|pdf=|usr=}}
{{tp|p=33652653|t=2021. Notable Developments for Vitamin D Amid the COVID-19 Pandemic, but Caution Warranted Overall: A Narrative Review.|pdf=|usr=}}
{{tp|p=33668240|t=2021. Vitamin D and Lung Outcomes in Elderly COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33671491|t=2021. The Antiviral Properties of Human Milk: A Multitude of Defence Tools from Mother Nature.|pdf=|usr=}}
{{tp|p=33611766|t=2021. Roux-en-Y Gastric Bypass Downregulates Angiotensin-Converting Enzyme 2 (ACE2) Gene Expression in Subcutaneous White Adipose Tissue: A Putative Protective Mechanism Against Severe COVID-19.|pdf=|usr=}}
{{tp|p=33537364|t=2021. Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis.|pdf=|usr=}}
{{tp|p=33628858|t=2021. Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?|pdf=|usr=}}
{{tp|p=33628857|t=2021. Impact of Interleukin-6 Receptor Blockade With Tocilizumab on Cardiac Injury in Patients With COVID-19: A Retrospective Cohort Study.|pdf=|usr=}}
{{tp|p=33623808|t=2021. Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19.|pdf=|usr=}}
{{tp|p=33604400|t=2021. Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33556157|t=2021. Real-World Inpatient Use of Medications Repurposed for Coronavirus Disease 2019 in United States Hospitals, March-May 2020.|pdf=|usr=}}
{{tp|p=33553472|t=2021. A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals.|pdf=|usr=}}
{{tp|p=33553467|t=2021. Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma.|pdf=|usr=}}
{{tp|p=33741691|t=2021. Melatonin may decrease risk for and aid treatment of COVID-19 and other RNA viral infections.|pdf=|usr=}}
{{tp|p=33778162|t=2021. Judicious use of low-dosage corticosteroids for non-severe COVID-19: A case report.|pdf=|usr=}}
{{tp|p=33717367|t=2020. Novel and Controversial Therapies in COVID-19.|pdf=|usr=}}
{{tp|p=33675508|t=2021. Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders.|pdf=|usr=}}
{{tp|p=33628371|t=2021. Oxidative Imbalance as a Crucial Factor in Inflammatory Lung Diseases: Could Antioxidant Treatment Constitute a New Therapeutic Strategy?|pdf=|usr=}}
{{tp|p=33691012|t=2021. Feasibility of the vaccine development for SARS-CoV-2 and other viruses using the shell disorder analysis.|pdf=|usr=}}
{{tp|p=33691011|t=2021. SARS-CoV-2 Drug Discovery based on Intrinsically Disordered Regions.|pdf=|usr=}}
{{tp|p=33605425|t=2021. Do Corticosteroid Injections for the Treatment of Pain Influence the Efficacy of mRNA COVID-19 Vaccines?|pdf=|usr=}}
{{tp|p=33623607|t=2020. Psychiatric side effects of chloroquine in COVID-19 patients: two case reports.|pdf=|usr=}}
{{tp|p=33623604|t=2020. Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for people with COVID-19.|pdf=|usr=}}
{{tp|p=33534822|t=2021. Rational design of multi epitope-based subunit vaccine by exploring MERS-COV proteome: Reverse vaccinology and molecular docking approach.|pdf=|usr=}}
{{tp|p=33765086|t=2021. Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection.|pdf=|usr=}}
{{tp|p=33765062|t=2021. Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.|pdf=|usr=}}
{{tp|p=33657135|t=2021. A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33571304|t=2021. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors.|pdf=|usr=}}
{{tp|p=33644964|t=2021. The essential role of a physiatrist in recommending a COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33589486|t=2021. Inadvertent subcutaneous injection of COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33770348|t=2021. The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development.|pdf=|usr=}}
{{tp|p=33537958|t=2021. Systematic Network and Meta-analysis on the Antiviral Mechanisms of Probiotics: A Preventive and Treatment Strategy to Mitigate SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33597253|t=2021. Bepridil is potent against SARS-CoV-2 in vitro.|pdf=|usr=}}
{{tp|p=33688035|t=2021. One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection.|pdf=|usr=}}
{{tp|p=33688034|t=2021. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike.|pdf=|usr=}}
{{tp|p=33568500|t=2021. Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors.|pdf=|usr=}}
{{tp|p=33526596|t=2021. Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP.|pdf=|usr=}}
{{tp|p=33766889|t=2021. Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing.|pdf=|usr=}}
{{tp|p=33636189|t=2021. Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors.|pdf=|usr=}}
{{tp|p=33770364|t=2021. Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33586288|t=2021. Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naive human antibody library.|pdf=|usr=}}
{{tp|p=33771367|t=2021. Vaccination for COVID-19: benchmarks in public health and virus transmission.|pdf=|usr=}}
{{tp|p=33743214|t=2021. Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes.|pdf=|usr=}}

{{tp|p=33685998|t=2021. SARS-CoV-2 vaccines in patients with SLE.|pdf=|usr=}}
{{tp|p=33627228|t=2021. Liquen plano en una paciente tras SARS-CoV-2 tratado con lopinavir/ritonavir.|pdf=|usr=}}
{{tp|p=33593637|t=2021. Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33622529|t=2021. Glucocorticoides solos versus tocilizumab solo o glucocorticoides mas tocilizumab en pacientes con neumonia grave por SARS-CoV-2 e inflamacion moderada.|pdf=|usr=}}
{{tp|p=33715841|t=2021. Tocilizumab en el paciente con COVID-19.|pdf=|usr=}}
{{tp|p=33778159|t=2021. Lichen planus after SARS-CoV-2 infection treated with lopinavir/ritonavir.|pdf=|usr=}}
{{tp|p=33589878|t=2021. Transfusion reaction to hyperimmune plasma in patients with severe COVID-19 infection.|pdf=|usr=}}
{{tp|p=33585689|t=2021. Effectiveness of glucocorticoids in patients hospitalized for severe SARS-CoV-2 pneumonia.|pdf=|usr=}}
{{tp|p=33686372|t=2021. Indication of glucocorticoid pulses for patients with SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33763598|t=2021. Tocilizumab in patients infected by SARS-CoV2.|pdf=|usr=}}
{{tp|p=33817623|t=2021. Network bioinformatics analysis provides insight into drug repurposing for COVID-19.|pdf=|usr=}}
{{tp|p=33780778|t=2021. Anticholinergic drugs versus preprocedural mouth rinses for reduction of SARS-CoV-2 load in dental aerosols.|pdf=|usr=}}
{{tp|p=33780777|t=2021. Aminoglycosides and their potential as SARS-CoV-2 antivirals.|pdf=|usr=}}
{{tp|p=33735762|t=2021. Clofazimine: A potential therapeutic option for severe COVID-19.|pdf=|usr=}}
{{tp|p=33730601|t=2021. Etoricoxib may inhibit cytokine storm to treat COVID-19.|pdf=|usr=}}
{{tp|p=33571758|t=2021. Antihistamine and cationic amphiphilic drugs, old molecules as new tools against the COVID-19?|pdf=|usr=}}
{{tp|p=33561624|t=2021. The potential use of lactate blockers for the prevention of COVID-19 worst outcome, insights from exercise immunology.|pdf=|usr=}}
{{tp|p=33549964|t=2021. Airways to heaven: Caution needed when exercising during COVID-19.|pdf=|usr=}}
{{tp|p=33529978|t=2021. Could diet and exercise reduce risk of COVID-19 syndemic?|pdf=|usr=}}
{{tp|p=33657458|t=2021. Autism Spectrum Disorder patients may be susceptible to COVID-19 disease due to deficiency in melatonin.|pdf=|usr=}}
{{tp|p=33647606|t=2021. Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C.|pdf=|usr=}}
{{tp|p=33640714|t=2021. Can bilirubin nanomedicine become a hope for the management of COVID-19?|pdf=|usr=}}
{{tp|p=33636587|t=2021. COVID-19, colchicine and glycemia.|pdf=|usr=}}
{{tp|p=33636586|t=2021. COVID-19-related arrhythmias and the possible effects of ranolazine.|pdf=|usr=}}
{{tp|p=33621842|t=2021. Pulmonary lipid modulation: A possible therapeutic target for SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33607405|t=2021. A genetic insight into vitamin D binding protein and COVID-19.|pdf=|usr=}}
{{tp|p=33744019|t=2021. Corticosteroids in COVID-19: A double-edged sword - a retrospective study.|pdf=|usr=}}
{{tp|p=33816370|t=2020. Efficacy and safety of chloroquine and hydroxychloroquine for COVID-19: A comprehensive evidence synthesis of clinical, animal, and in vitro studies.|pdf=|usr=}}
{{tp|p=33571171|t=2021. Risk Factors of Coronavirus Disease 2019-Related Mortality and Optimal Treatment Regimens: A Retrospective Study.|pdf=|usr=}}
{{tp|p=33776574|t=2021. Corticosteroid Pulses for Hospitalized Patients with COVID-19: Effects on Mortality.|pdf=|usr=}}
{{tp|p=33673527|t=2021. Antiviral and Immunomodulation Effects of Artemisia.|pdf=|usr=}}
{{tp|p=33673004|t=2021. Natural Products and Nutrients against Different Viral Diseases: Prospects in Prevention and Treatment of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33655919|t=2021. Oral high dose vitamin D for the treatment of diabetic patients with COVID-19: A protocol for systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33761696|t=2021. Role of tocilizumab for concomitant systemic fungal infection in severe COVID-19 patient: Case report.|pdf=|usr=}}
{{tp|p=33725851|t=2021. Low-dose oral hydroxychloroquine led to impaired vision in a child with renal failure: Case report and literature review.|pdf=|usr=}}
{{tp|p=33530261|t=2021. Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33578548|t=2021. Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19.|pdf=|usr=}}
{{tp|p=33623561|t=2020. Immunity, parasites, genetics and sex hormones: contributors to mild inflammatory responses in COVID-19?|pdf=|usr=}}
{{tp|p=33623551|t=2020. An alert on the incautious use of herbal medicines by sub-Saharan African populations to fight against the COVID-19.|pdf=|usr=}}
{{tp|p=33573530|t=2021. Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials.|pdf=|usr=}}
{{tp|p=33682640|t=2021. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33573221|t=2021. Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization.|pdf=|usr=}}
{{tp|p=33669635|t=2021. Hypothiocyanite and Hypothiocyanite/Lactoferrin Mixture Exhibit Virucidal Activity In Vitro against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33671315|t=2021. Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19.|pdf=|usr=}}
{{tp|p=33621264|t=2021. Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33621254|t=2021. Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19.|pdf=|usr=}}
{{tp|p=33606790|t=2021. Observational study of haloperidol in hospitalized patients with COVID-19.|pdf=|usr=}}
{{tp|p=33606702|t=2021. A Bayesian reanalysis of the effects of hydroxychloroquine and azithromycin on viral carriage in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33596235|t=2021. Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase.|pdf=|usr=}}
{{tp|p=33596218|t=2021. Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro.|pdf=|usr=}}
{{tp|p=33592050|t=2021. Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study.|pdf=|usr=}}
{{tp|p=33571320|t=2021. Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae.|pdf=|usr=}}
{{tp|p=33727066|t=2021. Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects.|pdf=|usr=}}
{{tp|p=33643864|t=2021. mRNA Vaccines for COVID-19: A Simple Explanation.|pdf=|usr=}}
{{tp|p=33677593|t=2021. The potential risks of delaying the second vaccine dose during the SARS-CoV-2 pandemic.|pdf=|usr=}}
{{tp|p=33486522|t=2021. Vitamin D supplementation, COVID-19 and disease severity: a meta-analysis.|pdf=|usr=}}
{{tp|p=33647971|t=2021. COVID-19 vaccine-related myositis.|pdf=|usr=}}
{{tp|p=33599247|t=2021. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos.|pdf=|usr=}}
{{tp|p=33778667|t=2021. Axillary Lymphadenopathy After mRNA COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=33625301|t=2021. Evolution of Lymphadenopathy at PET/MRI after COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=33625299|t=2021. Adenopathy Following COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=33625300|t=2021. Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncology Patients.|pdf=|usr=}}
{{tp|p=33625298|t=2021. Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel.|pdf=|usr=}}
{{tp|p=33723519|t=2021. Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19.|pdf=|usr=}}
{{tp|p=33542837|t=2021. Low-Level Laser Therapy in Prevention of the Development of Endothelial Dysfunction and Clinical Experience of Treatment and Rehabilitation of COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33547007|t=2021. Sustained coronavirus disease 2019-related organizing pneumonia successfully treated with corticosteroid.|pdf=|usr=}}
{{tp|p=33550151|t=2021. Colchicine and SARS-CoV-2: Management of the hyperinflammatory state.|pdf=|usr=}}
{{tp|p=33721697|t=2021. SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity.|pdf=|usr=}}
{{tp|p=33552890|t=2021. COVID-19 acute respiratory distress syndrome: can iloprost have a role for the treatment?|pdf=|usr=}}
{{tp|p=33657448|t=2021. Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury.|pdf=|usr=}}
{{tp|p=33658032|t=2021. Circulating Vitamin D levels status and clinical prognostic indices in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33815804|t=2021. Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=33732466|t=2021. Multimodality treatment in immunocompromised patients with severe COVID-19: the role of IL-6 inhibitor, intravenous immunoglobulin, and haemoperfusion.|pdf=|usr=}}
{{tp|p=33619449|t=2021. An integrated virtual screening of compounds from Carica papaya leaves against multiple protein targets of SARS-Coronavirus-2.|pdf=|usr=}}
{{tp|p=33677945|t=2021. Vitamin D and disease severity in coronavirus disease 19 (COVID-19).|pdf=|usr=}}
{{tp|p=33716310|t=2021. Precaucion con el uso de dexametasona en pacientes con COVID-19 en sus fases iniciales.|pdf=|usr=}}
{{tp|p=33776190|t=2021. Miocarditis aguda tras administracion de vacuna BNT162b2 contra la COVID-19.|pdf=|usr=}}
{{tp|p=33675220|t=2021. Real-life use of remdesivir in hospitalized patients with COVID-19.|pdf=|usr=}}
{{tp|p=33654051|t=2021. Impacto de la COVID-19 sobre las listas de espera quirurgicas.|pdf=|usr=}}
{{tp|p=33399749|t=2020. Tratamientos experimentales y coronavirus.|pdf=|usr=}}
{{tp|p=33480368|t=2020. El dilema de COVID-19: inverted question marksangre suficiente versus plasma convaleciente?|pdf=|usr=}}
{{tp|p=33612319|t=2021. Chez des sujets de 16 ans et plus, est-ce que le vaccin BNT162b2, un vaccin a ARN messager contre la COVID-19, est efficace et securitaire ?|pdf=|usr=}}
{{tp|p=33594794|t=2021. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.|pdf=|usr=}}
{{tp|p=33666285|t=2021. Vaccines for SARS coronavirus 2 and the new normal in vaccinology.|pdf=|usr=}}
{{tp|p=33621405|t=2021. Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics.|pdf=|usr=}}
{{tp|p=33580566|t=2020. Background to new treatments for COVID-19, including its chronicity, through altering elements of the cytokine storm.|pdf=|usr=}}
{{tp|p=33764494|t=2021. Vacunacion frente al SARS-CoV-2 en pacientes con esclerosis multiple.|pdf=|usr=}}
{{tp|p=33710296|t=2021. COVID-19 vaccination and antirheumatic therapy.|pdf=|usr=}}
{{tp|p=33542047|t=2021. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial.|pdf=|usr=}}
{{tp|p=33544784|t=2020. Natural and semisynthetic candidate molecules for COVID-19 prophylaxis and treatment.|pdf=|usr=}}
{{tp|p=33776395|t=2021. Synthesis, Molecular Docking, In Silico ADME Predictions, and Toxicity Studies of N-Substituted-5-(4-Chloroquinolin-2-yl)-1,3,4-Thiadiazol-2-Amine Derivatives as COVID-19 Inhibitors.|pdf=|usr=}}
{{tp|p=33753960|t=2021. Natural product remedies for COVID-19: A focus on safety.|pdf=|usr=}}
{{tp|p=33614035|t=2021. Deficiency of antioxidants and increased oxidative stress in COVID-19 patients: A cross-sectional comparative study in Jigawa, Northwestern Nigeria.|pdf=|usr=}}
{{tp|p=33796310|t=2021. Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=33656132|t=2021. Critical analysis on the use of cholecalciferol as a COVID-19 intervention: a narrative review.|pdf=|usr=}}
{{tp|p=33649700|t=2021. Screening of drug databank against WT and mutant main protease of SARS-CoV-2: Towards finding potential compound for repurposing against COVID-19.|pdf=|usr=}}
{{tp|p=33642896|t=2021. In silico analysis of quranic and prophetic medicinals plants for the treatment of infectious viral diseases including corona virus.|pdf=|usr=}}
{{tp|p=33732045|t=2021. Nano-formulation of herbo-mineral alternative medicine from linga chenduram and evaluation of antiviral efficacy.|pdf=|usr=}}
{{tp|p=33758570|t=2021. Structure insights of SARS-CoV-2 open state envelope protein and inhibiting through active phytochemical of ayurvedic medicinal plants from Withania somnifera.|pdf=|usr=}}
{{tp|p=33746538|t=2021. A comprehensive insight into the role of zinc deficiency in the renin-angiotensin and kinin-kallikrein system dysfunctions in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33654454|t=2021. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.|pdf=|usr=}}
{{tp|p=33551661|t=2021. Computational drug screening against the SARS-CoV-2 Saudi Arabia isolates through a multiple-sequence alignment approach.|pdf=|usr=}}
{{tp|p=33526965|t=2021. Identification of natural compounds as potent inhibitors of SARS-CoV-2 main protease using combined docking and molecular dynamics simulations.|pdf=|usr=}}
{{tp|p=33722251|t=2021. Extracorporeal cardiopulmonary resuscitation for severe chloroquine intoxication in a child - a case report.|pdf=|usr=}}
{{tp|p=33741598|t=2021. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates.|pdf=|usr=}}
{{tp|p=33608249|t=2021. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans.|pdf=|usr=}}
{{tp|p=33597251|t=2021. An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants.|pdf=|usr=}}
{{tp|p=33547083|t=2021. A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33536217|t=2021. Leveraging systems biology for predicting modulators of inflammation in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33686143|t=2021. The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication.|pdf=|usr=}}
{{tp|p=33664446|t=2021. Polyunsaturated omega-3 fatty acids inhibit ACE2-controlled SARS-CoV-2 binding and cellular entry.|pdf=|usr=}}
{{tp|p=33664393|t=2021. Potential neutralizing antibodies discovered for novel corona virus using machine learning.|pdf=|usr=}}

{{tp|p=33576820|t=2021. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial.|pdf=|usr=}}
{{tp|p=33576814|t=2021. Supplements for the Treatment of Mild COVID-19-Challenging Health Beliefs With Science From A to Z.|pdf=|usr=}}
{{tp|p=33769311|t=2021. IgV somatic mutation of human anti-SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity.|pdf=|usr=}}
{{tp|p=33529170|t=2021. Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33571168|t=2021. Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.|pdf=|usr=}}
{{tp|p=33724265|t=2020. No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19.|pdf=|usr=}}
{{tp|p=33666263|t=2021. Nutrition evaluation and management of critically ill patients with COVID-19 during post-intensive care rehabilitation.|pdf=|usr=}}
{{tp|p=33756482|t=2021. Pathophysiological Implication of Vitamin D in Diabetic Kidney Disease.|pdf=|usr=}}
{{tp|p=33647327|t=2021. Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective case-noncase study.|pdf=|usr=}}
{{tp|p=33775674|t=2021. Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients.|pdf=|usr=}}
{{tp|p=33585728|t=2021. Systematic Review of Safety and Efficacy of COVID-19 Vaccines in Patients With Kidney Disease.|pdf=|usr=}}
{{tp|p=33706472|t=2021. Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=33617777|t=2021. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.|pdf=|usr=}}
{{tp|p=33617772|t=2021. MAb for symptomatic COVID-19 in correctional facilities: an important opportunity.|pdf=|usr=}}
{{tp|p=33610193|t=2021. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.|pdf=|usr=}}
{{tp|p=33640037|t=2021. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.|pdf=|usr=}}
{{tp|p=33705696|t=2021. (18)F-fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33676597|t=2021. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.|pdf=|usr=}}
{{tp|p=33640038|t=2021. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.|pdf=|usr=}}
{{tp|p=33684351|t=2021. Sex-disaggregated data in COVID-19 vaccine trials.|pdf=|usr=}}
{{tp|p=33545098|t=2021. Sputnik V COVID-19 vaccine candidate appears safe and effective.|pdf=|usr=}}
{{tp|p=33545094|t=2021. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.|pdf=|usr=}}
{{tp|p=33549168|t=2021. WHO international non-proprietary names: the need to distinguish COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=33545096|t=2021. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.|pdf=|usr=}}
{{tp|p=33765410|t=2021. Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection.|pdf=|usr=}}
{{tp|p=33743220|t=2021. Malnutrition risk in hospitalised COVID-19 patients receiving CPAP.|pdf=|usr=}}
{{tp|p=33770519|t=2021. WHO International Standard for anti-SARS-CoV-2 immunoglobulin.|pdf=|usr=}}
{{tp|p=33665645|t=2021. The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19.|pdf=|usr=}}
{{tp|p=33773111|t=2021. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.|pdf=|usr=}}
{{tp|p=33606999|t=2021. Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products.|pdf=|usr=}}
{{tp|p=33548196|t=2021. Inactivated COVID-19 vaccines to make a global impact.|pdf=|usr=}}
{{tp|p=33548194|t=2021. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.|pdf=|usr=}}
{{tp|p=33639103|t=2021. Bell's palsy and SARS-CoV-2 vaccines.|pdf=|usr=}}
{{tp|p=33778791|t=2021. Convalescent plasma from people vaccinated after COVID-19 infection.|pdf=|usr=}}
{{tp|p=33817676|t=2021. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19.|pdf=|usr=}}
{{tp|p=33655229|t=2021. COVID-19 drug practices risk antimicrobial resistance evolution.|pdf=|usr=}}
{{tp|p=33571468|t=2021. SARS-CoV-2 vaccination and phase 1 cancer clinical trials.|pdf=|usr=}}
{{tp|p=33556319|t=2021. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.|pdf=|usr=}}
{{tp|p=33817664|t=2021. Flare of rheumatoid arthritis after COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=33655225|t=2021. Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients?|pdf=|usr=}}
{{tp|p=33655224|t=2021. Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients? - Authors' reply.|pdf=|usr=}}
{{tp|p=33817665|t=2021. The role of antirheumatics in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33754144|t=2021. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.|pdf=|usr=}}
{{tp|p=33782671|t=2021. Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation.|pdf=|usr=}}
{{tp|p=33782670|t=2021. Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation - Authors' reply.|pdf=|usr=}}
{{tp|p=33655222|t=2021. Type I interferon, anti-interferon antibodies, and COVID-19.|pdf=|usr=}}
{{tp|p=33655221|t=2021. COVID-19 cytokine storm: targeting the appropriate cytokine.|pdf=|usr=}}
{{tp|p=33655220|t=2021. Perspective of patients with autoimmune diseases on COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=33655219|t=2021. Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases.|pdf=|usr=}}
{{tp|p=33655218|t=2021. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.|pdf=|usr=}}
{{tp|p=33619736|t=2021. The effect of climbing chalk powder on the infectivity of human coronavirus OC43.|pdf=|usr=}}
{{tp|p=33671893|t=2021. The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19.|pdf=|usr=}}
{{tp|p=33636175|t=2021. Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives.|pdf=|usr=}}
{{tp|p=33745895|t=2021. Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: A multicentral retrospective study.|pdf=|usr=}}
{{tp|p=33789145|t=2021. Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2.|pdf=|usr=}}
{{tp|p=33781826|t=2021. Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients.|pdf=|usr=}}
{{tp|p=33607159|t=2021. COVID-19, cytokines, inflammation, and spices: How are they related?|pdf=|usr=}}
{{tp|p=33593923|t=2021. A systems-based method to repurpose marketed therapeutics for antiviral use: a SARS-CoV-2 case study.|pdf=|usr=}}
{{tp|p=33687000|t=2021. Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19.|pdf=|usr=}}
{{tp|p=33686995|t=2021. Early experience with anti-interleukin-6 therapy in COVID-19 hyperinflammation.|pdf=|usr=}}
{{tp|p=33686972|t=2021. The link between vitamin D deficiency and COVID-19.|pdf=|usr=}}
{{tp|p=33666135|t=2021. Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33566210|t=2021. Photosynthetically Controlled Spirulina, but Not Solar Spirulina, Inhibits TNF-alpha Secretion: Potential Implications for COVID-19-Related Cytokine Storm Therapy.|pdf=|usr=}}
{{tp|p=33670191|t=2021. New Hopes for Drugs against COVID-19 Come from the Sea.|pdf=|usr=}}
{{tp|p=33589849|t=2021. Preparation of cerium molybdates and their antiviral activity against bacteriophage Phi6 and SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33628136|t=2020. Why Not Encourage Physical Activity Outdoors and Inhaling Through the Uncovered Nose During the Coronavirus Lockdown?|pdf=|usr=}}
{{tp|p=33718003|t=2021. Encapsulation of bioactive agent (Curcumin, Moringa) in electrospun nanofibers - Some insights into recent research trends.|pdf=|usr=}}
{{tp|p=33816131|t=2021. Repurposing antiviral drugs on recently emerged viral infections: A review article.|pdf=|usr=}}
{{tp|p=33757717|t=2021. Role of vitamin D supplementation in aging patients with COVID-19.|pdf=|usr=}}
{{tp|p=33673930|t=2021. In Reply - Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=33673929|t=2021. Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=33549269|t=2021. Elevated Rate of HLA Antibodies in Male COVID-19 Convalescent Plasma Donors: A Risk Factor for Transfusion-Related Acute Lung Injury.|pdf=|usr=}}
{{tp|p=33714594|t=2021. Vitamin D Status Is Associated With In-Hospital Mortality and Mechanical Ventilation: A Cohort of COVID-19 Hospitalized Patients.|pdf=|usr=}}
{{tp|p=33817559|t=2021. Anti-Inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort.|pdf=|usr=}}
{{tp|p=33748678|t=2021. Association Between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients With COVID-19.|pdf=|usr=}}
{{tp|p=33585799|t=2021. Safety and Efficacy of Convalescent Plasma in Elderly COVID-19 Patients: The RESCUE Trial.|pdf=|usr=}}
{{tp|p=33585798|t=2021. Viral Respiratory Infections: An Ounce of Prevention Is Worth a Pound of Cure.|pdf=|usr=}}
{{tp|p=33785634|t=2021. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.|pdf=|usr=}}
{{tp|p=33653892|t=2021. Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model.|pdf=|usr=}}
{{tp|p=33653891|t=2021. Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets.|pdf=|usr=}}
{{tp|p=33653888|t=2021. Genetically Engineered Live-Attenuated Middle East Respiratory Syndrome Coronavirus Viruses Confer Full Protection against Lethal Infection.|pdf=|usr=}}
{{tp|p=33653885|t=2021. The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19.|pdf=|usr=}}
{{tp|p=33563823|t=2021. Characterization of SARS-CoV-2 RNA, Antibodies, and Neutralizing Capacity in Milk Produced by Women with COVID-19.|pdf=|usr=}}
{{tp|p=33531392|t=2021. Reply to Marakasova and Baranova, "MMR Vaccine and COVID-19: Measles Protein Homology May Contribute to Cross-Reactivity or to Complement Activation Protection".|pdf=|usr=}}
{{tp|p=33531391|t=2021. MMR Vaccine and COVID-19: Measles Protein Homology May Contribute to Cross-Reactivity or to Complement Activation Protection.|pdf=|usr=}}
{{tp|p=33564221|t=2021. Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostat bound to the trypsin-like protease TMPRSS2.|pdf=|usr=}}
{{tp|p=33790352|t=2021. Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir.|pdf=|usr=}}
{{tp|p=33790308|t=2021. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.|pdf=|usr=}}
{{tp|p=33785846|t=2021. Ivermectin reduces in vivo coronavirus infection in a mouse experimental model.|pdf=|usr=}}
{{tp|p=33767276|t=2021. Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice.|pdf=|usr=}}
{{tp|p=33762619|t=2021. Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics.|pdf=|usr=}}
{{tp|p=33737631|t=2021. Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19.|pdf=|usr=}}
{{tp|p=33737545|t=2021. Computational evidence for nitro derivatives of quinoline and quinoline N-oxide as low-cost alternative for the treatment of SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33737523|t=2021. Prioritizing antiviral drugs against SARS-CoV-2 by integrating viral complete genome sequences and drug chemical structures.|pdf=|usr=}}
{{tp|p=33723270|t=2021. The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue.|pdf=|usr=}}
{{tp|p=33707532|t=2021. Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates.|pdf=|usr=}}
{{tp|p=33692457|t=2021. Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma.|pdf=|usr=}}
{{tp|p=33692386|t=2021. Blockade of SARS-CoV-2 spike protein-mediated cell-cell fusion using COVID-19 convalescent plasma.|pdf=|usr=}}
{{tp|p=33692377|t=2021. Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants.|pdf=|usr=}}
{{tp|p=33564039|t=2021. Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19.|pdf=|usr=}}
{{tp|p=33558635|t=2021. Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.|pdf=|usr=}}
{{tp|p=33547334|t=2021. An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study.|pdf=|usr=}}
{{tp|p=33542325|t=2021. DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice.|pdf=|usr=}}
{{tp|p=33542252|t=2021. Sensitive mass spectrometric determination of kinin-kallikrein system peptides in light of COVID-19.|pdf=|usr=}}
{{tp|p=33637783|t=2021. Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations.|pdf=|usr=}}
{{tp|p=33627767|t=2021. Identification of candidate repurposable drugs to combat COVID-19 using a signature-based approach.|pdf=|usr=}}
{{tp|p=33619344|t=2021. In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19.|pdf=|usr=}}
{{tp|p=33794459|t=2021. Virtual screening of plant-derived compounds against SARS-CoV-2 viral proteins using computational tools.|pdf=|usr=}}
{{tp|p=33578259|t=2021. Potential interactions between COVID-19 vaccines and antiepileptic drugs.|pdf=|usr=}}
{{tp|p=33677470|t=2021. Targeting glucose metabolism for treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33790219|t=2021. Newly synthesized M(pro) inhibitors as potential oral anti-SARS-CoV-2 agents.|pdf=|usr=}}
{{tp|p=33658482|t=2021. Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19.|pdf=|usr=}}

{{tp|p=33758167|t=2021. Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products.|pdf=|usr=}}
{{tp|p=33654055|t=2021. Study on the promotion of lymphocytes in patients with COVID-19 by broad-spectrum chemokine receptor inhibitor vMIP-II and its Mechanism of signal transmission in vitro.|pdf=|usr=}}
{{tp|p=33542181|t=2021. Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir.|pdf=|usr=}}
{{tp|p=33542177|t=2021. Evaluation of the immunomodulatory effects of anti-COVID-19 TCM formulae by multiple virus-related pathways.|pdf=|usr=}}
{{tp|p=33619243|t=2021. Therapeutic potential of C1632 by inhibition of SARS-CoV-2 replication and viral-induced inflammation through upregulating let-7.|pdf=|usr=}}
{{tp|p=33612824|t=2021. Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=}}
{{tp|p=33531462|t=2021. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.|pdf=|usr=}}
{{tp|p=33568628|t=2021. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.|pdf=|usr=}}
{{tp|p=33724070|t=2021. Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry.|pdf=|usr=}}
{{tp|p=33786372|t=2021. Ultraefficiently Calming Cytokine Storm Using Ti3C2T x MXene.|pdf=|usr=}}
{{tp|p=33778374|t=2021. Compassionate Use of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: a Case-Control Study.|pdf=|usr=}}
{{tp|p=33748676|t=2021. On BCG Vaccine Protection from COVID-19: A Review.|pdf=|usr=}}
{{tp|p=33644693|t=2021. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment.|pdf=|usr=}}
{{tp|p=33623865|t=2021. The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33558862|t=2021. Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells.|pdf=|usr=}}
{{tp|p=33688491|t=2021. Placenta-derived mesenchymal stem cells (P-MSCs) for COVID-19 pneumonia-a regenerative dogma.|pdf=|usr=}}
{{tp|p=33691145|t=2021. Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks.|pdf=|usr=}}
{{tp|p=33601098|t=2021. Medical progress: Stem cells as a new therapeutic strategy for COVID-19.|pdf=|usr=}}
{{tp|p=33550140|t=2021. Structural insights into SARS-CoV-2 infection and therapeutics development.|pdf=|usr=}}
{{tp|p=33648582|t=2021. Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?|pdf=|usr=}}
{{tp|p=33575962|t=2021. P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo-inflammation.|pdf=|usr=}}
{{tp|p=33575961|t=2021. Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19.|pdf=|usr=}}
{{tp|p=33586320|t=2021. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.|pdf=|usr=}}
{{tp|p=33527780|t=2021. Mesenchymal stromal cell delivery via an ex vivo bioreactor preclinical test system attenuates clot formation for intravascular application.|pdf=|usr=}}
{{tp|p=33726854|t=2021. Direct and indirect evidence of efficacy and safety of rapid exercise tests for exertional desaturation in Covid-19: a rapid systematic review.|pdf=|usr=}}
{{tp|p=33765902|t=2021. Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33624533|t=2021. An overview of vaccine development for COVID-19.|pdf=|usr=}}
{{tp|p=33664866|t=2021. MERS-CoV and SARS-CoV-2 replication can be inhibited by targeting the interaction between the viral spike protein and the nucleocapsid protein.|pdf=|usr=}}
{{tp|p=33558079|t=2021. Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19.|pdf=|usr=}}
{{tp|p=33579777|t=2021. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19.|pdf=|usr=}}
{{tp|p=33662796|t=2021. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19.|pdf=|usr=}}
{{tp|p=33685103|t=2021. Covid-19-vaksiner gir okt risiko for anafylaksi.|pdf=|usr=}}
{{tp|p=33723507|t=2021. Use of ivermectin in the treatment of Covid-19: A pilot trial.|pdf=|usr=}}
{{tp|p=33733663|t=2021. COVID-19 vaccines for low- and middle-income countries.|pdf=|usr=}}
{{tp|p=33678561|t=2021. Convalescent blood plasma (CBP) donated by recovered COVID-19 patients - A comment.|pdf=|usr=}}
{{tp|p=33574010|t=2021. Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies.|pdf=|usr=}}
{{tp|p=33637467|t=2021. Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma.|pdf=|usr=}}
{{tp|p=33663928|t=2021. Facts and challenges on global deployment of vaccines for the immunotherapy of the evolving SARS Cov-2 variants: What a new year, with a fast spreading South African and the most fearful Brazilian variants, as the unwanted gifts, imposing enormous crises to surmount.|pdf=|usr=}}
{{tp|p=33610448|t=2021. Immunotherapy for COVID-19: Evolving treatment of viral infection and associated adverse immunological reactions.|pdf=|usr=}}
{{tp|p=33677086|t=2021. Constraints and challenges in convalescent plasma collection amidst the Covid 19 pandemic- strategies and recommendations to overcome these.|pdf=|usr=}}
{{tp|p=33675992|t=2021. Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency.|pdf=|usr=}}
{{tp|p=33604922|t=2021. High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples.|pdf=|usr=}}
{{tp|p=33604884|t=2021. A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibody kinetics: Proposals for better quality of CCP collections.|pdf=|usr=}}
{{tp|p=33590906|t=2021. Factors driving availability of COVID-19 convalescent plasma: Insights from a demand, production, and supply model.|pdf=|usr=}}
{{tp|p=33559248|t=2021. Impact of serological and PCR testing requirements on the selection of COVID-19 convalescent plasma donors.|pdf=|usr=}}
{{tp|p=33616966|t=2021. Decrease in serum antibodies to SARS-CoV-2 in convalescent plasma donors over time.|pdf=|usr=}}
{{tp|p=33615484|t=2021. Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations.|pdf=|usr=}}
{{tp|p=33586160|t=2021. COVID-19 convalescent plasma: Interim recommendations from the AABB.|pdf=|usr=}}
{{tp|p=33554362|t=2021. Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay.|pdf=|usr=}}
{{tp|p=33633933|t=2021. Association between vaccinations and clinical manifestations in children with COVID-19.|pdf=|usr=}}
{{tp|p=33610763|t=2021. Caution advised when considering "Exceptional" extended or single dose COVID-19 vaccination strategies.|pdf=|usr=}}
{{tp|p=33578045|t=2021. AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges, and solutions in Nepal.|pdf=|usr=}}
{{tp|p=33549822|t=2021. Reply to Alizazgar J. Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33535106|t=2021. Risk of Strongyloides Hyperinfection Syndrome when prescribing dexamethasone in severe COVID-19.|pdf=|usr=}}
{{tp|p=33558789|t=2021. Role of food nutrients and supplementation in fighting against viral infections and boosting immunity: A review.|pdf=|usr=}}
{{tp|p=33785249|t=2021. Therapeutic Potential of Metformin in COVID-19: Reasoning for Its Protective Role.|pdf=|usr=}}
{{tp|p=33541791|t=2021. Repurposing Antimalarials to Tackle the COVID-19 Pandemic: (Trends in Parasitology 37, 8-11; 2021).|pdf=|usr=}}
{{tp|p=33750432|t=2021. Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.|pdf=|usr=}}
{{tp|p=33573681|t=2021. Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial.|pdf=|usr=}}
{{tp|p=33779109|t=2021. The effect of the timing of dexamethasone administration in patients with COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=33679150|t=2021. Comparison of clinically approved molecules on SARS-CoV-2 drug target proteins: a molecular docking study.|pdf=|usr=}}
{{tp|p=33726487|t=2021. Antithrombin, COVID-19, and Fresh Frozen Plasma Treatment|pdf=|usr=}}
{{tp|p=33726482|t=2021. The Comparison of Lopinavir/Ritonavir Combination and Favipiravir In COVID-19 Treatment.|pdf=|usr=}}
{{tp|p=33646106|t=2021. Use of Hydroxychloroquine in Patients with COVID-19: A Retrospective Observational Study.|pdf=|usr=}}
{{tp|p=33676782|t=2021. Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.|pdf=|usr=}}
{{tp|p=33707061|t=2021. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.|pdf=|usr=}}
{{tp|p=33558107|t=2021. General determination of causation between Covid-19 vaccines and possible adverse events.|pdf=|usr=}}
{{tp|p=33640142|t=2021. Biosecurity risks associated with vaccine platform technologies.|pdf=|usr=}}
{{tp|p=33744042|t=2021. Natural unblinding of BCG vaccination trials.|pdf=|usr=}}
{{tp|p=33771389|t=2021. mRNA vaccines manufacturing: Challenges and bottlenecks.|pdf=|usr=}}
{{tp|p=33731271|t=2021. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.|pdf=|usr=}}
{{tp|p=33525459|t=2021. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies.|pdf=|usr=}}
{{tp|p=33567790|t=2021. Exploring the Effect of Probiotics, Prebiotics, and Postbiotics in Strengthening Immune Activity in the Elderly.|pdf=|usr=}}
{{tp|p=33562203|t=2021. HIV mRNA Vaccines-Progress and Future Paths.|pdf=|usr=}}
{{tp|p=33562141|t=2021. Localized and Systemic Immune Responses against SARS-CoV-2 Following Mucosal Immunization.|pdf=|usr=}}
{{tp|p=33546347|t=2021. COVID-19 Vaccination: From Interesting Agent to the Patient.|pdf=|usr=}}
{{tp|p=33672450|t=2021. Spike S2 Subunit: The Dark Horse in the Race for Prophylactic and Therapeutic Interventions against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33670630|t=2021. COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform.|pdf=|usr=}}
{{tp|p=33668613|t=2021. Therapeutic Antibodies for the Treatment of Respiratory Tract Infections-Current Overview and Perspectives.|pdf=|usr=}}
{{tp|p=33673048|t=2021. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond.|pdf=|usr=}}
{{tp|p=33670249|t=2021. Construction and Immunogenicity Comparison of Three Virus-Like Particles Carrying Different Combinations of Structural Proteins of Avian Coronavirus Infectious Bronchitis Virus.|pdf=|usr=}}
{{tp|p=33746069|t=2021. In silico Nigellidine (N. sativa) bind to viral spike/active-sites of ACE1/2, AT1/2 to prevent COVID-19 induced vaso-tumult/vascular-damage/comorbidity.|pdf=|usr=}}
{{tp|p=33638539|t=2020. Is the production of a Covid-19 vaccine using transformed Pasteurella plausible?|pdf=|usr=}}
{{tp|p=33781287|t=2021. Precision therapeutic targets for COVID-19.|pdf=|usr=}}
{{tp|p=33639976|t=2021. Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice.|pdf=|usr=}}
{{tp|p=33714753|t=2021. Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody.|pdf=|usr=}}
{{tp|p=33571798|t=2021. Exploring the efficacy of naturally occurring biflavone based antioxidants towards the inhibition of the SARS-CoV-2 spike glycoprotein mediated membrane fusion.|pdf=|usr=}}
{{tp|p=33660566|t=2021. Host Defence RNases as Antiviral Agents against Enveloped Single Stranded RNA Viruses.|pdf=|usr=}}
{{tp|p=33631219|t=2021. Protection against COVID-19 in African population: Immunology, genetics, and malaria clues for therapeutic targets.|pdf=|usr=}}
{{tp|p=33778130|t=2021. Vaccines and drugs under clinical trials for prevention and treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33778129|t=2021. Computationally approached inhibition potential of Tinospora cordifolia towards COVID-19 targets.|pdf=|usr=}}
{{tp|p=33758772|t=2021. A molecular docking study of SARS-CoV-2 main protease against phytochemicals of Boerhavia diffusa Linn. for novel COVID-19 drug discovery.|pdf=|usr=}}
{{tp|p=33748347|t=2021. Respiratory delivery of favipiravir-tocilizumab combination through mucoadhesive protein-lipidic nanovesicles: prospective therapeutics against COVID-19.|pdf=|usr=}}
{{tp|p=33532517|t=2021. In silico virtual screening-based study of nutraceuticals predicts the therapeutic potentials of folic acid and its derivatives against COVID-19.|pdf=|usr=}}
{{tp|p=33572467|t=2021. Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture.|pdf=|usr=}}
{{tp|p=33572452|t=2021. Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.|pdf=|usr=}}
{{tp|p=33567520|t=2021. The Key Role of Nucleic Acid Vaccines for One Health.|pdf=|usr=}}
{{tp|p=33546185|t=2021. Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus.|pdf=|usr=}}
{{tp|p=33673529|t=2021. Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF-kappaB: A Systematic Review.|pdf=|usr=}}
{{tp|p=33672333|t=2021. Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro.|pdf=|usr=}}
{{tp|p=33670023|t=2021. Rational Design of a Pan-Coronavirus Vaccine Based on Conserved CTL Epitopes.|pdf=|usr=}}
{{tp|p=33672785|t=2021. Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea.|pdf=|usr=}}
{{tp|p=33669550|t=2021. Viral Vectors for COVID-19 Vaccine Development.|pdf=|usr=}}
{{tp|p=33671334|t=2021. Targeting the Complement Serine Protease MASP-2 as a Therapeutic Strategy for Coronavirus Infections.|pdf=|usr=}}
{{tp|p=33669276|t=2021. Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19.|pdf=|usr=}}
{{tp|p=33669264|t=2021. Honeysuckle Aqueous Extracts Induced let-7a Suppress EV71 Replication and Pathogenesis In Vitro and In Vivo and Is Predicted to Inhibit SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33672054|t=2021. Structure-Based Identification of Natural Products as SARS-CoV-2 M(pro) Antagonist from Echinacea angustifolia Using Computational Approaches.|pdf=|usr=}}
{{tp|p=33670363|t=2021. Berberine and Obatoclax Inhibit SARS-Cov-2 Replication in Primary Human Nasal Epithelial Cells In Vitro.|pdf=|usr=}}
{{tp|p=33786383|t=2021. Hydroxychloroquine-Induced cutaneous reaction in treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33779831|t=2021. The advantages of drug treatment with statins in patients with SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33725201|t=2021. Profiles of current COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=33721102|t=2021. Strong correlation between prevalence of severe vitamin D deficiency and population mortality rate from COVID-19 in Europe.|pdf=|usr=}}

{{tp|p=33643762|t=2021. Cordifolioside: potent inhibitor against M(pro) of SARS-CoV-2 and immunomodulatory through human TGF-beta and TNF-alpha.|pdf=|usr=}}
{{tp|p=33585152|t=2021. Screening of JAK-STAT modulators from the antiviral plants of Indian traditional system of medicine with the potential to inhibit 2019 novel coronavirus using network pharmacology.|pdf=|usr=}}
{{tp|p=33552835|t=2021. Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements.|pdf=|usr=}}
{{tp|p=33560642|t=2021. Nebulized Nitroglycerin for Coronavirus Disease 2019-Associated Acute Respiratory Distress Syndrome: A Case Report.|pdf=|usr=}}
{{tp|p=33623818|t=2021. Rapidly Establishing a Hospital-Based Convalescent Plasma Collection Center With the Alyx Apheresis Collection Device.|pdf=|usr=}}
{{tp|p=33786375|t=2021. Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations.|pdf=|usr=}}
{{tp|p=33786374|t=2021. Potent SARS-CoV-2 Direct-Acting Antivirals Provide an Important Complement to COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=33527087|t=2021. A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice.|pdf=|usr=}}
{{tp|p=33527086|t=2021. Modeling the Binding Mechanism of Remdesivir, Favilavir, and Ribavirin to SARS-CoV-2 RNA-Dependent RNA Polymerase.|pdf=|usr=}}
{{tp|p=33527085|t=2021. De Novo Discovery of High-Affinity Peptide Binders for the SARS-CoV-2 Spike Protein.|pdf=|usr=}}
{{tp|p=33787221|t=2021. A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells.|pdf=|usr=}}
{{tp|p=33787218|t=2021. Novel Compounds Targeting Neuropilin Receptor 1 with Potential To Interfere with SARS-CoV-2 Virus Entry.|pdf=|usr=}}
{{tp|p=33783182|t=2021. Inhibition of Human Coronaviruses by Antimalarial Peroxides.|pdf=|usr=}}
{{tp|p=33645977|t=2021. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.|pdf=|usr=}}
{{tp|p=33570381|t=2021. Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19.|pdf=|usr=}}
{{tp|p=33793189|t=2021. Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape.|pdf=|usr=}}
{{tp|p=33734675|t=2021. Membrane Nanoparticles Derived from ACE2-Rich Cells Block SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33778286|t=2021. Ethyl Pyruvate as a Potential Defense Intervention against Cytokine Storm in COVID-19?|pdf=|usr=}}
{{tp|p=33778258|t=2021. Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms.|pdf=|usr=}}
{{tp|p=33644594|t=2021. Novel Development of Predictive Feature Fingerprints to Identify Chemistry-Based Features for the Effective Drug Design of SARS-CoV-2 Target Antagonists and Inhibitors Using Machine Learning.|pdf=|usr=}}
{{tp|p=33615173|t=2021. Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial.|pdf=|usr=}}
{{tp|p=33583027|t=2021. Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysis.|pdf=|usr=}}
{{tp|p=33533477|t=2021. Nitric oxide and COVID-19: Dose, timing and how to administer it might be crucial.|pdf=|usr=}}
{{tp|p=33583034|t=2021. Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis plan.|pdf=|usr=}}
{{tp|p=33525227|t=2020. Current Perspectives of convalescent plasma therapy in COVID-19.|pdf=|usr=}}
{{tp|p=33525212|t=2020. Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial.|pdf=|usr=}}
{{tp|p=33525254|t=2020. Treatment of COVID-19 in Pregnancy with Hydroxychloroquine and Azithromycin: a case report.|pdf=|usr=}}
{{tp|p=33582839|t=2021. Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study.|pdf=|usr=}}
{{tp|p=33818411|t=2021. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.|pdf=|usr=}}
{{tp|p=33527327|t=2021. Acute disseminated encephalomyelitis after severe acute respiratory syndrome coronavirus 2 vaccination: a case report.|pdf=|usr=}}
{{tp|p=33527456|t=2021. It's time to change the recommendations on COVID-19 and human milk donations.|pdf=|usr=}}
{{tp|p=33723501|t=2021. Repurposing CFDA-approved drug carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33614402|t=2021. Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase.|pdf=|usr=}}
{{tp|p=33642607|t=2020. COVID-19 and Oral Surgery: A narrative review of preoperative mouth rinses.|pdf=|usr=}}
{{tp|p=33612960|t=2021. Vitamine D et Covid-19.|pdf=|usr=}}
{{tp|p=33561453|t=2021. Current and prospective computational approaches and challenges for developing COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=33539853|t=2021. Microarray patches enable the development of skin-targeted vaccines against COVID-19.|pdf=|usr=}}
{{tp|p=33786537|t=2021. Adsorption of SARS-CoV-2 Spike Protein S1 at Oxide Surfaces Studied by High-Speed Atomic Force Microscopy.|pdf=|usr=}}
{{tp|p=33615316|t=2021. Adsorption of SARS-CoV-2 Spike Protein S1 at Oxide Surfaces Studied by High-Speed Atomic Force Microscopy.|pdf=|usr=}}
{{tp|p=33751020|t=2021. Association of Vitamin D Status with SARS-CoV-2 Infection or COVID-19 Severity: A Systematic Review and Meta-analysis.|pdf=|usr=}}
{{tp|p=33783468|t=2021. Perspective: Nutritional Strategies Targeting the Gut Microbiome to Mitigate COVID-19 Outcomes.|pdf=|usr=}}
{{tp|p=33747847|t=2021. Nephrotoxicity of Chloroquine and Hydroxychloroquine in COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33786369|t=2021. Drug Repurposing of Itraconazole and Estradiol Benzoate against COVID-19 by Blocking SARS-CoV-2 Spike Protein-Mediated Membrane Fusion.|pdf=|usr=}}
{{tp|p=33786368|t=2021. Sulfoglycodendrimer Therapeutics for HIV-1 and SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33678621|t=2021. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL(pro) through high-throughput virtual screening and molecular dynamics simulation.|pdf=|usr=}}
{{tp|p=33735836|t=2021. Convalescent plasma to treat COVID-19: clinical experience and efficacy.|pdf=|usr=}}
{{tp|p=33638944|t=2021. The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study.|pdf=|usr=}}
{{tp|p=33581688|t=2021. Chemical composition and pharmacological mechanism of ephedra-glycyrrhiza drug pair against coronavirus disease 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=33811756|t=2021. Beneficial effect of Arbidol in the management of COVID-19 infection.|pdf=|usr=}}
{{tp|p=33788172|t=2021. Severe vitamin D deficiency is not related to SARS-CoV-2 infection but may increase mortality risk in hospitalized adults: a retrospective case-control study in an Arab Gulf country.|pdf=|usr=}}
{{tp|p=33532128|t=2021. Metabolic Healthy Obesity, Vitamin D Status, and Risk of COVID-19.|pdf=|usr=}}
{{tp|p=33532123|t=2021. Low level of Vitamin C and dysregulation of Vitamin C transporter might be involved in the severity of COVID-19 Infection.|pdf=|usr=}}
{{tp|p=33815870|t=2021. Mesenchymal Stem Cells for the Compassionate Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID 19.|pdf=|usr=}}
{{tp|p=33815867|t=2021. SARS-CoV-2: the "Uncensored" Truth about Its Origin and Adipose-Derived Mesenchymal Stem Cells as New Potential Immune-Modulatory Weapon.|pdf=|usr=}}
{{tp|p=33738381|t=2021. Progress in the risk assessment of hydroxychloroquine in frail elderly people.|pdf=|usr=}}
{{tp|p=33659771|t=2021. Bacillus Calmette-Guerin (BCG): the adroit vaccine.|pdf=|usr=}}
{{tp|p=33643776|t=2021. Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA).|pdf=|usr=}}
{{tp|p=33657648|t=2021. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation.|pdf=|usr=}}
{{tp|p=33722299|t=2021. COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI).|pdf=|usr=}}
{{tp|p=33546745|t=2021. Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma.|pdf=|usr=}}
{{tp|p=33791156|t=2021. Screening strategy of TMPRSS2 inhibitors by FRET-based enzymatic activity for TMPRSS2-based cancer and COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33617817|t=2021. Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19.|pdf=|usr=}}
{{tp|p=33815925|t=2021. Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=}}
{{tp|p=33748918|t=2021. Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione.|pdf=|usr=}}
{{tp|p=33742196|t=2021. Vitamin D and COVID-19: Can it be protective?|pdf=|usr=}}
{{tp|p=33714645|t=2021. Emergency department administration of COVID-19 antibody therapies: Early experience.|pdf=|usr=}}
{{tp|p=33821938|t=2021. COVID-19 vaccines in tribal communities save lives, preserve culture.|pdf=|usr=}}
{{tp|p=33791780|t=2021. Children's hospital celebrates successful COVID-19 vaccine rollout.|pdf=|usr=}}
{{tp|p=33798480|t=2021. Anti-severe acute respiratory syndrome coronavirus 2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination.|pdf=|usr=}}
{{tp|p=33812808|t=2021. Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy.|pdf=|usr=}}
{{tp|p=33540139|t=2021. Coronavirus disease 2019 vaccine in pregnant women: not so far! The importance of counseling and the need for evidence-based data.|pdf=|usr=}}
{{tp|p=33822639|t=2021. In Silico investigation of the viroporin E as a vaccine target against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33534047|t=2021. Methylprednisolone in adults hospitalized with COVID-19 pneumonia : An open-label randomized trial (GLUCOCOVID).|pdf=|usr=}}
{{tp|p=33638618|t=2021. Silver nanoparticles as a potential treatment against SARS-CoV-2: A review.|pdf=|usr=}}
{{tp|p=33558825|t=2021. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee.|pdf=|usr=}}
{{tp|p=33747340|t=2021. May polyethylene glycol be the cause of anaphylaxis to mRNA COVID-19 vaccines?|pdf=|usr=}}
{{tp|p=33728315|t=2021. Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature.|pdf=|usr=}}
{{tp|p=33708343|t=2021. Targeting mesenchymal stem cell therapy for severe pneumonia patients.|pdf=|usr=}}
{{tp|p=33816150|t=2021. Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review.|pdf=|usr=}}
{{tp|p=33816149|t=2021. Bottom-up analysis of emergent properties of N-acetylcysteine as an adjuvant therapy for COVID-19.|pdf=|usr=}}
{{tp|p=33585175|t=2021. Emerging therapeutics in the management of COVID-19.|pdf=|usr=}}
{{tp|p=33691913|t=2021. Efficacy and safety of COVID-19 vaccines: a systematic review.|pdf=|usr=}}
{{tp|p=33606519|t=2021. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.|pdf=|usr=}}
{{tp|p=33738063|t=2021. Design and Structure-Activity Relationship of a Potent Furin Inhibitor Derived from Influenza Hemagglutinin.|pdf=|usr=}}
{{tp|p=33615193|t=2021. Glycosylation of SARS-CoV-2 Steers Evolutionary Outcomes in the Postvaccination Phase.|pdf=|usr=}}
{{tp|p=33615192|t=2021. Docking Prediction of Levodopa in the Receptor Binding Domain of Spike Protein of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33615189|t=2021. Identification of Novel MicroRNAs as Promising Therapeutics for SARS-CoV-2 by Regulating the EGFR-ADAM17 Axis: An In Silico Analysis.|pdf=|usr=}}
{{tp|p=33792500|t=2021. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society for Allergy and Clinical Immunology (BelSACI).|pdf=|usr=}}
{{tp|p=33547771|t=2021. Allergic Reactions to COVID-19 Vaccines: An Allergist's Perspective.|pdf=|usr=}}
{{tp|p=33779985|t=2021. The potential neurological effect of the COVID-19 vaccines: A review.|pdf=|usr=}}
{{tp|p=33710026|t=2021. Tenofovir-based PrEP for COVID-19: an untapped opportunity?|pdf=|usr=}}
{{tp|p=33619997|t=2021. Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia.|pdf=|usr=}}
{{tp|p=33750742|t=2021. New SARS-CoV-2 Variants Challenge Vaccines Protection.|pdf=|usr=}}
{{tp|p=33787294|t=2021. Reply to "Unilateral Axillary Lymphadenopathy After Coronavirus Disease (COVID-19) Vaccination".|pdf=|usr=}}
{{tp|p=33617289|t=2021. Unilateral Axillary Lymphadenopathy After Coronavirus Disease (COVID-19) Vaccination.|pdf=|usr=}}
{{tp|p=33646823|t=2021. COVID-19 Vaccination-Related Uptake on FDG PET/CT: An Emerging Dilemma and Suggestions for Management.|pdf=|usr=}}
{{tp|p=33543649|t=2021. Management of Unilateral Axillary Lymphadenopathy Detected on Breast MRI in the Era of Coronavirus Disease (COVID-19) Vaccination.|pdf=|usr=}}
{{tp|p=33624520|t=2021. Coronavirus Disease (COVID-19) Vaccination Associated Axillary Adenopathy: Imaging Findings and Follow-Up Recommendations in 23 Women.|pdf=|usr=}}
{{tp|p=33617288|t=2021. Mitigating the Impact of Coronavirus Disease (COVID-19) Vaccinations on Patients Undergoing Breast Imaging Examinations: A Pragmatic Approach.|pdf=|usr=}}
{{tp|p=33528947|t=2021. BCG immunization and COVID-19 disease association.|pdf=|usr=}}
{{tp|p=33528938|t=2021. Inhaled corticosteroids may have a protective effect against coronavirus infection.|pdf=|usr=}}
{{tp|p=33811364|t=2021. Vaccines and Allergic reactions: The past, the current COVID-19 pandemic, and future perspectives.|pdf=|usr=}}
{{tp|p=33811358|t=2021. Management of anaphylaxis due to COVID-19 vaccines in the elderly.|pdf=|usr=}}
{{tp|p=33811344|t=2021. Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing.|pdf=|usr=}}
{{tp|p=33609346|t=2021. Prakriti Analysis of COVID 19 Patients: An Observational Study.|pdf=|usr=}}
{{tp|p=33683189|t=2021. Add-On Chinese Medicine for Coronavirus Disease 2019 (ACCORD): A Retrospective Cohort Study of Hospital Registries.|pdf=|usr=}}
{{tp|p=33642127|t=2021. Neuroleptic malignant syndrome following COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=33784482|t=2021. A Recombinant Fragment of Human Surfactant Protein D Binds Spike Protein and Inhibits Infectivity and Replication of SARS-CoV-2 in Clinical Samples.|pdf=|usr=}}
{{tp|p=33770450|t=2021. COVID-19 and Coagulopathy.|pdf=|usr=}}
{{tp|p=33759735|t=2021. What Are COVID-19 Vaccines?|pdf=|usr=}}
{{tp|p=33590992|t=2021. "Remdesivir-Associated Pancreatitis".|pdf=|usr=}}

{{tp|p=33564823|t=2021. Biases in evaluating the safety and effectiveness of drugs for covid-19: designing real-world evidence studies.|pdf=|usr=}}
{{tp|p=33599721|t=2021. Impact of hydroxychloroquine on disease progression and ICU admissions in patients with SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33617629|t=2021. Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect.|pdf=|usr=}}
{{tp|p=33606296|t=2021. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=33580970|t=2021. Familial thrombocytopenia flare-up following the first dose of mRNA-1273 Covid-19 vaccine.|pdf=|usr=}}
{{tp|p=33476455|t=2021. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine.|pdf=|usr=}}
{{tp|p=33705721|t=2021. Bacillus Calmette-Guerin Vaccine and Nonspecific Immunity.|pdf=|usr=}}
{{tp|p=33667433|t=2021. Association of Pre-Admission Statin Use With Reduced In-Hospital Mortality in COVID-19.|pdf=|usr=}}
{{tp|p=33545113|t=2021. Inclusion of pregnant individuals among priority populations for coronavirus disease 2019 vaccination for all 50 states in the United States.|pdf=|usr=}}
{{tp|p=33539825|t=2021. Professionally responsible coronavirus disease 2019 vaccination counseling of obstetrical and gynecologic patients.|pdf=|usr=}}
{{tp|p=33529575|t=2021. The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations.|pdf=|usr=}}
{{tp|p=33775692|t=2021. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study.|pdf=|usr=}}
{{tp|p=33727113|t=2021. Prioritization of pregnant individuals in state plans for coronavirus disease 2019 vaccination.|pdf=|usr=}}
{{tp|p=33621715|t=2021. Reply: Coronavirus disease 2019 vaccines in pregnancy.|pdf=|usr=}}
{{tp|p=33621714|t=2021. Coronavirus disease 2019 vaccines in pregnancy.|pdf=|usr=}}
{{tp|p=33540140|t=2021. Reply to: Coronavirus disease 2019 vaccine in pregnant women: not so far! The importance of counseling and the need for evidence-based data.|pdf=|usr=}}
{{tp|p=33771762|t=2021. Pregnant women's perspectives on severe acute respiratory syndrome coronavirus 2 vaccine.|pdf=|usr=}}
{{tp|p=33561380|t=2021. Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures.|pdf=|usr=}}
{{tp|p=33632650|t=2021. The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine.|pdf=|usr=}}
{{tp|p=33641268|t=2021. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021.|pdf=|usr=}}
{{tp|p=33641264|t=2021. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020.|pdf=|usr=}}
{{tp|p=33555140|t=2021. The advisory Committee on Immunization practices' updated interim recommendation for allocation of COVID-19 vaccine-United states, December 2020.|pdf=|usr=}}
{{tp|p=33720844|t=2021. Dexamethasone and COVID-19: Strategies in Low- and Middle-Income Countries to Tackle Steroid-Related Strongyloides Hyperinfection.|pdf=|usr=}}
{{tp|p=33774261|t=2021. COVID-19 vaccines: A race against time.|pdf=|usr=}}
{{tp|p=33771754|t=2021. Even vaccinated against COVID-19, we must continue to wear a mask.|pdf=|usr=}}
{{tp|p=33608752|t=2021. Screening and evaluation of anti-SARS-CoV-2 components from Ephedra sinica by ACE2/CMC-HPLC-IT-TOF-MS approach.|pdf=|usr=}}
{{tp|p=33612558|t=2021. Optimization of Analytical Procedure for In-hospital Rapid Quantification of Serum Level of Favipiravir in the Pharmacological Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33606889|t=2021. Re(I) Tricarbonyl Complexes as Coordinate Covalent Inhibitors for the SARS-CoV-2 Main Cysteine Protease.|pdf=|usr=}}
{{tp|p=33655614|t=2021. Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors.|pdf=|usr=}}
{{tp|p=33561300|t=2021. Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection.|pdf=|usr=}}
{{tp|p=33775077|t=2021. Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.|pdf=|usr=}}
{{tp|p=33781933|t=2021. Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=33775902|t=2021. Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions: Early report.|pdf=|usr=}}
{{tp|p=33550776|t=2021. Review of COVID-19 Vaccines and Their Evidence in Older Adults.|pdf=|usr=}}
{{tp|p=33769829|t=2021. COVID-19 Vaccine: Practical Clinical Considerations.|pdf=|usr=}}
{{tp|p=33721523|t=2021. Correction: Remdesivir for Adults With COVID-19.|pdf=|usr=}}
{{tp|p=33560863|t=2021. Major Update: Remdesivir for Adults With COVID-19 : A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points.|pdf=|usr=}}
{{tp|p=33560862|t=2021. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).|pdf=|usr=}}
{{tp|p=33646837|t=2021. Risk Compensation and COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=33721540|t=2021. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19.|pdf=|usr=}}
{{tp|p=33721539|t=2021. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19.|pdf=|usr=}}
{{tp|p=33721533|t=2021. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19.|pdf=|usr=}}
{{tp|p=33617726|t=2021. Web Exclusive. Annals On Call - Pregnancy, Lactation, and the COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=33819057|t=2021. Administration of a Second Dose of the Moderna COVID-19 Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports.|pdf=|usr=}}
{{tp|p=33620016|t=2021. Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial.|pdf=|usr=}}
{{tp|p=33815783|t=2021. Oxford-AstraZeneca COVID-19 vaccine (AZD1222) is ideal for resource-constrained low- and middle-income countries.|pdf=|usr=}}
{{tp|p=33585031|t=2021. "Tocilizumab-an option for patients with COVID-19 associated cytokine release syndrome: A single center experience", a retrospective study-original article.|pdf=|usr=}}
{{tp|p=33552506|t=2021. SARS-CoV-2 vaccine candidates: A beginning of the end of COVID-19 pandemic- Editorial.|pdf=|usr=}}
{{tp|p=33794291|t=2021. Estrogen and COVID-19: friend or foe?|pdf=|usr=}}
{{tp|p=33691446|t=2021. The pharmacological mechanism of Huashi Baidu Formula for the treatment of COVID-19 by combined network pharmacology and molecular docking.|pdf=|usr=}}
{{tp|p=33762264|t=2021. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.|pdf=|usr=}}
{{tp|p=33563595|t=2021. EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs.|pdf=|usr=}}
{{tp|p=33547062|t=2021. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19.|pdf=|usr=}}
{{tp|p=33589438|t=2021. Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider.|pdf=|usr=}}
{{tp|p=33807320|t=2021. Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia.|pdf=|usr=}}
{{tp|p=33809983|t=2021. Comparative Investigation of Composition, Antifungal, and Anti-Inflammatory Effects of the Essential Oil from Three Industrial Hemp Varieties from Italian Cultivation.|pdf=|usr=}}
{{tp|p=33558301|t=2021. Remdesivir for COVID-19: Why Not Dose Higher?|pdf=|usr=}}
{{tp|p=33558300|t=2021. Considering Personalized Interferon Beta Therapy for COVID-19.|pdf=|usr=}}
{{tp|p=33558299|t=2021. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33558296|t=2021. Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33526482|t=2021. Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33649117|t=2021. The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells.|pdf=|usr=}}
{{tp|p=33649113|t=2021. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33593840|t=2021. Anaphylaxis Due to Remdesivir.|pdf=|usr=}}
{{tp|p=33578849|t=2021. Potential Role of Antioxidant and Anti-Inflammatory Therapies to Prevent Severe SARS-Cov-2 Complications.|pdf=|usr=}}
{{tp|p=33535459|t=2021. Native High-Density Lipoproteins (HDL) with Higher Paraoxonase Exerts a Potent Antiviral Effect against SARS-CoV-2 (COVID-19), While Glycated HDL Lost the Antiviral Activity.|pdf=|usr=}}
{{tp|p=33713730|t=2021. Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors.|pdf=|usr=}}
{{tp|p=33813272|t=2021. ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model.|pdf=|usr=}}
{{tp|p=33808612|t=2021. Changes in 25-(OH) Vitamin D Levels during the SARS-CoV-2 Outbreak: Lockdown-Related Effects and First-to-Second Wave Difference-An Observational Study from Northern Italy.|pdf=|usr=}}
{{tp|p=33799618|t=2021. Lymphadenopathy after BNT162b2 Covid-19 Vaccine: Preliminary Ultrasound Findings.|pdf=|usr=}}
{{tp|p=33801808|t=2021. Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33800947|t=2021. Targeting MMP-Regulation of Inflammation to Increase Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis.|pdf=|usr=}}
{{tp|p=33810129|t=2021. Antiviral Cyanometabolites-A Review.|pdf=|usr=}}
{{tp|p=33810011|t=2021. Deep Learning for Novel Antimicrobial Peptide Design.|pdf=|usr=}}
{{tp|p=33808721|t=2021. Comprehensive Virtual Screening of the Antiviral Potentialities of Marine Polycyclic Guanidine Alkaloids against SARS-CoV-2 (COVID-19).|pdf=|usr=}}
{{tp|p=33709491|t=2021. Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies.|pdf=|usr=}}
{{tp|p=33684258|t=2021. Neutralizing Aptamers Block S/RBD-ACE2 Interactions and Prevent Host Cell Infection.|pdf=|usr=}}
{{tp|p=33683787|t=2021. A SARS-CoV-2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD-Independent Mechanism.|pdf=|usr=}}
{{tp|p=33735603|t=2021. A Role for Steroids in COVID-19-associated Pneumonitis at Six-Week Follow-Up?|pdf=|usr=}}
{{tp|p=33735602|t=2021. Reply: A Role for Steroids in COVID-19-associated Pneumonitis at Six-Week Follow-Up?|pdf=|usr=}}
{{tp|p=33721541|t=2021. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19.|pdf=|usr=}}
{{tp|p=33646836|t=2021. In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 >/=14 d after the 2nd dose.|pdf=|usr=}}
{{tp|p=33646835|t=2021. In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.|pdf=|usr=}}
{{tp|p=33554941|t=2020. COVID-19 reminds us: community vitamin D deficiency.|pdf=|usr=}}
{{tp|p=33710649|t=2021. ANA Investigates: Neurological Complications of COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=33657863|t=2021. Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review.|pdf=|usr=}}
{{tp|p=33757968|t=2021. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.|pdf=|usr=}}
{{tp|p=33741555|t=2021. Safety ofthefirstdose ofmRNA SARS-CoV-2vaccines inpatients with rheumatic and musculoskeletal diseases.|pdf=|usr=}}
{{tp|p=33607929|t=2021. N-Acetylcysteine and Hydrogen Sulfide in Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=33704086|t=2020. The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review.|pdf=|usr=}}
{{tp|p=33568494|t=2021. SARS-CoV-2 genome and antibodies in breastmilk: a systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33740339|t=2021. No association between vitamin D status and COVID-19 infection in Sao Paulo, Brazil.|pdf=|usr=}}
{{tp|p=33636983|t=2021. Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit.|pdf=|usr=}}
{{tp|p=33770443|t=2021. Nutraceutical management of metabolic syndrome as a palliative and a therapeutic to coronavirus disease (COVID) crisis.|pdf=|usr=}}
{{tp|p=33779073|t=2021. Prophylaxis of COVID-19 with Hydroxychloroquine and Chloroquine.|pdf=|usr=}}
{{tp|p=33728796|t=2021. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1.|pdf=|usr=}}
{{tp|p=33645342|t=2021. Virus-associated ribozymes and nano carriers against COVID-19.|pdf=|usr=}}
{{tp|p=33786833|t=2021. SARS-CoV-2 (COVID-19) vaccination in dermatology patients on immunomodulatory and biologic agents: Recommendations from the Australasian Medical Dermatology Group.|pdf=|usr=}}
{{tp|p=33626309|t=2021. A clinical conundrum: clozapine and COVID-19.|pdf=|usr=}}
{{tp|p=33711361|t=2021. Mesenchymal stem cells: Biological characteristics and application in disease therapy.|pdf=|usr=}}
{{tp|p=33721722|t=2021. Wide-range direct detection of 25-hydroxyvitamin D3 using polyethylene-glycol-free gold nanorod based on LSPR aptasensor.|pdf=|usr=}}
{{tp|p=33797130|t=2021. Discovery of potent Covid-19 main protease inhibitors using integrated drug-repurposing strategy.|pdf=|usr=}}
{{tp|p=33687925|t=2021. Covid-19: Booster dose will be needed in autumn to avoid winter surge, says government adviser.|pdf=|usr=}}
{{tp|p=33664083|t=2021. Vitamin D and covid-19.|pdf=|usr=}}
{{tp|p=33658188|t=2021. Covid-19: Schedule breast screening before vaccine or 4 to 6 weeks after to avoid false positives, says guidance.|pdf=|usr=}}
{{tp|p=33757984|t=2021. Covid-19: variants and vaccination.|pdf=|usr=}}
{{tp|p=33757958|t=2021. Covid-19: Officials query data from AstraZeneca's US vaccine trial.|pdf=|usr=}}
{{tp|p=33753451|t=2021. Covid-19: AstraZeneca vaccine prevents 79% of symptomatic disease and 100% of severe disease, US study finds.|pdf=|usr=}}
{{tp|p=33653737|t=2021. Covid-19: Single dose of Pfizer and Oxford vaccines cuts risk of hospital admission by 80% in over 80s, data suggest.|pdf=|usr=}}
{{tp|p=33653708|t=2021. Covid-19: Where are we on vaccines and variants?|pdf=|usr=}}
{{tp|p=33741638|t=2021. Covid-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency.|pdf=|usr=}}
{{tp|p=33741559|t=2021. Covid-19: What do we know about Sputnik V and other Russian vaccines?|pdf=|usr=}}

{{tp|p=33711336|t=2021. Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E.|pdf=|usr=}}
{{tp|p=33549572|t=2021. Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir.|pdf=|usr=}}
{{tp|p=33714660|t=2021. Influence of Cytokine Release Syndrome in Severe COVID-19 Patients Treated With Tocilizumab Over the Quantiferon TB Gold Plus Results.|pdf=|usr=}}
{{tp|p=33527308|t=2021. DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?|pdf=|usr=}}
{{tp|p=33546870|t=2021. Immunoinformatics Approach for the Identification and Characterization of T Cell and B Cell Epitopes towards the Peptide-Based Vaccine against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33785208|t=2021. Probiotics in Prevention and Treatment of COVID-19: Current Perspective and Future Prospects.|pdf=|usr=}}
{{tp|p=33589286|t=2021. Bioinformatics Analysis for Screening of Therapeutic Drugs in COVID-19.|pdf=|usr=}}
{{tp|p=33747291|t=2021. It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?|pdf=|usr=}}
{{tp|p=33745067|t=2021. The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=33656063|t=2021. BRAZILIAN IBD STUDY GROUP POSITION STATEMENT ON SARS-COV2 VACCINATION.|pdf=|usr=}}
{{tp|p=33787036|t=2021. Nutritional practice in critically ill COVID-19 patients: A multicenter ambidirectional cohort study in Wuhan and Jingzhou.|pdf=|usr=}}
{{tp|p=33664546|t=2021. COVID-19 vaccines - are we there yet?|pdf=|usr=}}
{{tp|p=33664542|t=2021. Evolving evidence for immunosuppressants in COVID-19.|pdf=|usr=}}
{{tp|p=33629195|t=2021. Does remote ischaemic conditioning reduce inflammation? A focus on innate immunity and cytokine response.|pdf=|usr=}}
{{tp|p=33782651|t=2021. Perspectives on plant flavonoid quercetin-based drugs for novel SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33527080|t=2021. Virtual screening of phytochemical compounds as potential inhibitors against SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33526326|t=2021. The protective effect of rheumatic disease agents in COVID-19.|pdf=|usr=}}
{{tp|p=33723524|t=2021. Virus-inspired surface-nanoengineered antimicrobial liposome: A potential system to simultaneously achieve high activity and selectivity.|pdf=|usr=}}
{{tp|p=33527003|t=2021. Molecular dynamics analysis of phytochemicals from Ageratina adenophora against COVID-19 main protease (M(pro)) and human angiotensin-converting enzyme 2 (ACE2).|pdf=|usr=}}
{{tp|p=33520034|t=2021. Therapeutic potential of medicinal plants against COVID-19: The role of antiviral medicinal metabolites.|pdf=|usr=}}
{{tp|p=33817352|t=2021. Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor.|pdf=|usr=}}
{{tp|p=33681482|t=2021. In silico investigation of potential inhibitors to main protease and spike protein of SARS-CoV-2 in propolis.|pdf=|usr=}}
{{tp|p=33756342|t=2021. A tissue- and gender-specific regulation of the SARS-CoV-2 receptor ACE2 by p53 in pigs.|pdf=|usr=}}
{{tp|p=33571909|t=2021. 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro.|pdf=|usr=}}
{{tp|p=33588235|t=2021. EGCG, a green tea polyphenol, inhibits human coronavirus replication in vitro.|pdf=|usr=}}
{{tp|p=33722535|t=2021. Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?|pdf=|usr=}}
{{tp|p=33628506|t=2021. A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections.|pdf=|usr=}}
{{tp|p=33731300|t=2021. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate.|pdf=|usr=}}
{{tp|p=33552630|t=2021. Peptides-based vaccine against SARS-nCoV-2 antigenic fragmented synthetic epitopes recognized by T cell and beta-cell initiation of specific antibodies to fight the infection.|pdf=|usr=}}
{{tp|p=33532594|t=2021. IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development.|pdf=|usr=}}
{{tp|p=33795932|t=2021. The Relevance of Bioinformatics Applications in the Discovery of Vaccine Candidates and Potential Drugs for COVID-19 Treatment.|pdf=|usr=}}
{{tp|p=33693506|t=2021. COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases.|pdf=|usr=}}
{{tp|p=33630276|t=2021. The Role of Diet and Supplementation of Natural Products in COVID-19 Prevention.|pdf=|usr=}}
{{tp|p=33574654|t=2021. Convalescent Plasma for the Treatment of Severe COVID-19.|pdf=|usr=}}
{{tp|p=33736953|t=2021. Phytochemicals against SARS-CoV as potential drug leads.|pdf=|usr=}}
{{tp|p=33727051|t=2021. Development of multi-epitope peptide-based vaccines against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33727050|t=2021. A brief review on potential application of mesenchymal stem cell and secretome in combating mortality and morbidity in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33640332|t=2021. Exploring algae and cyanobacteria as a promising natural source of antiviral drug against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33608241|t=2021. Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33589377|t=2021. Neutralizing monoclonal antibodies for COVID-19 treatment and prevention.|pdf=|usr=}}
{{tp|p=33542545|t=2021. COVID-19, adrenal gland, glucocorticoids, and adrenal insufficiency.|pdf=|usr=}}
{{tp|p=33761591|t=2021. Research progress of traditional Chinese medicine against COVID-19.|pdf=|usr=}}
{{tp|p=33561649|t=2021. Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies.|pdf=|usr=}}
{{tp|p=33556871|t=2021. An update review of emerging small-molecule therapeutic options for COVID-19.|pdf=|usr=}}
{{tp|p=33550049|t=2021. Targets and strategies for vaccine development against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33529945|t=2021. Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review.|pdf=|usr=}}
{{tp|p=33721754|t=2021. Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33811098|t=2021. Impact of corticosteroids in hospitalised COVID-19 patients.|pdf=|usr=}}
{{tp|p=33792391|t=2021. Treatment of COVID-19: a review of current and prospective pharmacotherapies.|pdf=|usr=}}
{{tp|p=33769885|t=2021. COVID-19 vaccines and vaccine administration.|pdf=|usr=}}
{{tp|p=33641685|t=2021. Zinc deficiency as a possible risk factor for increased susceptibility and severe progression of Corona Virus Disease 19.|pdf=|usr=}}
{{tp|p=33811310|t=2021. Supplementary Therapeutic Possibilities to Alleviate Myocardial Damage Due to Microvascular Dysfunction in Coronavirus Disease 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=33811809|t=2021. BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33811811|t=2021. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2.|pdf=|usr=}}
{{tp|p=33799966|t=2021. Mesenchymal Stem Cell-Derived Exosomes Exhibit Promising Potential for Treating SARS-CoV-2-Infected Patients.|pdf=|usr=}}
{{tp|p=33798507|t=2021. Role of phytoconstituents in the management of COVID-19.|pdf=|usr=}}
{{tp|p=33821213|t=2021. COVID-19 into Chemical Science Perspective: Chemical Preventive Measures and Drug Development.|pdf=|usr=}}
{{tp|p=33820462|t=2021. Circadian clock modulating small molecules repurposing as inhibitors of SARS-CoV-2 M(pro) for pharmacological interventions in COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33821193|t=2021. Vitamin D and COVID-19 in an immunocompromised patient with multiple comorbidities-A Case Report.|pdf=|usr=}}
{{tp|p=33821192|t=2021. Combination of convalescent plasma therapy and repurposed drugs to treat severe COVID-19 patient with multimorbidity.|pdf=|usr=}}
{{tp|p=33558274|t=2021. Covid-19: First UK vaccine safety data are "reassuring," says regulator.|pdf=|usr=}}
{{tp|p=33541863|t=2021. Covid-19: Israel sees new infections plummet following vaccinations.|pdf=|usr=}}
{{tp|p=33536232|t=2021. Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing interval.|pdf=|usr=}}
{{tp|p=33536182|t=2021. Why aren't covid-19 vaccines being manufactured in standard prefilled syringes?|pdf=|usr=}}
{{tp|p=33632676|t=2021. Covid-19: Pfizer BioNTech vaccine reduced cases by 94% in Israel, shows peer reviewed study.|pdf=|usr=}}
{{tp|p=33627357|t=2021. Optimal dosing interval for covid-19 vaccines: we need clinical trial evidence and to consider past infection.|pdf=|usr=}}
{{tp|p=33622695|t=2021. Behind the scenes of the Pfizer BioNTech covid-19 vaccine trial.|pdf=|usr=}}
{{tp|p=33619168|t=2021. Defer vaccination of people who have had covid-19.|pdf=|usr=}}
{{tp|p=33619037|t=2021. Covid-19: First doses of vaccines in Scotland led to a substantial fall in hospital admissions.|pdf=|usr=}}
{{tp|p=33531342|t=2021. Covid-19: Russian vaccine efficacy is 91.6%, show phase III trial results.|pdf=|usr=}}
{{tp|p=33531333|t=2021. Covid-19: People who have had infection might only need one dose of mRNA vaccine.|pdf=|usr=}}
{{tp|p=33574097|t=2021. Covid-19: Arthritis drug tocilizumab reduces deaths in hospitalised patients, study shows.|pdf=|usr=}}
{{tp|p=33526412|t=2021. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant.|pdf=|usr=}}
{{tp|p=33795232|t=2021. Covid-19: Pfizer reports 100% vaccine efficacy in children aged 12 to 15.|pdf=|usr=}}
{{tp|p=33795218|t=2021. Covid-19: Moderna and Pfizer vaccines prevent infections as well as symptoms, CDC study finds.|pdf=|usr=}}
{{tp|p=33760277|t=2021. Will AstraZeneca be able to provide clinical trial data on its COVID-19 vaccine efficacy in older adults?|pdf=|usr=}}
{{tp|p=33763917|t=2021. Liver and kidney function in patients with Covid-19 treated with remdesivir.|pdf=|usr=}}
{{tp|p=33742473|t=2021. Zinc supplementation as an adjunct therapy for COVID-19: Challenges and opportunities.|pdf=|usr=}}
{{tp|p=33539240|t=2021. Corticosteroids, mortality and mechanical ventilation in COVID-19.|pdf=|usr=}}
{{tp|p=33539237|t=2021. COVID-19 vaccination in the UK: is it time to celebrate?|pdf=|usr=}}
{{tp|p=33632683|t=2021. COVID-19 vaccine availability: what are the side effects?|pdf=|usr=}}
{{tp|p=33769552|t=2021. Dual inhibition of CB1 receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID-19.|pdf=|usr=}}
{{tp|p=33729819|t=2021. Could boron-containing compounds (BCCs) be effective against SARS-CoV-2 as anti-viral agent?|pdf=|usr=}}
{{tp|p=33618530|t=2021. Potential therapeutic road for targeting the SARS-CoV-2 at throat.|pdf=|usr=}}
{{tp|p=33618529|t=2021. The relationship between vitamin D and the severity of COVID-19.|pdf=|usr=}}
{{tp|p=33622040|t=2021. The Canadian Society of Breast Imaging/ Canadian Association of Radiologists' Recommendations for the Management of Axillary Adenopathy in Patients With Recent COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=33534645|t=2021. Challenges and Opportunities for COVID-19 Vaccines in Patients with Cancer.|pdf=|usr=}}
{{tp|p=33740455|t=2021. Antivirals with common targets against highly pathogenic viruses.|pdf=|usr=}}
{{tp|p=33740454|t=2021. Novel approaches for vaccine development.|pdf=|usr=}}
{{tp|p=33653052|t=2021. Combination anti-coronavirus therapies based on nonlinear mathematical models.|pdf=|usr=}}
{{tp|p=33647240|t=2021. Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.|pdf=|usr=}}
{{tp|p=33651072|t=2021. Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides.|pdf=|usr=}}
{{tp|p=33719401|t=2021. Chemical and Biochemical Aspects of Molecular Hydrogen in Treating Kawasaki Disease and COVID-19.|pdf=|usr=}}
{{tp|p=33797868|t=2021. Inspecting the Mechanism of Fragment Hits Binding on SARS-CoV-2 M(pro) by Using Supervised Molecular Dynamics (SuMD) Simulations.|pdf=|usr=}}
{{tp|p=33660489|t=2021. 25-Hydroxyvitamin D concentrations in COVID-19 patients hospitalized in intensive care unit during the first wave and the second wave of the pandemic.|pdf=|usr=}}
{{tp|p=33554566|t=2021. Vitamin-D levels and intensive care unit outcomes of a cohort of critically ill COVID-19 patients.|pdf=|usr=}}
{{tp|p=33813758|t=2021. Adverse reactions to COVID-19 vaccines: A practical approach.|pdf=|usr=}}
{{tp|p=33719087|t=2021. Dietary deprivation during the COVID-19 pandemic producing acquired vulval zinc-deficiency dermatitis.|pdf=|usr=}}
{{tp|p=33577095|t=2021. The "coloring wipes" phenomenon: a peculiar skin pigmentation induced by ascorbic acid observed during lockdown.|pdf=|usr=}}
{{tp|p=33719081|t=2021. Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33684970|t=2021. Nicorandil a magic bullet or a double edged sword in critically ill COVID-19 patients?|pdf=|usr=}}
{{tp|p=33560913|t=2020. CRISPR-Cas13 as an Antiviral Strategy for Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=33769769|t=2021. Plasmapheresis Efficiency in Coronavirus Disease 2019: More Related to What You Add and Not What You Take Away?|pdf=|usr=}}
{{tp|p=33731635|t=2021. Is "Mega-Dose" IV Vitamin C Required for Septic and Critical Coronavirus Disease 2019 Patients?|pdf=|usr=}}
{{tp|p=33591008|t=2021. The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness.|pdf=|usr=}}
{{tp|p=33685299|t=2021. Lactoferrin: an overview of its main functions, immunomodulatory and antimicrobial role, and clinical significance.|pdf=|usr=}}
{{tp|p=33645486|t=2021. Integrated Nutritional Supports for Diabetic Patients during COVID-19 Infection: A Comprehensive Review.|pdf=|usr=}}
{{tp|p=33797367|t=2021. Novel Pulmonary Delivery of Antiviral Drugs for Treating COVID-19 in Patients with Parkinson's Disease.|pdf=|usr=}}
{{tp|p=33588727|t=2021. Small-molecule antiviral agents in ongoing clinical trials for COVID-19.|pdf=|usr=}}
{{tp|p=33781188|t=2021. Protein-ligand Docking Simulations with AutoDock4 Focused on the Main Protease of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33550959|t=2021. Natural Products as Potential Agents Against SARS-CoV and SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33563148|t=2021. Nucleoside Inhibitors of Coronaviruses.|pdf=|usr=}}

{{tp|p=33691249|t=2021. Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33662680|t=2021. Flavonoids against the SARS-CoV-2 induced inflammatory storm.|pdf=|usr=}}
{{tp|p=33732744|t=2021. Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients.|pdf=|usr=}}
{{tp|p=33728324|t=2021. Immunoinformatics and Molecular Docking Studies Predicted Potential Multiepitope-Based Peptide Vaccine and Novel Compounds against Novel SARS-CoV-2 through Virtual Screening.|pdf=|usr=}}
{{tp|p=33708993|t=2021. Impact of Ethnicity and Underlying Comorbidity on COVID-19 Inhospital Mortality: An Observational Study in Abu Dhabi, UAE.|pdf=|usr=}}
{{tp|p=33564683|t=2021. Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development.|pdf=|usr=}}
{{tp|p=33731494|t=2021. Antiviral Efficacy of Pralatrexate against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33557097|t=2021. In Silico Screening of Natural Products Isolated from Mexican Herbal Medicines against COVID-19.|pdf=|usr=}}
{{tp|p=33671652|t=2021. Screening and Molecular Modeling Evaluation of Food Peptides to Inhibit Key Targets of COVID-19 Virus.|pdf=|usr=}}
{{tp|p=33671255|t=2021. Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages.|pdf=|usr=}}
{{tp|p=33676041|t=2021. Molecular designing, crystal structure determination and in silico screening of copper(II) complexes bearing 8-hydroxyquinoline derivatives as anti-COVID-19.|pdf=|usr=}}
{{tp|p=33667900|t=2021. Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation.|pdf=|usr=}}
{{tp|p=33753260|t=2021. SARS-CoV-2 main protease inhibition by compounds isolated from Luffa cylindrica using molecular docking.|pdf=|usr=}}
{{tp|p=33689873|t=2021. Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33662537|t=2021. Design, synthesis and biological evaluation of 2-aminoquinazolin-4(3H)-one derivatives as potential SARS-CoV-2 and MERS-CoV treatments.|pdf=|usr=}}
{{tp|p=33775840|t=2021. Identification of non-covalent SARS-CoV-2 main protease inhibitors by a virtual screen of commercially available drug-like compounds.|pdf=|usr=}}
{{tp|p=33711743|t=2021. Evaluation of potential anti-RNA-dependent RNA polymerase (RdRP) drugs against the newly emerged model of COVID-19 RdRP using computational methods.|pdf=|usr=}}
{{tp|p=33585808|t=2021. An update to monoclonal antibody as therapeutic option against COVID-19.|pdf=|usr=}}
{{tp|p=33590853|t=2021. In vitro selection of an RNA aptamer yields an interleukin-6/interleukin-6 receptor interaction inhibitor.|pdf=|usr=}}
{{tp|p=33624754|t=2021. Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates.|pdf=|usr=}}
{{tp|p=33746182|t=2021. COVID-19 vaccine research focusses on safety, efficacy, immunoinformatics, and vaccine production and delivery: a bibliometric analysis based on VOSviewer.|pdf=|usr=}}
{{tp|p=33612990|t=2021. Coronavirus-Replikation: Mechanismus und Inhibition durch Remdesivir.|pdf=|usr=}}
{{tp|p=33612989|t=2021. COR-101, ein menschlicher Antikorper gegen COVID-19.|pdf=|usr=}}
{{tp|p=33629351|t=2021. Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID-19 and similar lung diseases.|pdf=|usr=}}
{{tp|p=33547723|t=2021. COVID-19 vaccines for rapid global impact.|pdf=|usr=}}
{{tp|p=33560402|t=2021. Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19.|pdf=|usr=}}
{{tp|p=33621948|t=2021. Effectiveness of convalescent plasma in Indian patients with COVID-19.|pdf=|usr=}}
{{tp|p=33789273|t=2021. Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment.|pdf=|usr=}}
{{tp|p=33721869|t=2021. Should the Therapeutic Apheresis Method Be Added to Treatment in the COVID-19 Outbreak?|pdf=|usr=}}
{{tp|p=33771096|t=2021. In silico comparative study of SARS-CoV-2 proteins and antigenic proteins in BCG, OPV, MMR and other vaccines: evidence of a possible putative protective effect.|pdf=|usr=}}
{{tp|p=33711981|t=2021. Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis.|pdf=|usr=}}
{{tp|p=33531083|t=2021. De novo design and bioactivity prediction of SARS-CoV-2 main protease inhibitors using recurrent neural network-based transfer learning.|pdf=|usr=}}
{{tp|p=33765919|t=2021. Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).|pdf=|usr=}}
{{tp|p=33673818|t=2021. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.|pdf=|usr=}}
{{tp|p=33761870|t=2021. Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial.|pdf=|usr=}}
{{tp|p=33706794|t=2021. Impact of previous exposure to systemic corticosteroids on unfavorable outcome in patients hospitalized for COVID-19.|pdf=|usr=}}
{{tp|p=33618696|t=2021. Proposal of selective wedge instillation of pulmonary surfactant for COVID-19 pneumonia based on computational fluid dynamics simulation.|pdf=|usr=}}
{{tp|p=33785004|t=2021. Protective role of intravesical BCG in COVID-19 severity.|pdf=|usr=}}
{{tp|p=33541971|t=2021. Steroid harms if given early in COVID-19 viraemia.|pdf=|usr=}}
{{tp|p=33622757|t=2021. COVID-19 cardiac injury and the use of colchicine.|pdf=|usr=}}
{{tp|p=33558355|t=2021. Examination of patient characteristics and hydroxychloroquine use based on the US Food and Drug Administration's recommendation: a cross-sectional analysis in New York.|pdf=|usr=}}
{{tp|p=33664123|t=2021. Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study.|pdf=|usr=}}
{{tp|p=33662986|t=2021. Desarrollo de vacunas contra el SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33564122|t=2021. Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection.|pdf=|usr=}}
{{tp|p=33823270|t=2021. Covid-19 vaccine and autoimmunity: Awakening the sleeping dragon.|pdf=|usr=}}
{{tp|p=33768222|t=2021. Single dose of a mRNA SARS-CoV-2 vaccine is associated with lower nasopharyngeal viral load among nursing home residents with asymptomatic COVID-19.|pdf=|usr=}}
{{tp|p=33749746|t=2021. Remdesivir: An antiviral still seeking a raison d'etre.|pdf=|usr=}}
{{tp|p=33819571|t=2021. Fourteen-day survival among older adults with severe infection with severe acute respiratory syndrome coronavirus 2 treated with corticosteroid: a cohort study.|pdf=|usr=}}
{{tp|p=33813110|t=2021. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial.|pdf=|usr=}}
{{tp|p=33705574|t=2021. Vaccines: Underlying Principles of Design and Testing.|pdf=|usr=}}
{{tp|p=33624299|t=2021. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33722106|t=2021. Adjunctive intravenous immunoglobulins (IVIg) for moderate-severe COVID-19: emerging therapeutic roles.|pdf=|usr=}}
{{tp|p=33810947|t=2021. Serum IP-10 and IL-7 levels are associated with disease severity of coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=33593661|t=2021. Granulocyte macrophage colony-stimulating factor has come of age: From a vaccine adjuvant to antiviral immunotherapy.|pdf=|usr=}}
{{tp|p=33814294|t=2021. Letter to the Editor in response to article: Hypocalcemia is associated with severe COVID-19: A systematic review and meta-analysis (Martha et al.).|pdf=|usr=}}
{{tp|p=33823331|t=2021. Impact of the vitamin D deficiency on COVID-19 infection and mortality in Asian countries.|pdf=|usr=}}
{{tp|p=33802453|t=2021. Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays.|pdf=|usr=}}
{{tp|p=33804914|t=2021. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=33588980|t=2021. Exploration of Association Between Respiratory Vaccinations With Infection and Mortality Rates of COVID-19.|pdf=|usr=}}
{{tp|p=33820650|t=2021. The Covid-19 infection: An opportunity to develop systematic vitamin D supplementation in psychiatry.|pdf=|usr=}}
{{tp|p=33819636|t=2021. Vitamin D Sufficiency and COVID-19: Is Vitamin D Binding Protein (and Its Polymorphism) the Missing Link?|pdf=|usr=}}
{{tp|p=33819635|t=2021. Authors' Reply: Vitamin D Sufficiency and COVID-19: Is Vitamin D Binding Protein (and Its Polymorphism) the Missing Link?|pdf=|usr=}}
{{tp|p=33769268|t=2021. Biological drugs in paediatric COVID-19 infection: what patients, which drug, how much and how long.|pdf=|usr=}}
{{tp|p=33635229|t=2021. The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events.|pdf=|usr=}}
{{tp|p=33527123|t=2021. On Setting Expectations for a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.|pdf=|usr=}}
{{tp|p=33782318|t=2021. 18F-FDG-Avid Lymph Nodes After COVID-19 Vaccination on 18F-FDG PET/CT.|pdf=|usr=}}
{{tp|p=33782299|t=2021. Axillary Lymph Nodes Hypermetabolism After BNT162b2 mRNA COVID-19 Vaccination in Cancer Patients Undergoing 18F-FDG PET/CT: A Cohort Study.|pdf=|usr=}}
{{tp|p=33661194|t=2021. COVID-19 Vaccine-Related Local FDG Uptake.|pdf=|usr=}}
{{tp|p=33661193|t=2021. COVID-19 Vaccination Manifesting as Incidental Lymph Nodal Uptake on 18F-FDG PET/CT.|pdf=|usr=}}
{{tp|p=33661192|t=2021. FDG PET Findings Post-COVID Vaccinations: Signs of the Times?|pdf=|usr=}}
{{tp|p=33795589|t=2021. DOTATATE -Avid Bilateral Axilla and Subpectoral Lymphadenopathy Induced From COVID-19 mRNA Vaccination Visualized on PET/CT.|pdf=|usr=}}
{{tp|p=33591026|t=2021. COVID-19 mRNA Vaccination-Induced Lymphadenopathy Mimics Lymphoma Progression on FDG PET/CT.|pdf=|usr=}}
{{tp|p=33793179|t=2021. Emergency Use Authorization for Bamlanivimab in Mild to Moderate COVID-19: Implications for CNS Practice.|pdf=|usr=}}
{{tp|p=33793172|t=2021. Emergency Use Authorization for Bamlanivimab in Mild to Moderate COVID-19: Implications for Clinical Nurse Specialist Practice.|pdf=|usr=}}
{{tp|p=33534255|t=2021. COVID-19 Vaccine: Development, Testing, and Distribution.|pdf=|usr=}}
{{tp|p=33534247|t=2021. COVID-19 Vaccine: Development, Testing, and Distribution.|pdf=|usr=}}
{{tp|p=33759449|t=2021. Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data.|pdf=|usr=}}
{{tp|p=33792037|t=2021. Effect of Corticosteroids on Mortality in Hospitalized COVID-19 Patients Not Receiving Invasive Mechanical Ventilation.|pdf=|usr=}}
{{tp|p=33769172|t=2021. Toxicity resulting from colchicine used to treat COVID-19 patients: a new challenge for clinical toxicologists.|pdf=|usr=}}
{{tp|p=33786990|t=2021. Adverse Drug Event Risk Assessment by the Virtual Addition of COVID-19 Repurposed Drugs to Medicare and Commercially Insured Patients' Drug Regimens: A Drug Safety Simulation Study.|pdf=|usr=}}
{{tp|p=33786981|t=2021. In vitro safety "clinical trial" of the cardiac liability of drug polytherapy.|pdf=|usr=}}
{{tp|p=33724440|t=2021. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease.|pdf=|usr=}}
{{tp|p=33765340|t=2021. Contested effects and chaotic policies: the 2020 story of (hydroxy) chloroquine for treating COVID-19.|pdf=|usr=}}
{{tp|p=33734435|t=2021. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.|pdf=|usr=}}
{{tp|p=33538665|t=2021. An Urgent Industrial Scheme both for Total Synthesis, and for Pharmaceutical Analytical Analysis of Umifenovir as an Anti-Viral API for Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33563150|t=2021. Targeting Viral RNA-Dependent RNA Polymerases as an Antiviral Therapy.|pdf=|usr=}}
{{tp|p=33605848|t=2021. Advances of Inorganic Materials in the Detection and Therapeutic Uses Against Coronaviruses.|pdf=|usr=}}
{{tp|p=33602071|t=2021. Viral Envelope Membrane: A Special Entry Pathway and a Promising Drug Target.|pdf=|usr=}}
{{tp|p=33622224|t=2021. SARS-CoV-2 proteins: Are they useful as targets for COVID-19 drugs and vaccines?|pdf=|usr=}}
{{tp|p=33535951|t=2021. Molecular Elucidation and Therapeutic Targeting for combating COVID19: Current Scenario and Future Prospective.|pdf=|usr=}}
{{tp|p=33602083|t=2021. Phyto-compounds from a rather poisonous plant, Strychnos nux-vomica, show high potency against SARS-CoV-2 RNA-dependent RNA polymerase.|pdf=|usr=}}
{{tp|p=33587365|t=2021. Coronavirus disease 2019 pandemic and alterations of body composition.|pdf=|usr=}}
{{tp|p=33629969|t=2021. Host-directed therapies for COVID-19.|pdf=|usr=}}
{{tp|p=33749558|t=2021. Herbal Medicine in Fighting Against COVID-19: New Battle with an Old Weapon.|pdf=|usr=}}
{{tp|p=33530904|t=2021. BCG Vaccination Program mitigates COVID19 Related Mortality: A Reality check.|pdf=|usr=}}
{{tp|p=33593256|t=2021. Unravelling The Immune Modulatory Effect Of Indian Spices To Impede The Transmission Of Covid-19: A Promising Approach.|pdf=|usr=}}
{{tp|p=33719967|t=2021. Tocilizumab: From Rheumatic Diseases to COVID-19.|pdf=|usr=}}
{{tp|p=33550966|t=2021. The Computational Intervention of Macrolide Antibiotics in the Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33591423|t=2021. mRNA-Based Vaccines and Mode of Action.|pdf=|usr=}}
{{tp|p=33751756|t=2021. Chitin-lipid interactions and the potential relationship between Demodex and SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33547204|t=2021. Association Between DPP-4 Inhibitors and COVID-19-Related Outcomes Among Patients With Type 2 Diabetes.|pdf=|usr=}}
{{tp|p=33663970|t=2021. Reply to letter of Davie et al. regarding the article: "Vitamin D concentrations and COVID-19 infection in UK Biobank" (Hastie et al.).|pdf=|usr=}}
{{tp|p=33652503|t=2021. Potential mechanisms of action of convalescent plasma in COVID-19.|pdf=|usr=}}
{{tp|p=33820581|t=2021. Roll out of COVID-19 vaccination in India: A SWOT analysis.|pdf=|usr=}}
{{tp|p=33817811|t=2021. Crocetin and related oxygen diffusion-enhancing compounds: Review of chemical synthesis, pharmacology, clinical development, and novel therapeutic applications.|pdf=|usr=}}
{{tp|p=33581321|t=2021. A new horizon for the old antibacterial drug clofoctol.|pdf=|usr=}}
{{tp|p=33770833|t=2021. CYP2D6 and CYP3A4 variants influence the risk and outcome of COVID-19 infection among rheumatoid arthritis patients maintained on hydroxychloroquine.|pdf=|usr=}}
{{tp|p=33757133|t=2021. Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review.|pdf=|usr=}}
{{tp|p=33726658|t=2021. The Biochemical Parameters and Vitamin D Levels in ICU Patients with Covid-19: A Cross-Sectional Study.|pdf=|usr=}}
{{tp|p=33725359|t=2021. Response to: COVID-19 re-infection. Vaccinated individuals as a potential source of transmission.|pdf=|usr=}}
{{tp|p=33675065|t=2021. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33772778|t=2021. A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.|pdf=|usr=}}

{{tp|p=33685635|t=2021. Putative antiviral effects of propofol in COVID-19.|pdf=|usr=}}
{{tp|p=33795925|t=2020. Neprilysin Inhibitors and Angiotensin(1-7) in COVID-19.|pdf=|usr=}}
{{tp|p=33609410|t=2021. Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action.|pdf=|usr=}}
{{tp|p=33608891|t=2021. Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study.|pdf=|usr=}}
{{tp|p=33580602|t=2021. Postvaccination anaphylaxis and mRNA-based SARS-CoV-2 vaccines-Much ado about nothing?|pdf=|usr=}}
{{tp|p=33685770|t=2021. Plant products in reducing spread of coronavirus infection (COVID-19).|pdf=|usr=}}
{{tp|p=33685772|t=2021. Supraclavicular lymphadenopathy following COVID-19 vaccination: an increasing presentation to the two-week wait neck lump clinic?|pdf=|usr=}}
{{tp|p=33761533|t=2021. SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.|pdf=|usr=}}
{{tp|p=33640910|t=2021. Berberine reduces circulating inflammatory mediators in patients with severe COVID-19.|pdf=|usr=}}
{{tp|p=33594349|t=2021. Bell's Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy.|pdf=|usr=}}
{{tp|p=33527097|t=2021. Clozapine, neutropenia and Covid-19: should clinicians be concerned? 3 months report.|pdf=|usr=}}
{{tp|p=33612882|t=2021. Immunonutrition in perioperative care of COVID-19 patients: an old weapon for a new disease?|pdf=|usr=}}
{{tp|p=33621543|t=2021. Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19.|pdf=|usr=}}
{{tp|p=33729394|t=2021. Immunity, virus evolution, and effectiveness of SARS-CoV-2 vaccines.|pdf=|usr=}}
{{tp|p=33623995|t=2021. A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an in silico investigation.|pdf=|usr=}}
{{tp|p=33592108|t=2021. Data science in unveiling COVID-19 pathogenesis and diagnosis: evolutionary origin to drug repurposing.|pdf=|usr=}}
{{tp|p=33583943|t=2021. Le vaccin a ARN pour la COVID-19 - quel risque allergique ?|pdf=|usr=}}
{{tp|p=33674059|t=2021. Vaccination anti COVID-19 pour les personnes souffrant de cancer : un imperatif medical et ethique.|pdf=|usr=}}
{{tp|p=33741139|t=2021. Nous devons respecter le schema vaccinal anti-SARS-CoV-2 sans decalage chez les patients atteints de cancer sous traitement.|pdf=|usr=}}
{{tp|p=33663776|t=2021. Repositionnement des antineoplasiques utilises en hematologie dans le traitement du COVID-19.|pdf=|usr=}}
{{tp|p=33788116|t=2021. Antiviral Drug Ivermectin at Nanomolar Concentrations Inhibits Glycine-Induced Chloride Current in Rat Hippocampal Neurons.|pdf=|usr=}}
{{tp|p=33727782|t=2021. In silico identification of compounds from Nigella sativa seed oil as potential inhibitors of SARS-CoV-2 targets.|pdf=|usr=}}
{{tp|p=33642851|t=2021. Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia.|pdf=|usr=}}
{{tp|p=33564223|t=2021. A proposed insight into the anti-viral potential of metallic nanoparticles against novel coronavirus disease-19 (COVID-19).|pdf=|usr=}}
{{tp|p=33654695|t=2020. Gut, metabolism and nutritional Support for COVID-19: Experiences from China.|pdf=|usr=}}
{{tp|p=33727379|t=2021. COVID-19 vaccine fast facts.|pdf=|usr=}}
{{tp|p=33727376|t=2021. Medication use during COVID-19: Review of recent evidence.|pdf=|usr=}}
{{tp|p=33689451|t=2021. Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 in vitro.|pdf=|usr=}}
{{tp|p=33688374|t=2021. Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients.|pdf=|usr=}}
{{tp|p=33747583|t=2021. Targeting Cytokine Storm in COVID-19: A Role of Online Hemodiafiltration with Asymmetric Cellulose Triacetate in Maintenance Hemodialysis Patients-A Report of 10 Cases.|pdf=|usr=}}
{{tp|p=33577765|t=2021. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33740443|t=2021. Messenger RNA vaccines against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33773105|t=2021. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.|pdf=|usr=}}
{{tp|p=33761326|t=2021. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33743213|t=2021. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.|pdf=|usr=}}
{{tp|p=33756110|t=2021. The antigenic anatomy of SARS-CoV-2 receptor binding domain.|pdf=|usr=}}
{{tp|p=33691139|t=2021. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.|pdf=|usr=}}
{{tp|p=33667349|t=2021. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.|pdf=|usr=}}
{{tp|p=33792836|t=2021. Piece of the puzzle: Remdesivir disassembles the multimeric SARS-CoV-2 RNA-dependent RNA polymerase complex.|pdf=|usr=}}
{{tp|p=33766136|t=2021. Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment.|pdf=|usr=}}
{{tp|p=33766124|t=2021. Characterization of SARS-CoV-2 proteins reveals Orf6 pathogenicity, subcellular localization, host interactions and attenuation by Selinexor.|pdf=|usr=}}
{{tp|p=33640032|t=2021. Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases.|pdf=|usr=}}
{{tp|p=33762578|t=2021. Inhibition of HECT E3 ligases as potential therapy for COVID-19.|pdf=|usr=}}
{{tp|p=33723251|t=2021. Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients.|pdf=|usr=}}
{{tp|p=33731711|t=2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.|pdf=|usr=}}
{{tp|p=33723226|t=2020. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33789084|t=2021. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite.|pdf=|usr=}}
{{tp|p=33705704|t=2021. Virus vaccines: proteins prefer prolines.|pdf=|usr=}}
{{tp|p=33592168|t=2021. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies.|pdf=|usr=}}
{{tp|p=33535027|t=2021. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.|pdf=|usr=}}
{{tp|p=33789085|t=2021. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera.|pdf=|usr=}}
{{tp|p=33705729|t=2021. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.|pdf=|usr=}}
{{tp|p=33657424|t=2021. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies.|pdf=|usr=}}
{{tp|p=33580169|t=2021. Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice.|pdf=|usr=}}
{{tp|p=33731916|t=2021. Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice.|pdf=|usr=}}
{{tp|p=33664486|t=2021. Systematic profiling of SARS-CoV-2-specific IgG epitopes at amino acid resolution.|pdf=|usr=}}
{{tp|p=33633321|t=2021. Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies.|pdf=|usr=}}
{{tp|p=33662255|t=2021. Use of convalescent serum reduces severity of COVID-19 in nonhuman primates.|pdf=|usr=}}
{{tp|p=33545052|t=2021. Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33784499|t=2021. Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication.|pdf=|usr=}}
{{tp|p=33778788|t=2021. A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses.|pdf=|usr=}}
{{tp|p=33754147|t=2021. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques.|pdf=|usr=}}
{{tp|p=33820686|t=2021. Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33812315|t=2021. Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists.|pdf=|usr=}}
{{tp|p=33823185|t=2021. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) proteases.|pdf=|usr=}}
{{tp|p=33539819|t=2021. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.|pdf=|usr=}}
{{tp|p=33755985|t=2021. Flight hormones as therapeutic target for novel Coronavirus infectious disease.|pdf=|usr=}}
{{tp|p=33755983|t=2021. Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?|pdf=|usr=}}
{{tp|p=33755951|t=2021. Hyperlipidemia management during the COVID-19 pandemic: PCSK9 inhibitors to enhance the antiviral action of interferon.|pdf=|usr=}}
{{tp|p=33755949|t=2021. Reply Letter - "Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis".|pdf=|usr=}}
{{tp|p=33823179|t=2021. Evidence that Maackia amurensis seed lectin (MASL) exerts pleiotropic actions on oral squamous cells with potential to inhibit SARS-CoV-2 infection and COVID-19 disease progression.|pdf=|usr=}}
{{tp|p=33593200|t=2021. Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents.|pdf=|usr=}}
{{tp|p=33781166|t=2021. System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India.|pdf=|usr=}}
{{tp|p=33759682|t=2021. Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: an observational prospective open label user survey.|pdf=|usr=}}
{{tp|p=33739215|t=2021. Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits.|pdf=|usr=}}
{{tp|p=33792473|t=2021. Perspective: the nose and the stomach play a critical role in the NZACE2-Patari (modified ACE2) drug treatment project of SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33706626|t=2021. Compounds of plants with activity against SARS-CoV-2 targets.|pdf=|usr=}}
{{tp|p=33787439|t=2021. Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases?|pdf=|usr=}}
{{tp|p=33822489|t=2021. iPSC screening for drug repurposing identifies anti-RNA virus agents modulating host cell susceptibility.|pdf=|usr=}}
{{tp|p=33823228|t=2021. Recent efforts for drug identification from phytochemicals against SARS-CoV-2: Exploration of the chemical space to identify druggable leads.|pdf=|usr=}}
{{tp|p=33818582|t=2021. SARS-CoV-2 vaccine development and how Brazil is contributing.|pdf=|usr=}}
{{tp|p=33822042|t=2021. Pan-selectin inhibitors as potential therapeutics for COVID-19 treatment: in silico screening study.|pdf=|usr=}}
{{tp|p=33820678|t=2021. COVID-19 vaccine challenges: What have we learned so far and what remains to be done?|pdf=|usr=}}
{{tp|p=33764160|t=2021. Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination.|pdf=|usr=}}
{{tp|p=33818480|t=2021. Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis.|pdf=|usr=}}
{{tp|p=33818476|t=2021. Inactivation of SARS-CoV-2 by gamma irradiation.|pdf=|usr=}}
{{tp|p=33818475|t=2021. Prediction of potential small interfering RNA molecules for silencing of the spike gene of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33818472|t=2021. Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial.|pdf=|usr=}}
{{tp|p=33818470|t=2021. Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach.|pdf=|usr=}}
{{tp|p=33818467|t=2021. Use of convalescent plasma for COVID-19 in India: A review & practical guidelines.|pdf=|usr=}}
{{tp|p=33563353|t=2021. Impact of coronavirus disease 2019 (COVID-19) vaccination program on healthcare worker infections in an academic hospital.|pdf=|usr=}}
{{tp|p=33780551|t=2021. Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment.|pdf=|usr=}}
{{tp|p=33608444|t=2021. Information on COVID-19 vaccines and vaccinations.|pdf=|usr=}}
{{tp|p=33611530|t=2020. Amiodarone as a possible therapy for coronavirus infection.|pdf=|usr=}}
{{tp|p=33757336|t=2021. COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development.|pdf=|usr=}}
{{tp|p=33719819|t=2021. Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials.|pdf=|usr=}}
{{tp|p=33620014|t=2021. Convalescent plasma and hyperimmune globulin therapy in COVID-19.|pdf=|usr=}}
{{tp|p=33769888|t=2021. Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights.|pdf=|usr=}}
{{tp|p=33749491|t=2021. Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19.|pdf=|usr=}}
{{tp|p=33749932|t=2021. A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study.|pdf=|usr=}}
{{tp|p=33617964|t=2021. Saponins: Extraction, bio-medicinal properties and way forward to anti-viral representatives.|pdf=|usr=}}
{{tp|p=33658420|t=2021. THE PECULIARITY OF COVID- 19 GENOME AND THE CORONAVIRUS RNA TRANSLATION PROCESS AS APOTENTIAL TARGET FOR ETIOTROPIC MEDICATIONSWITH ADENINE AND OTHER NUCLEOTIDE ANALOGUES (REVIEW).|pdf=|usr=}}
{{tp|p=33822348|t=2021. Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.|pdf=|usr=}}
{{tp|p=33618380|t=2021. Severe Acute Thromboinflammation: Case Report of Individualized Homeopathic Treatment.|pdf=|usr=}}
{{tp|p=33567460|t=2021. Clinical Characteristics and Remedy Profiles of Patients with COVID-19: A Retrospective Cohort Study.|pdf=|usr=}}
{{tp|p=33544528|t=2021. COVID-19 and nutritional deficiency: a review of existing knowledge.|pdf=|usr=}}
{{tp|p=33687303|t=2021. Research trends in COVID-19 vaccine: a bibliometric analysis.|pdf=|usr=}}
{{tp|p=33769207|t=2021. BCG vaccination potential for COVID-19: an analytical approach.|pdf=|usr=}}
{{tp|p=33545014|t=2021. Coronavirus (SARS-CoV-2): a systematic review for potential vaccines.|pdf=|usr=}}
{{tp|p=33544024|t=2021. Anticipated reduction in COVID-19 mortality due to population-wide BCG vaccination: evidence from Germany.|pdf=|usr=}}
{{tp|p=33687847|t=2021. CoronaPep: An Anti-coronavirus Peptide Generation Tool.|pdf=|usr=}}
{{tp|p=33779464|t=2021. B Cell Response to Vaccination.|pdf=|usr=}}

{{tp|p=33649747|t=2021. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters.|pdf=|usr=}}
{{tp|p=33782529|t=2021. Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms.|pdf=|usr=}}
{{tp|p=33731853|t=2021. Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies.|pdf=|usr=}}
{{tp|p=33629254|t=2021. CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33650894|t=2021. Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19.|pdf=|usr=}}
{{tp|p=33673459|t=2021. Upregulation of the Renin-Angiotensin System Pathways and SARS-CoV-2 Infection: The Rationale for the Administration of Zinc-Chelating Agents in COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33540625|t=2021. Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients?|pdf=|usr=}}
{{tp|p=33609497|t=2021. Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis.|pdf=|usr=}}
{{tp|p=33776550|t=2021. Make it clean, make it safe: A review on virus elimination via adsorption.|pdf=|usr=}}
{{tp|p=33762883|t=2021. Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19.|pdf=|usr=}}
{{tp|p=33776065|t=2021. In silico studies on stilbenolignan analogues as SARS-CoV-2 Mpro inhibitors.|pdf=|usr=}}
{{tp|p=33716308|t=2021. Inhibition of interferon-stimulated gene 15 and lysine 48-linked ubiquitin binding to the SARS-CoV-2 papain-like protease by small molecules: In silico studies.|pdf=|usr=}}
{{tp|p=33716307|t=2021. Biological perspective of thiazolide derivatives against Mpro and MTase of SARS-CoV-2: Molecular docking, DFT and MD simulation investigations.|pdf=|usr=}}
{{tp|p=33623170|t=2021. Identification of high affinity and low molecular alternatives of boceprevir against SARS-CoV-2 main protease: A virtual screening approach.|pdf=|usr=}}
{{tp|p=33558778|t=2021. QSAR study of unsymmetrical aromatic disulfides as potent avian SARS-CoV main protease inhibitors using quantum chemical descriptors and statistical methods.|pdf=|usr=}}
{{tp|p=33756475|t=2021. Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33540487|t=2021. An Androsterone-H2 @C60 hybrid: Synthesis, Properties and Molecular Docking Simulations with SARS-Cov-2.|pdf=|usr=}}
{{tp|p=33549598|t=2021. Should Antipyretics Be Used to Relieve Acute Adverse Events Related to COVID-19 Vaccines?|pdf=|usr=}}
{{tp|p=33621601|t=2021. Progesterone in Addition to Standard of Care vs Standard of Care Alone in the Treatment of Men Hospitalized With Moderate to Severe COVID-19: A Randomized, Controlled Pilot Trial.|pdf=|usr=}}
{{tp|p=33528745|t=2021. Thoughts on Traditional Chinese Medicine Treatment of Novel Coronavirus Pneumonia Based on Two Cases.|pdf=|usr=}}
{{tp|p=33544289|t=2021. Promising Antiviral Molecules from Ayurvedic Herbs and Spices against COVID-19.|pdf=|usr=}}
{{tp|p=33534076|t=2021. Effects of Chinese Medicine on Symptoms, Syndrome Evolution, and Lung Inflammation Absorption in COVID-19 Convalescent Patients during 84-Day Follow-up after Hospital Discharge: A Prospective Cohort and Nested Case-Control Study.|pdf=|usr=}}
{{tp|p=33618736|t=2021. Traditional Chinese herbal medicine-potential therapeutic application for the treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33617183|t=2020. Statins as candidate therapeutic agents for coronavirus disease 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=33555601|t=2021. Just the facts: updates in COVID-19 therapeutics.|pdf=|usr=}}
{{tp|p=33709361|t=2021. CJEM journal club: corticosteroids use for critically ill COVID-19 patients.|pdf=|usr=}}
{{tp|p=33534117|t=2021. Is dexamethasone an effective treatment for severe COVID-19 patients: Journal Club review.|pdf=|usr=}}
{{tp|p=33687984|t=2021. Vaccination for COVID-19: Is it important and what should you know about it?|pdf=|usr=}}
{{tp|p=33648932|t=2021. Anaphylaxis to vaccinations: A review of the literature and evaluation of the COVID-19 mRNA vaccinations.|pdf=|usr=}}
{{tp|p=33597176|t=2021. Monoclonal antibodies for treating COVID-19.|pdf=|usr=}}
{{tp|p=33648989|t=2021. Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer.|pdf=|usr=}}
{{tp|p=33628060|t=2021. A Phthalocyanine Derivate Mouthwash to Gargling/Rinsing as an Option to Reduce Clinical Symptoms of COVID-19: Case Series.|pdf=|usr=}}
{{tp|p=33754328|t=2021. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges.|pdf=|usr=}}
{{tp|p=33666256|t=2021. COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers.|pdf=|usr=}}
{{tp|p=33555252|t=2021. Vaccination against SARS-CoV-2 in patients with rheumatic diseases: doubts and perspectives.|pdf=|usr=}}
{{tp|p=33635218|t=2021. High-dose glucocorticoids pulse-therapy for beta-coronaviridae pneumonia: a systematic literature review and case-series of Coronavirus disease-2019.|pdf=|usr=}}
{{tp|p=33628750|t=2021. Current updates and research on plant-based vaccines for coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=33628749|t=2021. A review on the advancements in the development of vaccines to combat coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=33548200|t=2021. What Gastroenterologists Should Know About COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=33684527|t=2021. Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study.|pdf=|usr=}}
{{tp|p=33693610|t=2021. Impressive boosting of anti-S1/S2 IgG production in COVID-19-experienced patients after the first shot of the BNT162b2 mRNA COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=33693552|t=2021. Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=33693607|t=2021. Trends in Prescribing of Antibiotics and Drugs Investigated for COVID-19 Treatment in U.S. Nursing Home Residents During the COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33639622|t=2021. How to test SARS-CoV-2 vaccines ethically even after one is available.|pdf=|usr=}}
{{tp|p=33630997|t=2021. Reduced Vitamin K Status and Coronavirus Disease 2019: An Epiphenomenon of Impaired Kidney Function?|pdf=|usr=}}
{{tp|p=33654337|t=2021. SAFETY PROFILE OF TREATMENTS ADMINISTERED IN COVID 19 INFECTION IN PREGNANT WOMEN.|pdf=|usr=}}
{{tp|p=33762401|t=2021. SARS-CoV-2 infection despite vaccination: an under-reported COVID-19 cohort.|pdf=|usr=}}
{{tp|p=33593830|t=2021. Perspective: Vitamin D supplementation prevents rickets and acute respiratory infections when given as daily maintenance but not as intermittent bolus: implications for COVID-19.|pdf=|usr=}}
{{tp|p=33705848|t=2021. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis - Author's reply.|pdf=|usr=}}
{{tp|p=33705849|t=2021. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.|pdf=|usr=}}
{{tp|p=33549765|t=2021. Re: 'Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis' by Tleyjeh et al.|pdf=|usr=}}
{{tp|p=33647441|t=2021. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.|pdf=|usr=}}
{{tp|p=33564204|t=2021. Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19.|pdf=|usr=}}
{{tp|p=33631509|t=2021. Can pulse steroid therapy increase the risk of infection by COVID-19 in patients with multiple sclerosis?|pdf=|usr=}}
{{tp|p=33745749|t=2021. Vitamin D deficiency in critically ill COVID-19 ARDS patients.|pdf=|usr=}}
{{tp|p=33745628|t=2021. The prevalence of malnutrition and analysis of related factors among adult patients with the Coronavirus Disease 2019 (COVID 19) in a tertiary government hospital: The MalnutriCoV study.|pdf=|usr=}}
{{tp|p=33745598|t=2021. Evaluation of vitamin D levels in COVID-19 patients referred to Labafinejad hospital in Tehran and its relationship with disease severity and mortality.|pdf=|usr=}}
{{tp|p=33745593|t=2021. Are history of dietary intake and food habits of patients with clinical symptoms of COVID 19 different from healthy controls? A case-control study.|pdf=|usr=}}
{{tp|p=33745572|t=2021. Trajectories of eating behavior during COVID-19 lockdown: Longitudinal analyses of 22,374 adults.|pdf=|usr=}}
{{tp|p=33745566|t=2021. Healthy nutritional behavior during COVID-19 lockdown: A cross-sectional study.|pdf=|usr=}}
{{tp|p=33782830|t=2021. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.|pdf=|usr=}}
{{tp|p=33641159|t=2021. Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies.|pdf=|usr=}}
{{tp|p=33547636|t=2021. Neglecting Plasma Protein Binding in COVID-19 Patients Leads to a Wrong Interpretation of Lopinavir Overexposure.|pdf=|usr=}}
{{tp|p=33529354|t=2021. Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19.|pdf=|usr=}}
{{tp|p=33798755|t=2021. Predictive analysis of COVID-19 eradication with vaccination in India, Brazil, and U.S.A.|pdf=|usr=}}
{{tp|p=33819681|t=2021. Immunogenicity and antigenicity based T-cell and B-cell epitopes identification from conserved regions of 10664 SARS-CoV-2 genomes.|pdf=|usr=}}
{{tp|p=33783508|t=2021. Safety of Tofacitinib in the COVID-19 Pandemic-Enough Is Not Enough.|pdf=|usr=}}
{{tp|p=33772572|t=2021. Development of COVID-19 vaccines utilizing gene therapy technology.|pdf=|usr=}}
{{tp|p=33812260|t=2021. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=}}
{{tp|p=33803339|t=2021. Approaches to Nutritional Screening in Patients with Coronavirus Disease 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=33801651|t=2021. A Rapid Review of COVID-19 Vaccine Prioritization in the U.S.: Alignment between Federal Guidance and State Practice.|pdf=|usr=}}
{{tp|p=33809918|t=2021. Linear B-Cell Epitope Prediction for In Silico Vaccine Design: A Performance Review of Methods Available via Command-Line Interface.|pdf=|usr=}}
{{tp|p=33808940|t=2021. Identification of Anti-Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Oxysterol Derivatives In Vitro.|pdf=|usr=}}
{{tp|p=33808574|t=2021. Dietary and Protective Factors to Halt or Mitigate Progression of Autoimmunity, COVID-19 and Its Associated Metabolic Diseases.|pdf=|usr=}}
{{tp|p=33802761|t=2021. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.|pdf=|usr=}}
{{tp|p=33802729|t=2021. SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity.|pdf=|usr=}}
{{tp|p=33804129|t=2021. Metal-Bound Methisazone; Novel Drugs Targeting Prophylaxis and Treatment of SARS-CoV-2, a Molecular Docking Study.|pdf=|usr=}}
{{tp|p=33802169|t=2021. A Novel Computational Approach for the Discovery of Drug Delivery System Candidates for COVID-19.|pdf=|usr=}}
{{tp|p=33797236|t=2021. Stealth Fluorescence Labeling for Live Microscopy Imaging of mRNA Delivery.|pdf=|usr=}}
{{tp|p=33792713|t=2021. Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU-authors' response.|pdf=|usr=}}
{{tp|p=33758946|t=2021. Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials.|pdf=|usr=}}
{{tp|p=33784944|t=2021. Design and synthesis of novel phe-phe hydroxyethylene derivatives as potential coronavirus main protease inhibitors.|pdf=|usr=}}
{{tp|p=33645490|t=2021. COVID-19: Potential Repurposing Drugs.|pdf=|usr=}}
{{tp|p=33602078|t=2021. Natural Derived Nasal Spray; a Proposed Approach for COVID-19 Disease Control.|pdf=|usr=}}
{{tp|p=33573449|t=2021. Effects of tocilizumab versus hemoadsorption combined with tocilizumab in patients with SARS-CoV-2 pneumonia: Preliminary results.|pdf=|usr=}}
{{tp|p=33624584|t=2021. Bioequivalence study of two favipiravir tablet formulations in healthy male subjects.|pdf=|usr=}}
{{tp|p=33624583|t=2021. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.|pdf=|usr=}}
{{tp|p=33605875|t=2021. COVID-19 double whammy - Vaccine and variants.|pdf=|usr=}}
{{tp|p=33763939|t=2021. Investigation of SARS-CoV-2 RNA in milk produced by women with COVID-19 and follow-up of their infants: A preliminary study.|pdf=|usr=}}
{{tp|p=33759318|t=2021. Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey.|pdf=|usr=}}
{{tp|p=33743543|t=2021. Investigation of the disease process and drug combinations in patients with suspected/confirmed COVID-19 using favipiravir.|pdf=|usr=}}
{{tp|p=33797849|t=2021. Detectable respiratory SARS-CoV-2 RNA is associated with low vitamin D levels and high social deprivation.|pdf=|usr=}}
{{tp|p=33752299|t=2021. Does therapeutic drug monitoring of hydroxychloroquine improve treatment outcome in intensive care unit patients with COVID-19?|pdf=|usr=}}
{{tp|p=33682604|t=2021. Exploring the rationale for thermotherapy in COVID-19.|pdf=|usr=}}
{{tp|p=33822495|t=2021. Chaga Medicinal Mushroom Inonotus obliquus (Agaricomycetes) Terpenoids May Interfere with SARS-CoV-2 Spike Protein Recognition of the Host Cell: A Molecular Docking Study.|pdf=|usr=}}
{{tp|p=33725395|t=2021. The effect of Chinese herbal medicine on digestive system and liver functions should not be neglected in COVID-19: An updated systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33749986|t=2021. Identification of mutation resistance coldspots for targeting the SARS-CoV2 main protease.|pdf=|usr=}}
{{tp|p=33691499|t=2021. Mycobacterium vaccae Nebulization in the Treatment of COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial.|pdf=|usr=}}
{{tp|p=33596158|t=2021. l-Cysteine Stimulates the Effect of Vitamin D on Inhibition of Oxidative Stress, IL-8, and MCP-1 Secretion in High Glucose Treated Monocytes.|pdf=|usr=}}
{{tp|p=33768521|t=2021. Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study.|pdf=|usr=}}
{{tp|p=33762353|t=2021. SARS-CoV-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know?|pdf=|usr=}}
{{tp|p=33526471|t=2021. A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids.|pdf=|usr=}}
{{tp|p=33527804|t=2021. Itolizumab Treatment for Cytokine Release Syndrome in Moderate to Severe Acute Respiratory Distress Syndrome Due to COVID-19: Clinical Outcomes, A Retrospective Study.|pdf=|usr=}}
{{tp|p=33594850|t=2021. In silico approach: docking study of oxindole derivatives against the main protease of COVID-19 and its comparison with existing therapeutic agents.|pdf=|usr=}}
{{tp|p=33594843|t=2021. Evidence that Ginkgo Biloba could use in the influenza and coronavirus COVID-19 infections.|pdf=|usr=}}
{{tp|p=33682642|t=2021. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.|pdf=|usr=}}
{{tp|p=33682639|t=2021. Binding and inhibitory effect of ravidasvir on 3CL(pro) of SARS-CoV-2: a molecular docking, molecular dynamics and MM/PBSA approach.|pdf=|usr=}}
{{tp|p=33682633|t=2021. Structural insight into the binding interactions of NTPs and nucleotide analogues to RNA dependent RNA polymerase of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33682632|t=2021. Structure-based virtual screening, molecular dynamics and binding affinity calculations of some potential phytocompounds against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33682606|t=2021. Flavonoids as potential therapeutics against novel coronavirus disease-2019 (nCOVID-19).|pdf=|usr=}}
{{tp|p=33663346|t=2021. Metadynamics-based enhanced sampling protocol for virtual screening: case study for 3CLpro protein for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33764269|t=2021. Isatin-based virtual high throughput screening, molecular docking, DFT, QM/MM, MD and MM-PBSA study of novel inhibitors of SARS-CoV-2 main protease.|pdf=|usr=}}

{{tp|p=33751280|t=2021. A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review.|pdf=|usr=}}
{{tp|p=33579547|t=2021. The COVID-19 mRNA Vaccines and the Pandemic: Do They Represent the Beginning of the End or the End of the Beginning?|pdf=|usr=}}
{{tp|p=33549310|t=2021. A Critical Appraisal of the Effects of Anesthetics on Immune-system Modulation in Critically Ill Patients With COVID-19.|pdf=|usr=}}
{{tp|p=33641562|t=2021. Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series.|pdf=|usr=}}
{{tp|p=33728279|t=2021. Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review.|pdf=|usr=}}
{{tp|p=33732459|t=2021. Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2.|pdf=|usr=}}
{{tp|p=33635001|t=2021. Bromelain inhibits SARS-CoV-2 infection via targeting ACE-2, TMPRSS2, and spike protein.|pdf=|usr=}}
{{tp|p=33634996|t=2021. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial.|pdf=|usr=}}
{{tp|p=33634979|t=2021. Ring vaccination of COVID-19 vaccines in medium- and high-risk areas of countries with low incidence of SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33620150|t=2021. Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19.|pdf=|usr=}}
{{tp|p=33606912|t=2021. Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33606894|t=2021. Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=}}
{{tp|p=33595145|t=2021. Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: Early single-center experience.|pdf=|usr=}}
{{tp|p=33535811|t=2021. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.|pdf=|usr=}}
{{tp|p=33530721|t=2021. An ethics framework for consolidating and prioritizing COVID-19 clinical trials.|pdf=|usr=}}
{{tp|p=33787678|t=2021. COVID-19 and Thromboinflammation: Is There a Role for Statins?|pdf=|usr=}}
{{tp|p=33692091|t=2021. Tocilizumab for hospitalized patients with COVID-19.|pdf=|usr=}}
{{tp|p=33552306|t=2021. Deep Learning-Based Potential Ligand Prediction Framework for COVID-19 with Drug-Target Interaction Model.|pdf=|usr=}}
{{tp|p=33564211|t=2021. Nano-size dependence in the adsorption by the SARS-CoV-2 spike protein over gold colloid.|pdf=|usr=}}
{{tp|p=33795896|t=2020. COVID-19: The Ivermectin African Enigma.|pdf=|usr=}}
{{tp|p=33564093|t=2021. Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33627795|t=2021. Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy.|pdf=|usr=}}
{{tp|p=33580154|t=2021. Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection.|pdf=|usr=}}
{{tp|p=33551714|t=2021. Critical roles of TLRs on the polarization of mesenchymal stem cells for cell therapy of viral infections: a notice for COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33677227|t=2021. Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 M(Pro) by targeting the cysteine 145.|pdf=|usr=}}
{{tp|p=33751995|t=2021. Structural insights on the interaction potential of natural leads against major protein targets of SARS-CoV-2: Molecular modelling, docking and dynamic simulation studies.|pdf=|usr=}}
{{tp|p=33721736|t=2021. Deep learning model for virtual screening of novel 3C-like protease enzyme inhibitors against SARS coronavirus diseases.|pdf=|usr=}}
{{tp|p=33705994|t=2021. A hijack mechanism of Indian SARS-CoV-2 isolates for relapsing contemporary antiviral therapeutics.|pdf=|usr=}}
{{tp|p=33535144|t=2021. Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design.|pdf=|usr=}}
{{tp|p=33662683|t=2021. Targeting multiple conformations of SARS-CoV2 Papain-Like Protease for drug repositioning: An in-silico study.|pdf=|usr=}}
{{tp|p=33662681|t=2021. Network pharmacology and RNA-sequencing reveal the molecular mechanism of Xuebijing injection on COVID-19-induced cardiac dysfunction.|pdf=|usr=}}
{{tp|p=33777333|t=2021. Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design.|pdf=|usr=}}
{{tp|p=33680350|t=2021. COVID-19 pandemic: Can zinc supplementation provide an additional shield against the infection?|pdf=|usr=}}
{{tp|p=33680348|t=2021. Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19.|pdf=|usr=}}
{{tp|p=33552444|t=2021. Current concepts in the development of therapeutics against human and animal coronavirus diseases by targeting NP.|pdf=|usr=}}
{{tp|p=33619460|t=2021. Covid-19 treatment: Investigation on the phytochemical constituents of Vernonia amygdalina as potential Coronavirus-2 inhibitors.|pdf=|usr=}}
{{tp|p=33553857|t=2021. Screening possible drug molecules for Covid-19. The example of vanadium (III/IV/V) complex molecules with computational chemistry and molecular docking.|pdf=|usr=}}
{{tp|p=33532671|t=2021. From genomes to molecular dynamics - A bottom up approach in extrication of SARS CoV-2 main protease inhibitors.|pdf=|usr=}}
{{tp|p=33557911|t=2021. Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients.|pdf=|usr=}}
{{tp|p=33786440|t=2021. New Decade, Old Debate: Blocking the Cytokine Pathways in Infection-Induced Cytokine Cascade.|pdf=|usr=}}
{{tp|p=33817660|t=2021. Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2.|pdf=|usr=}}
{{tp|p=33660966|t=2021. Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?|pdf=|usr=}}
{{tp|p=33786251|t=2021. Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=33717715|t=2021. Predictors of Mortality Amongst Tocilizumab Administered COVID-19 Asian Indians: A Predictive Study From a Tertiary Care Centre.|pdf=|usr=}}
{{tp|p=33786231|t=2021. Lymphadenopathy Associated With the COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=33633920|t=2021. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial.|pdf=|usr=}}
{{tp|p=33758714|t=2021. Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=33643746|t=2021. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical).|pdf=|usr=}}
{{tp|p=33532161|t=2020. The History of Methylprednisolone, Ascorbic Acid, Thiamine, and Heparin Protocol and I-MASK+ Ivermectin Protocol for COVID-19.|pdf=|usr=}}
{{tp|p=33686365|t=2021. Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines.|pdf=|usr=}}
{{tp|p=33582901|t=2021. Corticosteroids Treatment of Patients with Coronavirus Disease 2019: A Propensity Score Matching Study.|pdf=|usr=}}
{{tp|p=33680715|t=2021. Determination of Potential Drug Candidate Molecules of the Hypericum perforatum for COVID-19 Treatment.|pdf=|usr=}}
{{tp|p=33619447|t=2021. Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone.|pdf=|usr=}}
{{tp|p=33773396|t=2021. Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication.|pdf=|usr=}}
{{tp|p=33714693|t=2021. The conundrum of current anti-SARS-CoV-2 vaccines.|pdf=|usr=}}
{{tp|p=33776206|t=2021. Taming of Covid-19: potential and emerging application of mesenchymal stem cells.|pdf=|usr=}}
{{tp|p=33797339|t=2021. COVID19-inhibitory activity of withanolides involves targeting of the host cell surface receptor ACE2: insights from computational and biochemical assays.|pdf=|usr=}}
{{tp|p=33784094|t=2021. Lead Discovery of SARS-CoV-2 Main Protease Inhibitors through Covalent Docking-Based Virtual Screening.|pdf=|usr=}}
{{tp|p=33821020|t=2021. Cytotoxicity, anti-microbial studies of M(II)-dithiocarbamate complexes, and molecular docking study against SARS COV2 RNA-dependent RNA polymerase.|pdf=|usr=}}
{{tp|p=33822770|t=2021. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63.|pdf=|usr=}}
{{tp|p=33808205|t=2021. Effects of Different Dialysis Strategies on Inflammatory Cytokine Profile in Maintenance Hemodialysis Patients with COVID-19: A Randomized Trial.|pdf=|usr=}}
{{tp|p=33805760|t=2021. Angiotensin-(1-7)-A Potential Remedy for AKI: Insights Derived from the COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33798667|t=2021. The dawn of mRNA vaccines: The COVID-19 case.|pdf=|usr=}}
{{tp|p=33818731|t=2021. Retrospective analysis of vitamin D status on inflammatory markers and course of the disease in patients with COVID-19 infection.|pdf=|usr=}}
{{tp|p=33813013|t=2021. Antiviral effect of fufang yinhua jiedu (FFYH) granules against influenza A virus through regulating the inflammatory responses by TLR7/MyD88 signaling pathway.|pdf=|usr=}}
{{tp|p=33811961|t=2021. BNT 13b2 Pfizer vaccine protects against SARS-CoV-2 respiratory mucosal colonization even after prolonged exposure to positive family members.|pdf=|usr=}}
{{tp|p=33811939|t=2021. Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers.|pdf=|usr=}}
{{tp|p=33761582|t=2021. Super-rapid race for saving lives by developing COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=33743557|t=2021. Special issue on COVID-19 data integration opportunities and vaccine development strategies.|pdf=|usr=}}
{{tp|p=33759703|t=2021. A computational study on active constituents of Habb-ul-aas and Tabasheer as inhibitors of SARS-CoV-2 main protease.|pdf=|usr=}}
{{tp|p=33759690|t=2021. In silico screening of therapeutic potentials from Strychnos nux-vomica against the dimeric main protease (M(pro)) structure of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33749547|t=2021. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies.|pdf=|usr=}}
{{tp|p=33749545|t=2021. On the search for COVID-19 therapeutics: identification of potential SARS-CoV-2 main protease inhibitors by virtual screening, pharmacophore modeling and molecular dynamics.|pdf=|usr=}}
{{tp|p=33749538|t=2021. Phylogenic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs.|pdf=|usr=}}
{{tp|p=33749528|t=2021. Repurposing of anticancer phytochemicals for identifying potential fusion inhibitor for SARS-CoV-2 using molecular docking and molecular dynamics (MD) simulations.|pdf=|usr=}}
{{tp|p=33749496|t=2021. Cyanobacterial natural products as sources for antiviral drug discovery against COVID-19.|pdf=|usr=}}
{{tp|p=33734021|t=2021. Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.|pdf=|usr=}}
{{tp|p=33719855|t=2021. Potentiality of Moringa oleifera against SARS-CoV-2: identified by a rational computer aided drug design method.|pdf=|usr=}}
{{tp|p=33706683|t=2021. Potential inhibitors of angiotensin converting enzyme 2 receptor of COVID-19 by Corchorus olitorius Linn using docking, molecular dynamics, conceptual DFT investigation and pharmacophore mapping.|pdf=|usr=}}
{{tp|p=33715598|t=2021. A rational design of a multi-epitope vaccine against SARS-CoV-2 which accounts for the glycan shield of the spike glycoprotein.|pdf=|usr=}}
{{tp|p=33715595|t=2021. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.|pdf=|usr=}}
{{tp|p=33715592|t=2021. In silico drug designing for COVID-19: an approach of high-throughput virtual screening, molecular, and essential dynamics simulations.|pdf=|usr=}}
{{tp|p=33554747|t=2021. Targeting the N-terminal domain of the RNA-binding protein of the SARS-CoV-2 with high affinity natural compounds to abrogate the protein-RNA interaction: a molecular dynamics study.|pdf=|usr=}}
{{tp|p=33645457|t=2021. Targeting allosteric pockets of SARS-CoV-2 main protease M(pro).|pdf=|usr=}}
{{tp|p=33625318|t=2021. 4-acetamido-3-nitrobenzoic acid - structural, quantum chemical studies, ADMET and molecular docking studies of SARS-CoV2.|pdf=|usr=}}
{{tp|p=33618628|t=2021. Investigation of the inhibitory activity of some dietary bioactive flavonoids against SARS-CoV-2 using molecular dynamics simulations and MM-PBSA calculations.|pdf=|usr=}}
{{tp|p=33618621|t=2021. Structural stability predictions and molecular dynamics simulations of RBD and HR1 mutations associated with SARS-CoV-2 spike glycoprotein.|pdf=|usr=}}
{{tp|p=33615998|t=2021. In silico evaluation of isatin-based derivatives with RNA-dependent RNA polymerase of the novel coronavirus SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33586620|t=2021. Whole proteome screening and identification of potential epitopes of SARS-CoV-2 for vaccine design-an immunoinformatic, molecular docking and molecular dynamics simulation accelerated robust strategy.|pdf=|usr=}}
{{tp|p=33810774|t=2021. In silico inquest reveals the efficacy of Cannabis in the treatment of post-Covid-19 related neurodegeneration.|pdf=|usr=}}
{{tp|p=33648025|t=2021. Rapid development of a de novo convalescent plasma program in response to a global pandemic: A large southeastern U.S. blood center's experience.|pdf=|usr=}}
{{tp|p=33768612|t=2021. QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID-19.|pdf=|usr=}}
{{tp|p=33650415|t=2021. The Effect of Tocilizumab on Inflammatory Markers in Survivors and Non-survivors of Severe COVID-19.|pdf=|usr=}}
{{tp|p=33787192|t=2021. The effects of combination of Zingiber officinale and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19 outpatients: a randomized controlled trial.|pdf=|usr=}}
{{tp|p=33544526|t=2021. Preventive aspect of ayurveda and yoga towards newly emerging disease COVID-19.|pdf=|usr=}}
{{tp|p=33713492|t=2021. Drug repositioning to target NSP15 protein on SARS-CoV-2 as possible COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33638924|t=2021. Herpes zoster following inactivated COVID-19 vaccine: A coexistence or coincidence?|pdf=|usr=}}
{{tp|p=33682615|t=2021. Trace Minerals, Vitamins and Nutraceuticals in Prevention and Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33594938|t=2021. Potential Efficacy of Nutrient Supplements for Treatment or Prevention of COVID-19.|pdf=|usr=}}
{{tp|p=33683080|t=2021. Coronavirus Vaccination Adverse Reactions and the Role of the Dermatologist.|pdf=|usr=}}
{{tp|p=33528149|t=2020. The Relevance of Vitamin D Supplementation for People of Color in the Era of COVID-19.|pdf=|usr=}}
{{tp|p=33783873|t=2021. Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. 'COVID-arm': a clinical and histological characterization.|pdf=|usr=}}
{{tp|p=33783855|t=2021. Extraordinary claims without extraordinary evidence: controversy on anti-androgen therapy for COVID-19.|pdf=|usr=}}
{{tp|p=33783017|t=2021. Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33780556|t=2021. Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know.|pdf=|usr=}}
{{tp|p=33725406|t=2021. Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination.|pdf=|usr=}}
{{tp|p=33617431|t=2021. Early and Significant Reduction in C-Reactive Protein Levels After Corticosteroid Therapy Is Associated With Reduced Mortality in Patients With COVID-19.|pdf=|usr=}}
{{tp|p=33576702|t=2021. Letter to the editor: COVID-19 Vaccines and Breastfeeding.|pdf=|usr=}}
{{tp|p=33735530|t=2021. A UK survey of nutritional care pathways for patients with COVID-19 prior to and post-hospital stay.|pdf=|usr=}}
{{tp|p=33632000|t=2021. A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19.|pdf=|usr=}}
{{tp|p=33621130|t=2021. Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19.|pdf=|usr=}}
{{tp|p=33822418|t=2021. Reply letter to: Inhibition of SARS-CoV-2 replication using calcineurin inhibitors: Are concentrations required clinically achievable?|pdf=|usr=}}

{{tp|p=33560802|t=2021. Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine.|pdf=|usr=}}
{{tp|p=33744398|t=2021. Increased mortality risk associated with statins in the CORONADO study.|pdf=|usr=}}
{{tp|p=33752274|t=2021. Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19.|pdf=|usr=}}
{{tp|p=33662839|t=2021. Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA.|pdf=|usr=}}
{{tp|p=33662837|t=2021. COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges.|pdf=|usr=}}
{{tp|p=33528920|t=2021. Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study.|pdf=|usr=}}
{{tp|p=33606909|t=2021. Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33594475|t=2021. The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation.|pdf=|usr=}}
{{tp|p=33625613|t=2021. Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=33625612|t=2021. More Than Just Heartburn: Does Famotidine Effectively Treat Patients with COVID-19?|pdf=|usr=}}
{{tp|p=33535388|t=2021. Targeting NSP16 Methyltransferase for the Broad-Spectrum Clinical Management of Coronaviruses: Managing the Next Pandemic.|pdf=|usr=}}
{{tp|p=33689074|t=2021. Thermovaccination: Thermoheliox as an Immune Response Stimulant. Kinetics of Antibodies and C-Reactive Protein Synthesis in Coronaviral Infection.|pdf=|usr=}}
{{tp|p=33694083|t=2021. Advances in vaccine delivery systems against viral infectious diseases.|pdf=|usr=}}
{{tp|p=33762818|t=2021. Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms.|pdf=|usr=}}
{{tp|p=33737804|t=2021. Withanone from Withania somnifera Attenuates SARS-CoV-2 RBD and Host ACE2 Interactions to Rescue Spike Protein Induced Pathologies in Humanized Zebrafish Model.|pdf=|usr=}}
{{tp|p=33692615|t=2021. Beware of Steroid-Induced Avascular Necrosis of the Femoral Head in the Treatment of COVID-19-Experience and Lessons from the SARS Epidemic.|pdf=|usr=}}
{{tp|p=33612572|t=2021. Multidrug treatment for COVID-19.|pdf=|usr=}}
{{tp|p=33775925|t=2021. Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33609782|t=2021. Inflammation control and improvement of cognitive function in COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition?|pdf=|usr=}}
{{tp|p=33609783|t=2021. Developing new drugs that activate the protective arm of the renin-angiotensin system as a potential treatment for respiratory failure in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33683968|t=2021. In quest of a new therapeutic approach in COVID-19: the endocannabinoid system.|pdf=|usr=}}
{{tp|p=33666902|t=2021. Safety Consequences of Off-Label Drugs Used for COVID-19.|pdf=|usr=}}
{{tp|p=33683637|t=2021. BNT162b2 mRNA COVID-19 Vaccine: First Approval.|pdf=|usr=}}
{{tp|p=33782908|t=2021. Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry.|pdf=|usr=}}
{{tp|p=33638807|t=2021. MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19.|pdf=|usr=}}
{{tp|p=33643421|t=2021. The race to a COVID-19 vaccine: opportunities and challenges in development and distribution.|pdf=|usr=}}
{{tp|p=33569736|t=2021. Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS).|pdf=|usr=}}
{{tp|p=33780993|t=2021. SARS-CoV-2-Impfungen - Was muss der Nephrologe wissen?|pdf=|usr=}}
{{tp|p=33676899|t=2021. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.|pdf=|usr=}}
{{tp|p=33752131|t=2021. COVID19 therapeutics: Expanding the antiviral arsenal.|pdf=|usr=}}
{{tp|p=33752127|t=2021. Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial.|pdf=|usr=}}
{{tp|p=33681731|t=2021. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial.|pdf=|usr=}}
{{tp|p=33615206|t=2021. Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: A propensity-score analysis.|pdf=|usr=}}
{{tp|p=33589884|t=2021. Can existing unrelated vaccines boost a COVID-19 vaccine prime?|pdf=|usr=}}
{{tp|p=33558858|t=2021. Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis?|pdf=|usr=}}
{{tp|p=33787663|t=2021. Use of mouthwashes in the management of COVID-19 patients in intensive care units: recommendations and current evidence.|pdf=|usr=}}
{{tp|p=33682678|t=2021. An open label trial of anakinra to prevent respiratory failure in COVID-19.|pdf=|usr=}}
{{tp|p=33691606|t=2021. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates.|pdf=|usr=}}
{{tp|p=33691601|t=2021. The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract.|pdf=|usr=}}
{{tp|p=33560940|t=2021. The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor.|pdf=|usr=}}
{{tp|p=33555988|t=2021. A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques.|pdf=|usr=}}
{{tp|p=33538646|t=2021. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33649739|t=2021. Potential Applications of Conducting Polymers to Reduce Secondary Bacterial Infections among COVID-19 Patients: a Review.|pdf=|usr=}}
{{tp|p=33744444|t=2021. Vitamin D and Its Potential Benefit for the COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33705975|t=2021. Association of Vitamin D Status With Hospital Morbidity and Mortality in Adult Hospitalized Patients With COVID-19.|pdf=|usr=}}
{{tp|p=33738708|t=2021. Hypovitaminosis D and the endocrine phenotype of COVID-19.|pdf=|usr=}}
{{tp|p=33585705|t=2021. Therapeutic plasma exchange for persistent encephalopathy associated with Covid-19.|pdf=|usr=}}
{{tp|p=33741148|t=2021. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.|pdf=|usr=}}
{{tp|p=33691157|t=2021. Selenium (Se) plays a key role in the biological effects of some viruses: Implications for COVID-19.|pdf=|usr=}}
{{tp|p=33809879|t=2021. Prevention of Covid-19 Infection and Related Complications by Ozonized Oils.|pdf=|usr=}}
{{tp|p=33821145|t=2021. COVID-19: Filling the Many Knowledge Gaps and Supporting Evidence-Based Vaccination.|pdf=|usr=}}
{{tp|p=33530857|t=2021. Trajectory of individual immunity and vaccination required for SARS-CoV-2 community immunity: a conceptual investigation.|pdf=|usr=}}
{{tp|p=33821691|t=2021. Medicolegal consequences of altered COVID-19 vaccine administration.|pdf=|usr=}}
{{tp|p=33772577|t=2021. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33627390|t=2021. Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model.|pdf=|usr=}}
{{tp|p=33555305|t=2021. Outpatient Dietary Management of Electrolyte Disorders During COVID-19: Food as Medicine.|pdf=|usr=}}
{{tp|p=33821223|t=2021. Timing of COVID-19 Vaccine in the Setting of Anti-CD20 Therapy: A Primer for Nephrologists.|pdf=|usr=}}
{{tp|p=33676614|t=2021. Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster.|pdf=|usr=}}
{{tp|p=33798498|t=2021. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?|pdf=|usr=}}
{{tp|p=33798499|t=2021. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.|pdf=|usr=}}
{{tp|p=33798464|t=2021. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.|pdf=|usr=}}
{{tp|p=33798462|t=2021. Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?|pdf=|usr=}}
{{tp|p=33811822|t=2021. COVID-19 vaccines for patients with haematological conditions.|pdf=|usr=}}
{{tp|p=33733767|t=2021. Weinreb Amide Approach to the Practical Synthesis of a Key Remdesivir Intermediate.|pdf=|usr=}}
{{tp|p=33634692|t=2021. Practical Remdesivir Synthesis through One-Pot Organocatalyzed Asymmetric (S)-P-Phosphoramidation.|pdf=|usr=}}
{{tp|p=33817870|t=2021. The precautionary principle, the AstraZeneca COVID-19 vaccine and mixed messaging.|pdf=|usr=}}
{{tp|p=33625085|t=2021. Favorable Outcome of COVID-19 Infection in a Pediatric Cancer Patient Receiving an Anti-PD-L1/Anti-CTLA-4 Combination.|pdf=|usr=}}
{{tp|p=33620123|t=2021. Acute and chronic inflammatory neuropathies and COVID-19 vaccines: Practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP).|pdf=|usr=}}
{{tp|p=33779758|t=2021. Isatis indigotica: a review of phytochemistry, pharmacological activities and clinical applications.|pdf=|usr=}}
{{tp|p=33759631|t=2021. Interleukin-6 Antagonists: Lessons From Cytokine Release Syndrome to the Therapeutic Application in Severe COVID-19 Infection.|pdf=|usr=}}
{{tp|p=33736526|t=2021. Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series.|pdf=|usr=}}
{{tp|p=33719698|t=2021. A Review of the Evidence for Corticosteroids in COVID-19.|pdf=|usr=}}
{{tp|p=33622090|t=2021. Remdesivir for the Treatment of COVID-19: A Need for Combined In Vivo and In Vitro Studies to Evaluate the Efficacy.|pdf=|usr=}}
{{tp|p=33760611|t=2021. Unveiling the Molecular Structure of Antimalarial Drugs Chloroquine and Hydroxychloroquine in Solution through Analysis of (1)H NMR Chemical Shifts.|pdf=|usr=}}
{{tp|p=33759236|t=2021. Melatonin multifaceted pharmacological actions on melatonin receptors converging to abrogate COVID-19.|pdf=|usr=}}
{{tp|p=33758126|t=2021. The Potential Role of Radiogenomics in Precision Medicine for COVID-19.|pdf=|usr=}}
{{tp|p=33783953|t=2021. A case report of acquired hemophilia following COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33789993|t=2021. The Physiological TMPRSS2 Inhibitor HAI-2 Alleviates SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33692215|t=2021. Cryo-EM structure of S-Trimer, a subunit vaccine candidate for COVID-19.|pdf=|usr=}}
{{tp|p=33720292|t=2021. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.|pdf=|usr=}}
{{tp|p=33739374|t=2021. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination.|pdf=|usr=}}
{{tp|p=33544136|t=2021. Monoclonal Antibodies for COVID-19.|pdf=|usr=}}
{{tp|p=33635310|t=2021. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.|pdf=|usr=}}
{{tp|p=33566091|t=2021. Experts Discuss COVID-19-Vaccine Doses, Virus Variants, and More.|pdf=|usr=}}
{{tp|p=33533893|t=2021. Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=33724312|t=2021. Helping Manufacturers Navigate Novel Coronavirus Variants.|pdf=|usr=}}
{{tp|p=33595641|t=2021. Vitamin D3 to Treat COVID-19: Different Disease, Same Answer.|pdf=|usr=}}
{{tp|p=33595634|t=2021. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.|pdf=|usr=}}
{{tp|p=33576785|t=2021. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021.|pdf=|usr=}}
{{tp|p=33818592|t=2021. Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=33620389|t=2021. Locating COVID-19 Monoclonal Antibody Therapies.|pdf=|usr=}}
{{tp|p=33729423|t=2021. COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough.|pdf=|usr=}}
{{tp|p=33662101|t=2021. Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy.|pdf=|usr=}}
{{tp|p=33635317|t=2021. SARS-CoV-2 Vaccines.|pdf=|usr=}}
{{tp|p=33704352|t=2021. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.|pdf=|usr=}}
{{tp|p=33683290|t=2021. Acute Allergic Reactions to mRNA COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=33646285|t=2021. The Johnson & Johnson Vaccine for COVID-19.|pdf=|usr=}}
{{tp|p=33662102|t=2021. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.|pdf=|usr=}}
{{tp|p=33646292|t=2021. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33818614|t=2021. Tocilizumab in Treatment for Patients With COVID-19.|pdf=|usr=}}
{{tp|p=33818612|t=2021. Tocilizumab in Treatment for Patients With COVID-19.|pdf=|usr=}}
{{tp|p=33818610|t=2021. Tocilizumab in Treatment for Patients With COVID-19-Reply.|pdf=|usr=}}
{{tp|p=33818607|t=2021. Tocilizumab in Treatment for Patients With COVID-19-Reply.|pdf=|usr=}}
{{tp|p=33818593|t=2021. Tocilizumab in Treatment for Patients With COVID-19.|pdf=|usr=}}
{{tp|p=33538761|t=2021. Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A Randomized Clinical Trial.|pdf=|usr=}}
{{tp|p=33797950|t=2021. Is It Safe to Use Long-Acting G-CSF for Febrile Neutropenia Prophylaxis in COVID-19 Pandemic?|pdf=|usr=}}
{{tp|p=33793342|t=2021. Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis.|pdf=|usr=}}
{{tp|p=33728687|t=2021. Nutrition care practice patterns for patients with COVID-19-A preliminary report.|pdf=|usr=}}
{{tp|p=33694246|t=2021. Modified minimal-contact COVID-19 workflow allows for safe, remote parenteral nutrition prescribing in non-critically ill patients.|pdf=|usr=}}
{{tp|p=33734044|t=2021. Hydroxychloroquine in patients with novel coronavirus infection (COVID-19): a case-control study.|pdf=|usr=}}
{{tp|p=33734043|t=2021. Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study.|pdf=|usr=}}
{{tp|p=33798465|t=2021. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials.|pdf=|usr=}}

{{tp|p=33651292|t=2021. Correlation between polio immunization coverage and overall morbidity and mortality for COVID-19: an epidemiological study.|pdf=|usr=}}
{{tp|p=33722335|t=2021. Association between live childhood vaccines and COVID-19 outcomes: a national-level analysis.|pdf=|usr=}}
{{tp|p=33816594|t=2021. A double-blind randomised controlled trial of protein supplementation to enhance exercise capacity in COPD during pulmonary rehabilitation: a pilot study.|pdf=|usr=}}
{{tp|p=33573712|t=2021. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021.|pdf=|usr=}}
{{tp|p=33727943|t=2021. Phytochemicals of Rhus spp. as Potential Inhibitors of the SARS-CoV-2 Main Protease: Molecular Docking and Drug-Likeness Study.|pdf=|usr=}}
{{tp|p=33680061|t=2021. The Hydroalcoholic Extract of Uncaria tomentosa (Cat's Claw) Inhibits the Infection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) In Vitro.|pdf=|usr=}}
{{tp|p=33763230|t=2021. Mismatch: a comparative study of vitamin D status in British-Bangladeshi migrants.|pdf=|usr=}}
{{tp|p=33732462|t=2021. Conflicts over calcium and the treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33746666|t=2021. A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms.|pdf=|usr=}}
{{tp|p=33628162|t=2021. Insights into the actions of angiotensin-1 receptor (AT1R) inverse agonists: Perspectives and implications in COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33628159|t=2021. All-cause mortality among patients treated with repurposed antivirals and antibiotics for COVID-19 in Mexico City: A real-world observational study.|pdf=|usr=}}
{{tp|p=33542677|t=2020. Ivermectin: Panacea or true promise for COVID-19.|pdf=|usr=}}
{{tp|p=33622217|t=2021. Mesenchymal Stem Cell-Derived Extracellular Vesicles: Promising Treatment for COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33605203|t=2021. Feasibility of Convalescent Plasma Therapy in Kidney Transplant Recipients With Severe COVID-19: A Single-Center Prospective Cohort Study.|pdf=|usr=}}
{{tp|p=33544007|t=2021. PDE3-inhibitor enoximone prevented mechanical ventilation in patients with SARS-CoV-2 pneumonia.|pdf=|usr=}}
{{tp|p=33790994|t=2021. Severe acute respiratory syndrome coronavirus 2 ORF3a induces the expression of ACE2 in oral and pulmonary epithelial cells and the food supplement Vita Deyun((R)) diminishes this effect.|pdf=|usr=}}
{{tp|p=33747178|t=2021. Acidic preconditioning reduces lipopolysaccharide-induced acute lung injury by upregulating the expression of angiotensin-converting enzyme 2.|pdf=|usr=}}
{{tp|p=33603870|t=2021. Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (Review).|pdf=|usr=}}
{{tp|p=33603836|t=2021. Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19.|pdf=|usr=}}
{{tp|p=33732293|t=2021. Anti-infection mechanism of phosphodiesterase-5 inhibitors and their roles in coronavirus disease 2019 (Review).|pdf=|usr=}}
{{tp|p=33732292|t=2021. Immunoregulatory therapy strategies that target cytokine storms in patients with COVID-19 (Review).|pdf=|usr=}}
{{tp|p=33724123|t=2021. Does hydroxychloroquine still have any role in the COVID-19 pandemic?|pdf=|usr=}}
{{tp|p=33586566|t=2021. Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection?|pdf=|usr=}}
{{tp|p=33733058|t=2021. Sialylation of host proteins as targetable risk factor for COVID-19 susceptibility and spreading: A hypothesis.|pdf=|usr=}}
{{tp|p=33577131|t=2021. Associations of essential and toxic metals/metalloids in whole blood with both disease severity and mortality in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33566370|t=2021. A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice.|pdf=|usr=}}
{{tp|p=33621437|t=2021. The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection.|pdf=|usr=}}
{{tp|p=33722600|t=2021. Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.|pdf=|usr=}}
{{tp|p=33794307|t=2021. The effects of some essential and toxic metals/metalloids in COVID-19: A review.|pdf=|usr=}}
{{tp|p=33640537|t=2021. Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review.|pdf=|usr=}}
{{tp|p=33592201|t=2021. Glossary of phytoconstituents: Can these be repurposed against SARS CoV-2? A quick in silico screening of various phytoconstituents from plant Glycyrrhiza glabra with SARS CoV-2 main protease.|pdf=|usr=}}
{{tp|p=33578926|t=2021. Fruits and Vegetables in the Management of Underlying Conditions for COVID-19 High-Risk Groups.|pdf=|usr=}}
{{tp|p=33718452|t=2021. Single-Cell Transcriptome Analysis Decipher New Potential Regulation Mechanism of ACE2 and NPs Signaling Among Heart Failure Patients Infected With SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33681310|t=2021. Case Report: Hyperbilirubinemia in Gilbert Syndrome Attenuates Covid-19-Induced Metabolic Disturbances.|pdf=|usr=}}
{{tp|p=33791293|t=2021. Coronavirus-Induced Host Cubic Membranes and Lipid-Related Antiviral Therapies: A Focus on Bioactive Plasmalogens.|pdf=|usr=}}
{{tp|p=33718360|t=2021. SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy.|pdf=|usr=}}
{{tp|p=33659247|t=2021. Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives.|pdf=|usr=}}
{{tp|p=33634100|t=2020. Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients.|pdf=|usr=}}
{{tp|p=33614627|t=2020. Targeting Lipid Rafts as a Strategy Against Coronavirus.|pdf=|usr=}}
{{tp|p=33796489|t=2021. Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.|pdf=|usr=}}
{{tp|p=33732682|t=2020. Evaluation of Annona muricata Acetogenins as Potential Anti-SARS-CoV-2 Agents Through Computational Approaches.|pdf=|usr=}}
{{tp|p=33614597|t=2020. In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease.|pdf=|usr=}}
{{tp|p=33614592|t=2020. In Silico Study of Coumarins and Quinolines Derivatives as Potent Inhibitors of SARS-CoV-2 Main Protease.|pdf=|usr=}}
{{tp|p=33585398|t=2020. Microsecond MD Simulation and Multiple-Conformation Virtual Screening to Identify Potential Anti-COVID-19 Inhibitors Against SARS-CoV-2 Main Protease.|pdf=|usr=}}
{{tp|p=33553109|t=2020. Computational Characterizations of the Interactions Between the Pontacyl Violet 6R and Exoribonuclease as a Potential Drug Target Against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33815295|t=2021. The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review.|pdf=|usr=}}
{{tp|p=33716989|t=2021. Vitamin D Association With Macrophage-Derived Cytokines in Polycystic Ovary Syndrome: An Enhanced Risk of COVID-19 Infection?|pdf=|usr=}}
{{tp|p=33664772|t=2021. Perspectives About Modulating Host Immune System in Targeting SARS-CoV-2 in India.|pdf=|usr=}}
{{tp|p=33815368|t=2021. Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33777055|t=2021. Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.|pdf=|usr=}}
{{tp|p=33777030|t=2021. Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen.|pdf=|usr=}}
{{tp|p=33777024|t=2021. Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment.|pdf=|usr=}}
{{tp|p=33821251|t=2021. Tackling the pillars of ageing to fight COVID-19.|pdf=|usr=}}
{{tp|p=33812495|t=2021. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.|pdf=|usr=}}
{{tp|p=33676592|t=2021. IL-6 blockade for COVID-19: a global scientific call to arms.|pdf=|usr=}}
{{tp|p=33676590|t=2021. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.|pdf=|usr=}}
{{tp|p=33676589|t=2021. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial.|pdf=|usr=}}
{{tp|p=33806274|t=2021. Therapeutic Potential of EGCG, a Green Tea Polyphenol, for Treatment of Coronavirus Diseases.|pdf=|usr=}}
{{tp|p=33805385|t=2021. In Vitro Evaluation of the Activity of Terpenes and Cannabidiol against Human Coronavirus E229.|pdf=|usr=}}
{{tp|p=33803014|t=2021. Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey.|pdf=|usr=}}
{{tp|p=33802763|t=2021. Effects and Safety of Convalescent Plasma Administration in a Group of Polish Pediatric Patients with COVID-19: A Case Series.|pdf=|usr=}}
{{tp|p=33814087|t=2021. Vitamin D and COVID-19.|pdf=|usr=}}
{{tp|p=33823371|t=2021. Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19.|pdf=|usr=}}
{{tp|p=33799158|t=2021. Methylene blue: Subduing the post COVID-19 blues!|pdf=|usr=}}
{{tp|p=33801645|t=2021. The Role of Nutrition in the COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33804603|t=2021. Ketogenic Diet as a Preventive and Supportive Care for COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33803015|t=2021. COVID-19: Role of Nutrition and Supplementation.|pdf=|usr=}}
{{tp|p=33799985|t=2021. In Vitro Effects of Doxycycline on Replication of Feline Coronavirus.|pdf=|usr=}}
{{tp|p=33804294|t=2021. Differential Effects of Antiseptic Mouth Rinses on SARS-CoV-2 Infectivity In Vitro.|pdf=|usr=}}
{{tp|p=33799977|t=2021. Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study.|pdf=|usr=}}
{{tp|p=33807743|t=2021. Rapamycin: Drug Repurposing in SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33806331|t=2021. Repurposing of Some Natural Product Isolates as SARS-COV-2 Main Protease Inhibitors via In Vitro Cell Free and Cell-Based Antiviral Assessments and Molecular Modeling Approaches.|pdf=|usr=}}
{{tp|p=33807248|t=2021. Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids.|pdf=|usr=}}
{{tp|p=33808025|t=2021. Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33802215|t=2021. Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters.|pdf=|usr=}}
{{tp|p=33811957|t=2021. Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms.|pdf=|usr=}}
{{tp|p=33799224|t=2021. Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: A national retrospective registry study.|pdf=|usr=}}
{{tp|p=33810568|t=2021. Synthesis and Characterization of a Minophosphonate Containing Chitosan Polymer Derivatives: Investigations of Cytotoxic Activity and in Silico Study of SARS-CoV-19.|pdf=|usr=}}
{{tp|p=33810527|t=2021. Niclosamide-Clay Intercalate Coated with Nonionic Polymer for Enhanced Bioavailability toward COVID-19 Treatment.|pdf=|usr=}}
{{tp|p=33705727|t=2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.|pdf=|usr=}}
{{tp|p=33705726|t=2021. Adjuvantation helps to optimise COVID-19 vaccine candidate.|pdf=|usr=}}
{{tp|p=33676591|t=2021. COVID-19 and inhaled corticosteroids-another piece in an expanding puzzle.|pdf=|usr=}}
{{tp|p=33684947|t=2021. Allergische Reaktionen auf COVID-19-Impfungen - Was HNO-Arzte wissen sollten - Teil 1: Immunologische Grundlagen von Allergien auf Impfstoffe, Immunmechanismen von allergischen und pseudoallergischen Reaktionen; Teil 2: Charakteristika der mRNA-Impfstoffe BNT162b2- und mRNA-1273 zur Prophylaxe von COVID-19 und assoziierte Immunphanomene; Teil 3: Praktische Aspekte der Prophylaxe, Diagnostik und Therapie von Allergien auf COVID-19-Impfstoffe.|pdf=|usr=}}
{{tp|p=33729089|t=2021. Convalescent hyperimmune plasma in patients with hematologic malignancies and severe COVID-19 infections.|pdf=|usr=}}
{{tp|p=33742475|t=2021. Plain (1) H nuclear magnetic resonance analysis streamlines the quality control of antiviral favipiravir and congeneric World Health Organization essential medicines.|pdf=|usr=}}
{{tp|p=33574017|t=2021. Magnesium therapeutic potential against Covid-19: Could it be an "All-in-one" therapy?|pdf=|usr=}}
{{tp|p=33678604|t=2020. Dysmagnesemia in Covid-19 cohort patients: prevalence and associated factors.|pdf=|usr=}}
{{tp|p=33613817|t=2021. Efficacy of Traditional Chinese Medicine on COVID-19: Two Case Reports.|pdf=|usr=}}
{{tp|p=33613815|t=2021. Medical Acupuncture as a Treatment for Novel COVID-19-Related Respiratory Distress: Personal Experience from a Frontline Anesthesiologist.|pdf=|usr=}}
{{tp|p=33613814|t=2021. Properties of the Novel Chinese Herbal Medicine Formula Qu Du Qiang Fei I Hao Fang Warrant Further Research to Determine Its Clinical Efficacy in COVID-19 Treatment.|pdf=|usr=}}
{{tp|p=33563156|t=2021. Coumarins and Quinolones as Effective Multiple Targeted Agents Versus Covid-19: An in Silico Study.|pdf=|usr=}}
{{tp|p=33666909|t=2021. Treating COVID-19 Acute Severe Hypoxemic Respiratory Failure: First Case Report Utilizing Dexamethasone, Remdesivir, and Convalescent Plasma in Operation Inherent Resolve.|pdf=|usr=}}
{{tp|p=33684922|t=2021. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in Neonatal Cord Blood After Vaccination in Pregnancy.|pdf=|usr=}}
{{tp|p=33583812|t=2020. Review: Herbs, Immunity and nCOVID-19: Old performers in new Pandemic.|pdf=|usr=}}
{{tp|p=33769223|t=2021. SUMO: a novel target for anti-coronavirus therapy.|pdf=|usr=}}
{{tp|p=33579813|t=2021. Remestemcel-L Therapy for COVID-19-Associated Multisystem Inflammatory Syndrome in Children.|pdf=|usr=}}
{{tp|p=33772933|t=2021. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33722710|t=2021. Resveratrol-mediated attenuation of superantigen-driven acute respiratory distress syndrome is mediated by microbiota in the lungs and gut.|pdf=|usr=}}
{{tp|p=33714279|t=2021. A hypothesis: Bitter taste receptors as a therapeutic target for the clinical symptoms of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33711090|t=2021. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.|pdf=|usr=}}
{{tp|p=33688867|t=2021. 1'-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replication.|pdf=|usr=}}
{{tp|p=33713539|t=2021. Corticosteroids and pulmonary rehabilitation reducing long-term morbidity in a patient with post-COVID-19 pneumonitis: A case study.|pdf=|usr=}}
{{tp|p=33786876|t=2021. Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33778996|t=2021. Greater celandine (Chelidonium majus L.) for COVID-19: A twenty-case series.|pdf=|usr=}}
{{tp|p=33759279|t=2021. Plant-derived chemicals as potential inhibitors of SARS-CoV-2 main protease (6LU7), a virtual screening study.|pdf=|usr=}}
{{tp|p=33822421|t=2021. Silibinin as potential tool against SARS-Cov-2: In silico spike receptor-binding domain and main protease molecular docking analysis, and in vitro endothelial protective effects.|pdf=|usr=}}
{{tp|p=33817867|t=2021. Phyto-pharmacological perspective of Silymarin: A potential prophylactic or therapeutic agent for COVID-19, based on its promising immunomodulatory, anti-coagulant and anti-viral property.|pdf=|usr=}}
{{tp|p=33797123|t=2021. In silico approach of secondary metabolites from Brazilian herbal medicines to search for potential drugs against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33711848|t=2021. COVID-19-Impfungen bei Biologika-Therapie von Asthma bronchiale.|pdf=|usr=}}
{{tp|p=33583332|t=2021. Hydroxychloroquine Sulfate Related Hypoglycemia In A Non-Diabetic COVID-19 Patient: A Case Report and Literature Review.|pdf=|usr=}}
{{tp|p=33795478|t=2021. Clofazimine: another potential magic bullet for the treatment of COVID-19?|pdf=|usr=}}
{{tp|p=33591652|t=2021. [The role of supplying population with vitamin D in conditions of COVID-19 pandemic: foreign publications review].|pdf=|usr=}}

{{tp|p=33767711|t=2021. Editorial: Immune Responses to Persistent or Recurrent Antigens: Implications for Immunological Memory and Immunotherapy.|pdf=|usr=}}
{{tp|p=33767706|t=2021. The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33763085|t=2021. Vitamin D in Corona Virus Disease 2019 (COVID-19) Related Multisystem Inflammatory Syndrome in Children (MIS-C).|pdf=|usr=}}
{{tp|p=33763077|t=2021. The BCG Vaccine for COVID-19: First Verdict and Future Directions.|pdf=|usr=}}
{{tp|p=33746945|t=2021. Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.|pdf=|usr=}}
{{tp|p=33732258|t=2021. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.|pdf=|usr=}}
{{tp|p=33717181|t=2021. Microbiota Modulation of the Gut-Lung Axis in COVID-19.|pdf=|usr=}}
{{tp|p=33717077|t=2021. A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach.|pdf=|usr=}}
{{tp|p=33679771|t=2021. High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China.|pdf=|usr=}}
{{tp|p=33679770|t=2021. Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications.|pdf=|usr=}}
{{tp|p=33643316|t=2021. The Immunopathology of COVID-19 and the Cannabis Paradigm.|pdf=|usr=}}
{{tp|p=33643308|t=2021. Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19.|pdf=|usr=}}
{{tp|p=33613573|t=2021. The Relevance of a Physical Active Lifestyle and Physical Fitness on Immune Defense: Mitigating Disease Burden, With Focus on COVID-19 Consequences.|pdf=|usr=}}
{{tp|p=33643285|t=2020. VISTA: A Target to Manage the Innate Cytokine Storm.|pdf=|usr=}}
{{tp|p=33633726|t=2020. Activation of the Cholinergic Anti-Inflammatory Pathway as a Novel Therapeutic Strategy for COVID-19.|pdf=|usr=}}
{{tp|p=33613542|t=2020. Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects.|pdf=|usr=}}
{{tp|p=33584672|t=2020. Indicator Regularized Non-Negative Matrix Factorization Method-Based Drug Repurposing for COVID-19.|pdf=|usr=}}
{{tp|p=33584668|t=2020. Induction of SARS-CoV-2 Protein S-Specific CD8+ T Cells in the Lungs of gp96-Ig-S Vaccinated Mice.|pdf=|usr=}}
{{tp|p=33569053|t=2020. Could Perturbation of Gut Microbiota Possibly Exacerbate the Severity of COVID-19 via Cytokine Storm?|pdf=|usr=}}
{{tp|p=33687643|t=2021. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial.|pdf=|usr=}}
{{tp|p=33816521|t=2021. Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33816515|t=2021. Case Report: Administration of Amniotic Fluid-Derived Nanoparticles in Three Severely Ill COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33777973|t=2021. COVID-19 Therapy: Could a Copper Derivative of Chlorophyll a Be Used to Treat Lymphopenia Associated With Severe Symptoms of SARS-CoV-2 Infection?|pdf=|usr=}}
{{tp|p=33768100|t=2021. D-Limonene Is a Potential Monoterpene to Inhibit PI3K/Akt/IKK-alpha/NF-kappaB p65 Signaling Pathway in Coronavirus Disease 2019 Pulmonary Fibrosis.|pdf=|usr=}}
{{tp|p=33718411|t=2021. COVID-19 and Risk of Acute Ischemic Stroke and Acute Lung Injury in Patients With Type II Diabetes Mellitus: The Anti-inflammatory Role of Metformin.|pdf=|usr=}}
{{tp|p=33718395|t=2021. Glucocorticoids Should Be Used With Caution in Patients With SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33681257|t=2021. An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19.|pdf=|usr=}}
{{tp|p=33644099|t=2021. Furin Expression in Patients With Psoriasis-A Patient Cohort Endangered to SARS-COV2?|pdf=|usr=}}
{{tp|p=33634148|t=2021. Adverse Outcomes Associated With Corticosteroid Use in Critical COVID-19: A Retrospective Multicenter Cohort Study.|pdf=|usr=}}
{{tp|p=33614688|t=2021. Decreased Mortality Rate Among COVID-19 Patients Prescribed Statins: Data From Electronic Health Records in the US.|pdf=|usr=}}
{{tp|p=33585529|t=2021. Effect of Convalescent Plasma in Critically Ill Patients With COVID-19: An Observational Study.|pdf=|usr=}}
{{tp|p=33585519|t=2020. Commentary: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.|pdf=|usr=}}
{{tp|p=33585508|t=2020. Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=33553219|t=2020. Can GPR4 Be a Potential Therapeutic Target for COVID-19?|pdf=|usr=}}
{{tp|p=33537320|t=2020. Vitamin C and COVID-19.|pdf=|usr=}}
{{tp|p=33746908|t=2020. Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33763450|t=2021. Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives.|pdf=|usr=}}
{{tp|p=33718434|t=2021. Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection.|pdf=|usr=}}
{{tp|p=33659275|t=2021. Molecular Mechanisms Behind Anti SARS-CoV-2 Action of Lactoferrin.|pdf=|usr=}}
{{tp|p=33628764|t=2020. New Insights Into Potential Benefits of Bioactive Compounds of Bee Products on COVID-19: A Review and Assessment of Recent Research.|pdf=|usr=}}
{{tp|p=33614709|t=2020. Therapeutic Strategies in the Management of COVID-19.|pdf=|usr=}}
{{tp|p=33569392|t=2020. Elucidating the Interactions Between Heparin/Heparan Sulfate and SARS-CoV-2-Related Proteins-An Important Strategy for Developing Novel Therapeutics for the COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33542917|t=2020. In silico Screening of Natural Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike RBD: Targets for COVID-19.|pdf=|usr=}}
{{tp|p=33816542|t=2021. The Looming Effects of Estrogen in Covid-19: A Rocky Rollout.|pdf=|usr=}}
{{tp|p=33748170|t=2021. Negative Association Between Mediterranean Diet Adherence and COVID-19 Cases and Related Deaths in Spain and 23 OECD Countries: An Ecological Study.|pdf=|usr=}}
{{tp|p=33634160|t=2021. Plant-Derived Food Grade Substances (PDFGS) Active Against Respiratory Viruses: A Systematic Review of Non-clinical Studies.|pdf=|usr=}}
{{tp|p=33553234|t=2020. The Burden of Malnutrition and Fatal COVID-19: A Global Burden of Disease Analysis.|pdf=|usr=}}
{{tp|p=33708752|t=2020. Case Report: Use of Anakinra in Multisystem Inflammatory Syndrome During COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33815126|t=2021. Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug.|pdf=|usr=}}
{{tp|p=33790785|t=2021. Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis.|pdf=|usr=}}
{{tp|p=33776767|t=2021. Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing.|pdf=|usr=}}
{{tp|p=33767626|t=2021. Anti-IL5 Drugs in COVID-19 Patients: Role of Eosinophils in SARS-CoV-2-Induced Immunopathology.|pdf=|usr=}}
{{tp|p=33767623|t=2021. The Anti-inflammatory Effect of the Tricyclic Antidepressant Clomipramine and Its High Penetration in the Brain Might Be Useful to Prevent the Psychiatric Consequences of SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33767619|t=2021. Plant Products as Inhibitors of Coronavirus 3CL Protease.|pdf=|usr=}}
{{tp|p=33762960|t=2021. Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis.|pdf=|usr=}}
{{tp|p=33762954|t=2021. An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?|pdf=|usr=}}
{{tp|p=33716752|t=2021. Discovering Potential RNA Dependent RNA Polymerase Inhibitors as Prospective Drugs Against COVID-19: An in silico Approach.|pdf=|usr=}}
{{tp|p=33716745|t=2021. The Potential Therapeutic Effect of RNA Interference and Natural Products on COVID-19: A Review of the Coronaviruses Infection.|pdf=|usr=}}
{{tp|p=33716737|t=2021. In silico Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19.|pdf=|usr=}}
{{tp|p=33692695|t=2021. Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease.|pdf=|usr=}}
{{tp|p=33584318|t=2021. Mitochondria Are Potential Targets for the Development of New Drugs Against Neutrophilic Inflammation in Severe Pneumonia Including COVID-19.|pdf=|usr=}}
{{tp|p=33815095|t=2020. A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review.|pdf=|usr=}}
{{tp|p=33776751|t=2020. A Retrospective Study on the Use of Chinese Patent Medicine in 24 Medical Institutions for COVID-19 in China.|pdf=|usr=}}
{{tp|p=33746739|t=2020. Molecular Mechanism of Action of Repurposed Drugs and Traditional Chinese Medicine Used for the Treatment of Patients Infected With COVID-19: A Systematic Scoping Review.|pdf=|usr=}}
{{tp|p=33737877|t=2020. Repurposing Treatment of Wernicke-Korsakoff Syndrome for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-Vitro Evidence and Pharmacokinetic Profile.|pdf=|usr=}}
{{tp|p=33737875|t=2020. Indian Medicinal Plants and Formulations and Their Potential Against COVID-19-Preclinical and Clinical Research.|pdf=|usr=}}
{{tp|p=33732148|t=2020. Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=33716728|t=2020. Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China.|pdf=|usr=}}
{{tp|p=33716720|t=2020. Chinese Herbal Medicine Used With or Without Conventional Western Therapy for COVID-19: An Evidence Review of Clinical Studies.|pdf=|usr=}}
{{tp|p=33708124|t=2020. Targeting Neurological Manifestations of Coronaviruses by Candidate Phytochemicals: A Mechanistic Approach.|pdf=|usr=}}
{{tp|p=33708112|t=2020. Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33708109|t=2020. Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19.|pdf=|usr=}}
{{tp|p=33692684|t=2020. Rational Drug Repurposing: Focus on Lysosomotropism, Targets in Disease Process, Drug Profile, and Pulmonary Tissue Accumulation in SARS-CoV-2 Infection/COVID-19.|pdf=|usr=}}
{{tp|p=33679384|t=2020. Potential Natural Products Against Respiratory Viruses: A Perspective to Develop Anti-COVID-19 Medicines.|pdf=|usr=}}
{{tp|p=33658931|t=2020. Phytochemicals: Potential Therapeutic Interventions Against Coronavirus-Associated Lung Injury.|pdf=|usr=}}
{{tp|p=33658924|t=2020. Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in Multiple Cell Lines and Tissues by Dynamic Imaging System and Physiologically Based Pharmacokinetic Model.|pdf=|usr=}}
{{tp|p=33643034|t=2020. Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33643033|t=2020. Modalities and Mechanisms of Treatment for Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=33628169|t=2020. COVIEdb: A Database for Potential Immune Epitopes of Coronaviruses.|pdf=|usr=}}
{{tp|p=33613282|t=2020. Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro.|pdf=|usr=}}
{{tp|p=33597888|t=2020. Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease.|pdf=|usr=}}
{{tp|p=33584306|t=2020. HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons.|pdf=|usr=}}
{{tp|p=33584285|t=2020. Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice.|pdf=|usr=}}
{{tp|p=33584268|t=2020. Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections.|pdf=|usr=}}
{{tp|p=33584267|t=2020. Nasal Delivery of Hesperidin/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury.|pdf=|usr=}}
{{tp|p=33574761|t=2020. Commentary: Paracetamol-Induced Glutathione Consumption: Is There a Link With Severe COVID-19 Illness?|pdf=|usr=}}
{{tp|p=33574756|t=2020. Potential of Immune-Related Therapy in COVID-19.|pdf=|usr=}}
{{tp|p=33542685|t=2020. Statins as Adjuvant Therapy for COVID-19 to Calm the Stormy Immunothrombosis and Beyond.|pdf=|usr=}}
{{tp|p=33636368|t=2021. Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation.|pdf=|usr=}}
{{tp|p=33787891|t=2021. COVID-19 vaccination-associated myelitis.|pdf=|usr=}}
{{tp|p=33642133|t=2021. VitaminD supplementation for the prevention and treatment of COVID-19: a position statement from the Spanish Society of Geriatrics and Gerontology.|pdf=|usr=}}
{{tp|p=33817742|t=2020. Letter to the Editor: Boron enhances the antiviral activity of the curcumin against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33795718|t=2021. Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity.|pdf=|usr=}}
{{tp|p=33602867|t=2021. SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model.|pdf=|usr=}}
{{tp|p=33688062|t=2021. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes.|pdf=|usr=}}
{{tp|p=33618635|t=2021. Mesenchymal Stem Cell Derived-Exosomes as Effective Factors in Reducing Cytokine Storm Symptoms of COVID-19.|pdf=|usr=}}
{{tp|p=33636424|t=2021. Imagining the COVID-19 pandemic through the minds of 9-11 years old: findings from an art exhibition in India.|pdf=|usr=}}
{{tp|p=33725726|t=2021. The Theoretical Value of Whole-Lung Irradiation for COVID-19 Pneumonia: A Reasonable and Safe Solution until Targeted Treatments are Developed.|pdf=|usr=}}
{{tp|p=33687358|t=2021. L'elogio dell'incertezza: una revisione sistematica living per valutare l'efficacia e la sicurezza dei trattamenti farmacologici per pazienti affetti da covid-19.|pdf=|usr=}}
{{tp|p=33687352|t=2021. Vaccino contro la covid-19: una questione aperta.|pdf=|usr=}}
{{tp|p=33631907|t=2020. Infeccion diseminada por vacuna con bacilo de Calmette-Guerin y coinfeccion por SARS-CoV-2 en paciente con deficiencia de la subunidad beta1 del receptor de IL-12.|pdf=|usr=}}
{{tp|p=33694220|t=2021. Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies.|pdf=|usr=}}
{{tp|p=33566918|t=2020. Transfusion de plasma convaleciente de pacientes con COVID-19.|pdf=|usr=}}
{{tp|p=33566898|t=2020. Dioxido de cloro y derivados del cloro para prevenir o tratar la COVID-19: revision sistematica.|pdf=|usr=}}
{{tp|p=33739711|t=2020. Hydroxychloroquine dans le Covid et liberte de prescription.|pdf=|usr=}}
{{tp|p=33551422|t=2021. [Successful steroid pulse therapy for COVID-19 associated respiratory failure initially mimicking bortezomib-induced lung injury].|pdf=|usr=}}
{{tp|p=33620985|t=2020. inverted question markEl plasma convaleciente es un tratamiento alternativo para pacientes con Covid-19?|pdf=|usr=}}
{{tp|p=33632917|t=2021. COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33632915|t=2021. Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus?|pdf=|usr=}}
{{tp|p=33795510|t=2021. WHO adds Janssen vaccine to list of safe and effective emergency tools against COVID-19.|pdf=|usr=}}
{{tp|p=33820835|t=2021. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.|pdf=|usr=}}
{{tp|p=33674471|t=2021. WHO's treatment megatrial is at a standstill.|pdf=|usr=}}

{{tp|p=33686419|t=2021. Exclusion of pregnant and lactating women from COVID-19 vaccine trials: a missed opportunity.|pdf=|usr=}}
{{tp|p=33569601|t=2021. Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians.|pdf=|usr=}}
{{tp|p=33770576|t=2021. SARS-CoV-2 vaccines for cancer patients: a call to action.|pdf=|usr=}}
{{tp|p=33743480|t=2021. SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC).|pdf=|usr=}}
{{tp|p=33393082|t=2021. Sustaining efficient immune functions with regular physical exercise in the COVID-19 era and beyond.|pdf=|usr=}}
{{tp|p=33742158|t=2021. Comments on nutritional recommendations for CoVID-19 quarantine.|pdf=|usr=}}
{{tp|p=33660020|t=2021. Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19.|pdf=|usr=}}
{{tp|p=33532896|t=2021. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials.|pdf=|usr=}}
{{tp|p=33634346|t=2021. External validity of phase III trials on vaccines against SARS-CoV-2 to a middle-aged and elderly Western European population.|pdf=|usr=}}
{{tp|p=33649879|t=2021. COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries.|pdf=|usr=}}
{{tp|p=33627476|t=2021. Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19.|pdf=|usr=}}
{{tp|p=33619027|t=2021. The European COVID-19 drugs calculation tool: an aid for the estimation of the drugs needed during the SARS-CoV 2 pandemic.|pdf=|usr=}}
{{tp|p=33576494|t=2021. High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33552315|t=2021. The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial.|pdf=|usr=}}
{{tp|p=33581979|t=2021. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.|pdf=|usr=}}
{{tp|p=33746777|t=2021. Practical Recommendations Relevant to the Use of Resistance Training for COVID-19 Survivors.|pdf=|usr=}}
{{tp|p=33574769|t=2021. Targeting Endolysosomal Two-Pore Channels to Treat Cardiovascular Disorders in the Novel COronaVIrus Disease 2019.|pdf=|usr=}}
{{tp|p=33584335|t=2020. The Impact of Polyphenols-Based Diet on the Inflammatory Profile in COVID-19 Elderly and Obese Patients.|pdf=|usr=}}
{{tp|p=33551833|t=2020. CSF3 Is a Potential Drug Target for the Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33719281|t=2021. Cinnamon and Hop Extracts as Potential Immunomodulators for Severe COVID-19 Cases.|pdf=|usr=}}
{{tp|p=33664752|t=2020. Carvacrol, a Plant Metabolite Targeting Viral Protease (M(pro)) and ACE2 in Host Cells Can Be a Possible Candidate for COVID-19.|pdf=|usr=}}
{{tp|p=33584747|t=2020. Development of Plant-Produced Recombinant ACE2-Fc Fusion Protein as a Potential Therapeutic Agent Against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33821255|t=2021. Use of SGLT-2 inhibitor in COVID-19: A cautionary tale.|pdf=|usr=}}
{{tp|p=33821254|t=2021. A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential.|pdf=|usr=}}
{{tp|p=33799535|t=2021. The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33807988|t=2021. Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates-A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics.|pdf=|usr=}}
{{tp|p=33806624|t=2021. SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention.|pdf=|usr=}}
{{tp|p=33810287|t=2021. Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines.|pdf=|usr=}}
{{tp|p=33804162|t=2021. COVID-19: Insights into Potential Vaccines.|pdf=|usr=}}
{{tp|p=33792313|t=2021. Role of Hydrogen Bonds in Formation of Co-amorphous Valsartan/Nicotinamide Compositions of High Solubility and Durability with Anti-hypertension and Anti-COVID-19 Potential.|pdf=|usr=}}
{{tp|p=33823303|t=2021. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.|pdf=|usr=}}
{{tp|p=33800013|t=2021. Structure-Based Virtual Screening Identifies Multiple Stable Binding Sites at the RecA Domains of SARS-CoV-2 Helicase Enzyme.|pdf=|usr=}}
{{tp|p=33807773|t=2021. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome.|pdf=|usr=}}
{{tp|p=33808054|t=2021. The Inhibitory Effects of Plant Derivate Polyphenols on the Main Protease of SARS Coronavirus 2 and Their Structure-Activity Relationship.|pdf=|usr=}}
{{tp|p=33805419|t=2021. Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform.|pdf=|usr=}}
{{tp|p=33810416|t=2021. Molecular Basis of the Therapeutical Potential of Clove (Syzygium aromaticum L.) and Clues to Its Anti-COVID-19 Utility.|pdf=|usr=}}
{{tp|p=33809963|t=2021. Medicinal Plants, Phytochemicals, and Herbs to Combat Viral Pathogens Including SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33801151|t=2021. Identification of Potential SARS-CoV-2 Main Protease and Spike Protein Inhibitors from the Genus Aloe: An In Silico Study for Drug Development.|pdf=|usr=}}
{{tp|p=33800977|t=2021. Natural Products from Medicinal Plants with Anti-Human Coronavirus Activities.|pdf=|usr=}}
{{tp|p=33802860|t=2021. Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study.|pdf=|usr=}}
{{tp|p=33799871|t=2021. Receptor-Based Pharmacophore Modeling in the Search for Natural Products for COVID-19 M(pro).|pdf=|usr=}}
{{tp|p=33794595|t=2021. The initial experience of COVID-19 vaccination from a tertiary care centre of India.|pdf=|usr=}}
{{tp|p=33755376|t=2021. SARS-CoV-2 Infection after Vaccination in Health Care Workers in California.|pdf=|usr=}}
{{tp|p=33755373|t=2021. BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers.|pdf=|usr=}}
{{tp|p=33755375|t=2021. Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.|pdf=|usr=}}
{{tp|p=33755374|t=2021. Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center.|pdf=|usr=}}
{{tp|p=33725432|t=2021. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.|pdf=|usr=}}
{{tp|p=33691060|t=2021. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.|pdf=|usr=}}
{{tp|p=33807206|t=2021. Pea Protein Nanoemulsion Effectively Stabilizes Vitamin D in Food Products: A Potential Supplementation during the COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33795671|t=2021. Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.|pdf=|usr=}}
{{tp|p=33795856|t=2021. Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination.|pdf=|usr=}}
{{tp|p=33597220|t=2021. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets.|pdf=|usr=}}
{{tp|p=33766944|t=2021. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33646996|t=2021. FDA authorizes Pfizer-BioNTech COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33739278|t=2021. L'ARN polymerase COVID-19 - Le talon d'Achille du SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33687881|t=2021. The situation of small molecules targeting key proteins to combat SARS-CoV-2: Synthesis, metabolic pathway, mechanism of action, and potential therapeutic applications.|pdf=|usr=}}
{{tp|p=33797374|t=2021. Effectiveness of Azithromycin as add-on Therapy in COVID-19 Management.|pdf=|usr=}}
{{tp|p=33663367|t=2021. Recent Advance in Natural Products with Antiviral Activities.|pdf=|usr=}}
{{tp|p=33573545|t=2021. S.A.R.S Covid-19 A Medicinal Chemistry Approach.|pdf=|usr=}}
{{tp|p=33550970|t=2021. Coronavirus (COVID -19): Chemical entities of biological interest.|pdf=|usr=}}
{{tp|p=33535950|t=2021. Natural substances and semisynthetic derivatives as potential alternative products against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33655830|t=2021. Treatment approaches for COVID-19: A critical review.|pdf=|usr=}}
{{tp|p=33632095|t=2021. Elucidating the drug repurposing spectra of COVID-19 with its analogues SARS and MERS.|pdf=|usr=}}
{{tp|p=33596800|t=2021. A review on Remdesivir: A broad-spectrum antiviral molecule for possible COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33568033|t=2021. Glycyrrhizin as a Potential Treatment for the Novel Coronavirus (COVID-19).|pdf=|usr=}}
{{tp|p=33787066|t=2021. An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main Protease.|pdf=|usr=}}
{{tp|p=33657301|t=2021. Audio Interview: A New SARS-CoV-2 Vaccine and a New Look at Treatment.|pdf=|usr=}}
{{tp|p=33596347|t=2021. Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination.|pdf=|usr=}}
{{tp|p=33567188|t=2021. Hydroxychloroquine in Hospitalized Patients with Covid-19. Reply.|pdf=|usr=}}
{{tp|p=33567187|t=2021. Hydroxychloroquine in Hospitalized Patients with Covid-19.|pdf=|usr=}}
{{tp|p=33534968|t=2021. Monoclonal Antibody for Patients with Covid-19. Reply.|pdf=|usr=}}
{{tp|p=33534967|t=2021. Monoclonal Antibody for Patients with Covid-19.|pdf=|usr=}}
{{tp|p=33730461|t=2021. Audio Interview: Efficacy of Current Covid-19 Vaccines against Variant Viruses.|pdf=|usr=}}
{{tp|p=33567190|t=2021. Maintaining Safety with SARS-CoV-2 Vaccines. Reply.|pdf=|usr=}}
{{tp|p=33567189|t=2021. Maintaining Safety with SARS-CoV-2 Vaccines.|pdf=|usr=}}
{{tp|p=33626259|t=2021. Audio Interview: The Real-World Effectiveness of Covid-19 Vaccination.|pdf=|usr=}}
{{tp|p=33822494|t=2021. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.|pdf=|usr=}}
{{tp|p=33596351|t=2021. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.|pdf=|usr=}}
{{tp|p=33596350|t=2021. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.|pdf=|usr=}}
{{tp|p=33596349|t=2021. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.|pdf=|usr=}}
{{tp|p=33596348|t=2021. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.|pdf=|usr=}}
{{tp|p=33657288|t=2021. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Reply.|pdf=|usr=}}
{{tp|p=33657287|t=2021. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Reply.|pdf=|usr=}}
{{tp|p=33657286|t=2021. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.|pdf=|usr=}}
{{tp|p=33536629|t=2021. Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents.|pdf=|usr=}}
{{tp|p=33623157|t=2021. Biological activity-based modeling identifies antiviral leads against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33796820|t=2021. A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing.|pdf=|usr=}}
{{tp|p=33782619|t=2021. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine.|pdf=|usr=}}
{{tp|p=33772244|t=2021. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.|pdf=|usr=}}
{{tp|p=33795870|t=2021. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33664494|t=2021. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.|pdf=|usr=}}
{{tp|p=33654292|t=2021. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.|pdf=|usr=}}
{{tp|p=33558724|t=2021. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.|pdf=|usr=}}
{{tp|p=33769143|t=2021. Chlorogenic acid, a natural product as potential inhibitor of COVID-19: virtual screening experiment based on network pharmacology and molecular docking.|pdf=|usr=}}
{{tp|p=33707753|t=2021. FDA authorizes first single-shot COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33633370|t=2021. Trends in COVID-19 therapeutic clinical trials.|pdf=|usr=}}
{{tp|p=33674802|t=2021. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin.|pdf=|usr=}}
{{tp|p=33780970|t=2021. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.|pdf=|usr=}}
{{tp|p=33767445|t=2021. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice.|pdf=|usr=}}
{{tp|p=33727703|t=2021. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33706364|t=2021. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.|pdf=|usr=}}
{{tp|p=33772237|t=2021. Coronapod: the Oxford-AstraZeneca COVID vaccine - what you need to know.|pdf=|usr=}}
{{tp|p=33767467|t=2021. Latest results put Oxford-AstraZeneca COVID vaccine back on track.|pdf=|usr=}}
{{tp|p=33742175|t=2021. Coronapod: Why COVID antibody treatments may not be the answer.|pdf=|usr=}}
{{tp|p=33654255|t=2021. J&J's single-dose COVID vaccine raises hopes for faster rollout.|pdf=|usr=}}
{{tp|p=33712752|t=2021. COVID antibody treatments show promise for preventing severe disease.|pdf=|usr=}}
{{tp|p=33654298|t=2021. Some antibodies can dampen antiviral defences in people with severe COVID.|pdf=|usr=}}
{{tp|p=33623151|t=2021. Why COVID vaccines are so difficult to compare.|pdf=|usr=}}
{{tp|p=33561864|t=2021. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.|pdf=|usr=}}
{{tp|p=33526898|t=2021. J&J's one-shot COVID vaccine offers hope for faster protection.|pdf=|usr=}}
{{tp|p=33811258|t=2021. Coronapod: How to define rare COVID vaccine side effects.|pdf=|usr=}}
{{tp|p=33707257|t=2021. Vaccine efficacy probable against COVID-19 variants.|pdf=|usr=}}

{{tp|p=33639344|t=2021. A new class of alpha-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.|pdf=|usr=}}
{{tp|p=33618158|t=2021. Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?|pdf=|usr=}}
{{tp|p=33609889|t=2021. Synthetic and medicinal perspective of quinolines as antiviral agents.|pdf=|usr=}}
{{tp|p=33588180|t=2021. Discovery and structural optimization of 3-O-beta-chacotriosyl oleanane-type triterpenoids as potent entry inhibitors of SARS-CoV-2 virus infections.|pdf=|usr=}}
{{tp|p=33573699|t=2021. Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial.|pdf=|usr=}}
{{tp|p=33537632|t=2020. Breastfeeding during the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33675368|t=2021. COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma.|pdf=|usr=}}
{{tp|p=33661328|t=2021. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]Choline PET/CT-not only an FDG finding.|pdf=|usr=}}
{{tp|p=33774684|t=2021. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [(18)F]FDG PET-CT and relevance to study interpretation.|pdf=|usr=}}
{{tp|p=33638003|t=2021. COVID-19 vaccination induced axillary nodal uptake on [18F]FDG PET/CT.|pdf=|usr=}}
{{tp|p=33585950|t=2021. A key role for vitamin D binding protein in COVID-19?|pdf=|usr=}}
{{tp|p=33576843|t=2021. Reply to: A key role for vitamin D binding protein in COVID-19?|pdf=|usr=}}
{{tp|p=33788001|t=2021. The association between vitamin D levels and the clinical severity and inflammation markers in pediatric COVID-19 patients: single-center experience from a pandemic hospital.|pdf=|usr=}}
{{tp|p=33617948|t=2021. In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach.|pdf=|usr=}}
{{tp|p=33775827|t=2021. In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2).|pdf=|usr=}}
{{tp|p=33667455|t=2021. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.|pdf=|usr=}}
{{tp|p=33639193|t=2021. Brief review on repurposed drugs and vaccines for possible treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33722593|t=2021. COVID-19 and IL-6: Why vitamin D (probably) helps but tocilizumab might not.|pdf=|usr=}}
{{tp|p=33607104|t=2021. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial.|pdf=|usr=}}
{{tp|p=33549577|t=2021. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33545161|t=2021. Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check?|pdf=|usr=}}
{{tp|p=33580785|t=2021. The strange case of hydroxychloroquine and COVID-19.|pdf=|usr=}}
{{tp|p=33623975|t=2020. QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine.|pdf=|usr=}}
{{tp|p=33624070|t=2020. Amiodarone in COVID-19: let's not forget its potential for pulmonary toxicity.|pdf=|usr=}}
{{tp|p=33585912|t=2021. The hydroxychloroquine debate: a therapeutic dilemma for general practitioners.|pdf=|usr=}}
{{tp|p=33542051|t=2021. Genetic polymorphisms, vitamin D binding protein and vitamin D deficiency in COVID-19.|pdf=|usr=}}
{{tp|p=33795322|t=2021. Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a RCT.|pdf=|usr=}}
{{tp|p=33602862|t=2021. Reply: Is high-dose glucocorticoid beneficial in COVID-19?|pdf=|usr=}}
{{tp|p=33574071|t=2021. Corticosteroids in COVID-19: one size does not fit all.|pdf=|usr=}}
{{tp|p=33568526|t=2021. Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?|pdf=|usr=}}
{{tp|p=33577063|t=2021. Effect of glucocorticoid therapy on the prognosis of patients with severe and critical COVID-19: a single-center retrospective cohort study.|pdf=|usr=}}
{{tp|p=33577009|t=2021. Molecular exploration of combinational therapy of orlistat with metformin prevents the COVID-19 consequences in obese diabetic patients.|pdf=|usr=}}
{{tp|p=33660833|t=2021. The interplay between vitamin D and COVID-19: protective or bystander?|pdf=|usr=}}
{{tp|p=33629336|t=2021. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.|pdf=|usr=}}
{{tp|p=33716536|t=2021. High-Dose Vitamin C Infusion for the Treatment of Covid-19: Beware of Paraben Intoxication.|pdf=|usr=}}
{{tp|p=33769252|t=2021. Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021.|pdf=|usr=}}
{{tp|p=33706861|t=2021. Acute onset supraclavicular lymphadenopathy coinciding with intramuscular mRNA vaccination against COVID-19 may be related to vaccine injection technique, Spain, January and February 2021.|pdf=|usr=}}
{{tp|p=33663646|t=2021. Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020.|pdf=|usr=}}
{{tp|p=33748066|t=2021. The Impact of Vitamin D Level on COVID-19 Infection: Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=33553096|t=2020. Vitamin D Deficiency as an Important Biomarker for the Increased Risk of Coronavirus (COVID-19) in People From Black and Asian Ethnic Minority Groups.|pdf=|usr=}}
{{tp|p=33778086|t=2021. Ethnomedicinal herbs in African traditional medicine with potential activity for the prevention, treatment, and management of coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=33754123|t=2021. Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials.|pdf=|usr=}}
{{tp|p=33576273|t=2021. Targeting the SARS-CoV-2 3CL(pro) and NO/cGMP/PDE5 pathway in COVID-19: a commentary on PDE5 inhibitors.|pdf=|usr=}}
{{tp|p=33590764|t=2021. De novo design of new chemical entities for SARS-CoV-2 using artificial intelligence.|pdf=|usr=}}
{{tp|p=33709775|t=2021. COVID-19 pneumonia: do not leave the corticosteroids behind!|pdf=|usr=}}
{{tp|p=33569984|t=2021. Dual targeting of Toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment.|pdf=|usr=}}
{{tp|p=33538178|t=2021. The right immune-modulation at the right time: thymosin alpha1 for prevention of severe COVID-19 in cancer patients.|pdf=|usr=}}
{{tp|p=33705746|t=2021. The associations between pharmacological gastric acid suppression and adverse outcomes in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33609504|t=2021. Lack of Consistent Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With Coronavirus Disease 2019: Meta-Analysis of Observational Studies.|pdf=|usr=}}
{{tp|p=33814381|t=2021. COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33814379|t=2021. Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus?|pdf=|usr=}}
{{tp|p=33795636|t=2021. Antimicrobial peptide DP7 with potential activity against SARS coronavirus infections.|pdf=|usr=}}
{{tp|p=33810926|t=2021. COVID-19 Vaccines Based on Adenovirus Vectors.|pdf=|usr=}}
{{tp|p=33814228|t=2021. The role of multiple SARS-CoV-2 viral antigens in a vaccine-induced integrated immune response.|pdf=|usr=}}
{{tp|p=33810907|t=2021. Are vaccines against COVID-19 tailored to the most vulnerable people?|pdf=|usr=}}
{{tp|p=33807818|t=2021. SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines.|pdf=|usr=}}
{{tp|p=33807579|t=2021. Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations.|pdf=|usr=}}
{{tp|p=33806646|t=2021. COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab.|pdf=|usr=}}
{{tp|p=33802467|t=2021. Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies.|pdf=|usr=}}
{{tp|p=33805473|t=2021. Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice.|pdf=|usr=}}
{{tp|p=33804981|t=2021. Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates.|pdf=|usr=}}
{{tp|p=33810026|t=2021. Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19.|pdf=|usr=}}
{{tp|p=33801380|t=2021. SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response.|pdf=|usr=}}
{{tp|p=33808708|t=2021. Opportunities for Refinement of Non-Human Primate Vaccine Studies.|pdf=|usr=}}
{{tp|p=33809002|t=2021. COVID-19 Vaccine Roll-Out in South Africa and Zimbabwe: Urgent Need to Address Community Preparedness, Fears and Hesitancy.|pdf=|usr=}}
{{tp|p=33799505|t=2021. Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19.|pdf=|usr=}}
{{tp|p=33802086|t=2021. COVID-19 Vaccines in the Pipeline, Are Antibodies Adequate?|pdf=|usr=}}
{{tp|p=33801926|t=2021. Simultaneous CD8(+) T-Cell Immune Response against SARS-Cov-2 S, M, and N Induced by Endogenously Engineered Extracellular Vesicles in Both Spleen and Lungs.|pdf=|usr=}}
{{tp|p=33801831|t=2021. Correlates of Vaccine-Induced Protection against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33800528|t=2021. Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19.|pdf=|usr=}}
{{tp|p=33800932|t=2021. The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33807957|t=2021. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33807839|t=2021. Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective.|pdf=|usr=}}
{{tp|p=33807769|t=2021. Antiviral Activity of the Propylamylatin(TM) Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions.|pdf=|usr=}}
{{tp|p=33807592|t=2021. Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.|pdf=|usr=}}
{{tp|p=33808275|t=2021. In Vitro Antiviral Activities of Salinomycin on Porcine Epidemic Diarrhea Virus.|pdf=|usr=}}
{{tp|p=33597779|t=2021. COVID vaccines and safety: what the research says.|pdf=|usr=}}
{{tp|p=33795861|t=2021. Why is it so hard to investigate the rare side effects of COVID vaccines?|pdf=|usr=}}
{{tp|p=33762708|t=2021. What scientists do and don't know about the Oxford-AstraZeneca COVID vaccine.|pdf=|usr=}}
{{tp|p=33567448|t=2021. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.|pdf=|usr=}}
{{tp|p=33737735|t=2020. Daily briefing: The five questions that scientists hunting a coronavirus vaccine must answer.|pdf=|usr=}}
{{tp|p=33723024|t=2021. Reader Response: A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City.|pdf=|usr=}}
{{tp|p=33722093|t=2021. Needlestick Injuries Among Healthcare Workers Administering COVID-19 Vaccinations in the United States.|pdf=|usr=}}
{{tp|p=33811162|t=2021. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.|pdf=|usr=}}
{{tp|p=33574203|t=2021. Single-domain antibodies make a difference.|pdf=|usr=}}
{{tp|p=33555845|t=2021. Comparison of Associations between Glucocorticoids Treatment and Mortality in COVID-19 Patients and SARS Patients: A Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=33715385|t=2021. Research Progress of Mesenchymal Stem Cell Therapy for Severe COVID-19.|pdf=|usr=}}
{{tp|p=33720635|t=2021. [BCG, muramylpeptides, trained immunity (part II): a low molecular weight alternative to multicomponent bacterial immunostimulants for prevention of respiratory infections during a pandemic].|pdf=|usr=}}
{{tp|p=33720613|t=2020. [The role of vitamin D in seasonal acute respiratory viral infections and COVID-19].|pdf=|usr=}}
{{tp|p=33720612|t=2020. [Umifenovir and coronavirus infections: a review of research results and clinical practice].|pdf=|usr=}}
{{tp|p=33720607|t=2020. [Administration of the immunomodulatory drug aminodihydrophthalazinedione sodium for prevention of progression pneumonia induced COVID-19].|pdf=|usr=}}
{{tp|p=33720594|t=2020. [BCG, muramylpeptides, trained immunity (part I): linkages in the light of the COVID-19 pandemic].|pdf=|usr=}}
{{tp|p=33720587|t=2020. [Experience of olokizumab use in COVID-19 patients].|pdf=|usr=}}
{{tp|p=33641131|t=2020. Our Best Shot: Texas Physicians Help Find Safe, Effective COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=33677827|t=2021. Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial.|pdf=|usr=}}
{{tp|p=33749020|t=2021. Deterrents in recruitment of COVID-19 convalescent plasma donors: Experience from a hospital-based blood centre in India.|pdf=|usr=}}
{{tp|p=33784412|t=2021. Convalescent plasma treatment of critically ill intensive care COVID-19 patients.|pdf=|usr=}}
{{tp|p=33734448|t=2021. A trend of dropping anti-SARS-CoV-2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors.|pdf=|usr=}}
{{tp|p=33723852|t=2021. COVID-19 convalescent plasma; time for "goal directed therapy"?|pdf=|usr=}}
{{tp|p=33760230|t=2021. Personalized collection of plasma from healthy donors: A randomized controlled trial of a novel technology-enabled nomogram.|pdf=|usr=}}
{{tp|p=33715160|t=2021. Brief report: Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.|pdf=|usr=}}
{{tp|p=33728702|t=2021. Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients?|pdf=|usr=}}
{{tp|p=33560728|t=2021. Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients.|pdf=|usr=}}
{{tp|p=33724242|t=2021. Casirivimab-Imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: an Early Experience.|pdf=|usr=}}
{{tp|p=33741844|t=2021. Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration.|pdf=|usr=}}
{{tp|p=33724250|t=2021. SARS-CoV-2 Vaccination and Solid Organ Transplant Patients: Data Needed to Inform Safety and Efficacy.|pdf=|usr=}}
{{tp|p=33612766|t=2020. Could antiseptic gargling prevent COVID-19?|pdf=|usr=}}
{{tp|p=33734065|t=2021. [SARS-CoV-2 vaccines].|pdf=|usr=}}
{{tp|p=33734074|t=2021. [Vaccination immunology in SARS-CoV-2].|pdf=|usr=}}
{{tp|p=33734524|t=2021. Benefits and potential harms of COVID-19 vaccination during pregnancy: evidence summary for patient counseling.|pdf=|usr=}}
{{tp|p=33648028|t=2021. Physiologic and biochemical rationale for treating COVID-19 patients with hyperbaric oxygen.|pdf=|usr=}}
{{tp|p=33810902|t=2021. The safety of BCG revaccination: A systematic review.|pdf=|usr=}}

{{tp|p=33737124|t=2021. Epidemiological transcriptomic data supports BCG protection in viral diseases including COVID-19.|pdf=|usr=}}
{{tp|p=33549712|t=2021. The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19.|pdf=|usr=}}
{{tp|p=33596123|t=2021. Adjusting extracellular pH to prevent entry of SARS-CoV-2 into human cells.|pdf=|usr=}}
{{tp|p=33722288|t=2021. SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription.|pdf=|usr=}}
{{tp|p=33569701|t=2021. The impact of immuno-aging on SARS-CoV-2 vaccine development.|pdf=|usr=}}
{{tp|p=33627051|t=2021. Making a COVID-19 vaccine that works for everyone: ensuring equity and inclusivity in clinical trials.|pdf=|usr=}}
{{tp|p=33688588|t=2021. COVID-19 vaccines: implementation, limitations and opportunities.|pdf=|usr=}}
{{tp|p=33669357|t=2021. The Effect of Chair-Based Exercise on Physical Function in Older Adults: A Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=33671943|t=2021. Global Impact of COVID-19 on Weight and Weight-Related Behaviors in the Adult Population: A Scoping Review.|pdf=|usr=}}
{{tp|p=33726557|t=2021. A review: Mechanism of action of antiviral drugs.|pdf=|usr=}}
{{tp|p=33746095|t=2021. Interim estimates in null models of COVID-19 vaccine effectiveness.|pdf=|usr=}}
{{tp|p=33746092|t=2021. A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test.|pdf=|usr=}}
{{tp|p=33647517|t=2021. A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis.|pdf=|usr=}}
{{tp|p=33794380|t=2021. Bacille Calmette-Guerin (BCG) vaccine and potential cross-protection against SARS-CoV-2 infection - Assumptions, knowns, unknowns and need for developing an accurate scientific evidence base.|pdf=|usr=}}
{{tp|p=33540128|t=2021. Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis.|pdf=|usr=}}
{{tp|p=33737128|t=2021. The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response.|pdf=|usr=}}
{{tp|p=33713817|t=2021. Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.|pdf=|usr=}}
{{tp|p=33652065|t=2021. COVID-19 vaccines: Global challenges and prospects forum recommendations.|pdf=|usr=}}
{{tp|p=33647515|t=2021. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study.|pdf=|usr=}}
{{tp|p=33636357|t=2021. Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1).|pdf=|usr=}}
{{tp|p=33609773|t=2021. Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study.|pdf=|usr=}}
{{tp|p=33607305|t=2021. Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients - propensity-score matched case-control study.|pdf=|usr=}}
{{tp|p=33607304|t=2021. The role of ibrutinib in COVID-19 hyperinflammation: A case report.|pdf=|usr=}}
{{tp|p=33601033|t=2021. Letter to the editor on "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.|pdf=|usr=}}
{{tp|p=33601032|t=2021. Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.|pdf=|usr=}}
{{tp|p=33592340|t=2021. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.|pdf=|usr=}}
{{tp|p=33592338|t=2021. Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies.|pdf=|usr=}}
{{tp|p=33578014|t=2021. Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.|pdf=|usr=}}
{{tp|p=33578007|t=2021. The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010-20.|pdf=|usr=}}
{{tp|p=33746604|t=2021. A network pharmacology based approach for predicting active ingredients and potential mechanism of Lianhuaqingwen capsule in treating COVID-19.|pdf=|usr=}}
{{tp|p=33746581|t=2021. Systematic elucidation of the mechanism of Jingyin granule in the treatment of Novel Coronavirus (COVID-19) Pneumonia via Network Pharmacology.|pdf=|usr=}}
{{tp|p=33628091|t=2021. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.|pdf=|usr=}}
{{tp|p=33532356|t=2021. A single dose of in situ gel formulation of antimalarial drug chloroquine phosphate as a sustained prophylactic candidate for COVID-19.|pdf=|usr=}}
{{tp|p=33552658|t=2021. Approved mRNA Vaccines for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33556464|t=2021. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=33711496|t=2021. A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies.|pdf=|usr=}}
{{tp|p=33766582|t=2021. Nonirritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine.|pdf=|usr=}}
{{tp|p=33529722|t=2021. The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis Risk While Safely Vaccinating the World.|pdf=|usr=}}
{{tp|p=33817690|t=2021. Toxicity of herbal medications suggested as treatment for COVID-19: A narrative review.|pdf=|usr=}}
{{tp|p=33605826|t=2021. An Evaluation of Serum 25-Hydroxy Vitamin D Levels in Patients with COVID-19 in New York City.|pdf=|usr=}}
{{tp|p=33600292|t=2021. Low Vitamin D Status at Admission as a Risk Factor for Poor Survival in Hospitalized Patients With COVID-19: An Italian Retrospective Study.|pdf=|usr=}}
{{tp|p=33713605|t=2021. Unilateral Lymphadenopathy After COVID-19 Vaccination: A Practical Management Plan for Radiologists Across Specialties.|pdf=|usr=}}
{{tp|p=33546986|t=2021. Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33561203|t=2021. Comment on: Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU.|pdf=|usr=}}
{{tp|p=33559270|t=2021. Soybean-associated endophytic fungi as potential source for anti-COVID-19 metabolites supported by docking analysis.|pdf=|usr=}}
{{tp|p=33776210|t=2021. Docking and in silico toxicity assessment of Arthrospira compounds as potential antiviral agents against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33600286|t=2021. Dexamethasone and transdehydroandrosterone significantly reduce pulmonary epithelial cell injuries associated with mechanical ventilation.|pdf=|usr=}}
{{tp|p=33577360|t=2021. Montelukast in hospitalized patients diagnosed with COVID-19.|pdf=|usr=}}
{{tp|p=33746457|t=2021. Modulation of neutrophil (dys)function by Ayurvedic herbs and its potential influence on SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33727768|t=2021. Ayurveda co-interventions have supported complete recovery in Severe COVID- 19 infection with a Chest Severity Score 18/25: A Case Report.|pdf=|usr=}}
{{tp|p=33548227|t=2021. How glycobiology can help us treat and beat the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33639165|t=2021. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and Influenza virus.|pdf=|usr=}}
{{tp|p=33571675|t=2021. Drug repurposing for COVID-19 via knowledge graph completion.|pdf=|usr=}}
{{tp|p=33645443|t=2021. A potential peptide inhibitor of SARS-CoV-2 S and human ACE2 complex.|pdf=|usr=}}
{{tp|p=33612076|t=2021. Identification of the binding interactions of some novel antiviral compounds against Nsp1 protein from SARS-CoV-2 (COVID-19) through high throughput screening.|pdf=|usr=}}
{{tp|p=33525993|t=2021. Impact of dimerization and N3 binding on molecular dynamics of SARS-CoV and SARS-CoV-2 main proteases.|pdf=|usr=}}
{{tp|p=33599180|t=2021. In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling.|pdf=|usr=}}
{{tp|p=33596787|t=2021. Metabolomic profiling of three Araucaria species, and their possible potential role against COVID-19.|pdf=|usr=}}
{{tp|p=33590806|t=2021. Repurposing drugs and identification of inhibitors of integral proteins (spike protein and main protease) of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33583350|t=2021. Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment.|pdf=|usr=}}
{{tp|p=33583328|t=2021. In silico identification and validation of natural antiviral compounds as potential inhibitors of SARS-CoV-2 methyltransferase.|pdf=|usr=}}
{{tp|p=33565387|t=2021. Artificially expanded genetic information systems (AEGISs) as potent inhibitors of the RNA-dependent RNA polymerase of the SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33526003|t=2021. Flavonol morin targets host ACE2, IMP-alpha, PARP-1 and viral proteins of SARS-CoV-2, SARS-CoV and MERS-CoV critical for infection and survival: a computational analysis.|pdf=|usr=}}
{{tp|p=33619888|t=2021. Blue photobiomodulation LED therapy impacts SARS-CoV-2 by limiting its replication in Vero cells.|pdf=|usr=}}
{{tp|p=33762863|t=2021. Correlation of Automated Chemiluminescent Method with Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titers in Convalescent COVID-19 Plasma Samples: Development of Rapid, Cost-Effective Semi-Quantitative Diagnostic Methods.|pdf=|usr=}}
{{tp|p=33673216|t=2021. Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review.|pdf=|usr=}}
{{tp|p=33619758|t=2021. Tetracycline as an inhibitor to the SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33768214|t=2021. Possible Therapeutic Use of Natural Compounds Against COVID-19.|pdf=|usr=}}
{{tp|p=33655751|t=2021. Biostructural Models for the Binding of Nucleoside Analogs to SARS-CoV-2 RNA-Dependent RNA Polymerase.|pdf=|usr=}}
{{tp|p=33619962|t=2021. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.|pdf=|usr=}}
{{tp|p=33538596|t=2021. Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: In Silico Modeling and In Vitro Screening.|pdf=|usr=}}
{{tp|p=33734704|t=2021. Macrolides May Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Entry into Cells: A Quantitative Structure Activity Relationship Study and Experimental Validation.|pdf=|usr=}}
{{tp|p=33756448|t=2021. Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma.|pdf=|usr=}}
{{tp|p=33544910|t=2021. Efficacy of convalescent plasma therapy for COVID-19: A systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33616257|t=2021. A matched cohort study of convalescent plasma therapy for COVID-19.|pdf=|usr=}}
{{tp|p=33587767|t=2021. Donor tolerability of convalescent plasma donation.|pdf=|usr=}}
{{tp|p=33578448|t=2021. The use of therapeutic plasma exchange as adjunctive therapy in the treatment of coronavirus disease 2019: A critical appraisal of the current evidence.|pdf=|usr=}}
{{tp|p=33536704|t=2021. Smell/Taste alteration in COVID-19 may reflect zinc deficiency.|pdf=|usr=}}
{{tp|p=33560344|t=2021. Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes.|pdf=|usr=}}
{{tp|p=33575003|t=2021. Is there scientific evidence of the mouthwashes effectiveness in reducing viral load in Covid-19? A systematic review.|pdf=|usr=}}
{{tp|p=33763778|t=2021. Interferon-beta Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33547548|t=2021. A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma.|pdf=|usr=}}
{{tp|p=33611660|t=2021. Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia.|pdf=|usr=}}
{{tp|p=33616813|t=2021. Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.|pdf=|usr=}}
{{tp|p=33621214|t=2021. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.|pdf=|usr=}}
{{tp|p=33571169|t=2021. Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality.|pdf=|usr=}}
{{tp|p=33726984|t=2021. Association between antecedent statin use and severe disease outcomes in COVID-19: A retrospective study with propensity score matching.|pdf=|usr=}}
{{tp|p=33669218|t=2021. The Rheumatology Drugs for COVID-19 Management: Which and When?|pdf=|usr=}}
{{tp|p=33672805|t=2021. Effects of Methylprednisolone on Ventilator-Free Days in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome and COVID-19: A Retrospective Study.|pdf=|usr=}}
{{tp|p=33578922|t=2021. The Use of Antiviral Agents against SARS-CoV-2: Ineffective or Time and Age Dependent Result? A Retrospective, Observational Study among COVID-19 Older Adults.|pdf=|usr=}}
{{tp|p=33645763|t=2021. Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS-CoV-2 infection?|pdf=|usr=}}
{{tp|p=33638257|t=2021. Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study.|pdf=|usr=}}
{{tp|p=33543766|t=2021. PEG That Reaction: A Case Series of Allergy to Polyethylene Glycol.|pdf=|usr=}}
{{tp|p=33552429|t=2021. Remdesivir in a pregnant patient with COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=33810356|t=2021. In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33804989|t=2021. Amantadine Inhibits SARS-CoV-2 In Vitro.|pdf=|usr=}}
{{tp|p=33804957|t=2021. NSP16 2'-O-MTase in Coronavirus Pathogenesis: Possible Prevention and Treatments Strategies.|pdf=|usr=}}
{{tp|p=33807095|t=2021. Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing.|pdf=|usr=}}
{{tp|p=33706965|t=2021. Melatonin and healthy aging.|pdf=|usr=}}
{{tp|p=33683065|t=2021. [Interferon gamma in the treatment of patients with moderate COVID-19].|pdf=|usr=}}
{{tp|p=33533219|t=2020. [The use of viral RNA polymerase inhibitors in combination with a fusion inhibitor in the treatment of patients with COVID-19: hypothesis].|pdf=|usr=}}
{{tp|p=33772791|t=2021. Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33745163|t=2021. High-titre anti-SARS-CoV-2 convalescent plasma donation after donors' vaccination.|pdf=|usr=}}
{{tp|p=33734455|t=2021. Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma.|pdf=|usr=}}
{{tp|p=33730761|t=2021. Understanding the role of therapeutic plasma exchange in COVID-19: preliminary guidance and practices.|pdf=|usr=}}
{{tp|p=33794556|t=2021. COVID-19 convalescent plasma therapy: hit fast, hit hard!|pdf=|usr=}}
{{tp|p=33798303|t=2021. [Observation of therapeutic effect on coronavirus disease 2019 with insomnia in treatment with baduanjin and auricular point sticking therapy].|pdf=|usr=}}
{{tp|p=33645139|t=2021. [Treatment strategy and thought on classical herbal formulae for coronavirus disease 2019].|pdf=|usr=}}
{{tp|p=33548966|t=2021. [Progress in the development of coronavirus disease 2019 vaccine].|pdf=|usr=}}
{{tp|p=33729129|t=2021. [Evaluation of the effects of immunotherapy and mesenchymal stem cells transplantation in the treatment of critically ill coronavirus disease 2019 patients].|pdf=|usr=}}
{{tp|p=33541491|t=2020. [Clinical efficacy and safety of different antiviral regimens in patients with coronavirus disease 2019].|pdf=|usr=}}
{{tp|p=33730835|t=2021. [Research study on nucleic acid testing of hemostatic stickers used and the surface of the recipients' hands after the inoculation of inactivated SARS-CoV-2 vaccine].|pdf=|usr=}}

{{tp|p=33631468|t=2021. Good nutrition critical to prevent Covid 19 mortality.|pdf=|usr=}}
{{tp|p=33817388|t=2021. Prediction of potential inhibitors of SARS-CoV-2 using 3D-QSAR, molecular docking modeling and ADMET properties.|pdf=|usr=}}
{{tp|p=33748511|t=2021. Use of vitamin/zinc supplements, medicinal plants, and immune boosting drinks during COVID-19 pandemic: A pilot study from Benha city, Egypt.|pdf=|usr=}}
{{tp|p=33748510|t=2021. Evaluation of flavonoids as 2019-nCoV cell entry inhibitor through molecular docking and pharmacological analysis.|pdf=|usr=}}
{{tp|p=33732940|t=2021. Discovery of Clioquinol and analogues as novel inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 infection, ACE2 and ACE2 - Spike protein interaction in vitro.|pdf=|usr=}}
{{tp|p=33693066|t=2021. Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation.|pdf=|usr=}}
{{tp|p=33688584|t=2021. The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing.|pdf=|usr=}}
{{tp|p=33532640|t=2021. Potential compounds from several Indonesian plants to prevent SARS-CoV-2 infection: A mini-review of SARS-CoV-2 therapeutic targets.|pdf=|usr=}}
{{tp|p=33655086|t=2021. Antiviral and immunomodulatory activity of curcumin: A case for prophylactic therapy for COVID-19.|pdf=|usr=}}
{{tp|p=33655082|t=2021. Exploring existing drugs: proposing potential compounds in the treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33615017|t=2021. Prospects of nutritional interventions in the care of COVID-19 patients.|pdf=|usr=}}
{{tp|p=33585706|t=2021. Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=33553708|t=2021. Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19.|pdf=|usr=}}
{{tp|p=33623886|t=2021. SARS-CoV-2 Vaccines in Patients With Multiple Myeloma.|pdf=|usr=}}
{{tp|p=33817558|t=2021. CHALLENGES IN THE PRODUCTION OF COVID19 CONVALESCENT PLASMA - ANALYSIS OF DONOR RECRUITMENT.|pdf=|usr=}}
{{tp|p=33778377|t=2021. Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33577086|t=2021. AASLD Expert Panel Consensus Statement: Vaccines to Prevent COVID-19 Infection in Patients with Liver Disease.|pdf=|usr=}}
{{tp|p=33790052|t=2021. Optimising vitamin D levels in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33677814|t=2021. COVID-19 vaccines: rapid development, implications, challenges and future prospects.|pdf=|usr=}}
{{tp|p=33527306|t=2021. mTOR inhibition: a double-edged sword in patients with COVID-19?|pdf=|usr=}}
{{tp|p=33640208|t=2021. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes.|pdf=|usr=}}
{{tp|p=33632561|t=2021. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade.|pdf=|usr=}}
{{tp|p=33577681|t=2021. Integration of genetically regulated gene expression and pharmacological library provides therapeutic drug candidates.|pdf=|usr=}}
{{tp|p=33567446|t=2021. Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19.|pdf=|usr=}}
{{tp|p=33526960|t=2021. Presence of antibodies against SARS-CoV-2 spike protein in bovine whey IgG enriched fraction.|pdf=|usr=}}
{{tp|p=33715009|t=2021. Interleukin-6: From arthritis to CAR-T cell therapy and COVID-19.|pdf=|usr=}}
{{tp|p=33571745|t=2021. Immune response scenario and vaccine development for SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33765614|t=2021. The potential for Lactoferrin to reduce SARS-CoV-2 induced cytokine storm.|pdf=|usr=}}
{{tp|p=33735712|t=2021. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.|pdf=|usr=}}
{{tp|p=33714884|t=2021. The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe patients.|pdf=|usr=}}
{{tp|p=33631512|t=2021. Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra.|pdf=|usr=}}
{{tp|p=33582019|t=2021. Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome.|pdf=|usr=}}
{{tp|p=33571819|t=2021. Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review.|pdf=|usr=}}
{{tp|p=33540249|t=2021. Interferon-based therapies in COVID-19.|pdf=|usr=}}
{{tp|p=33714420|t=2021. Balanced evaluation of preliminary data on a candidate COVID-19 hydroxychloroquine treatment.|pdf=|usr=}}
{{tp|p=33596459|t=2021. Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Herve Seligmann.|pdf=|usr=}}
{{tp|p=33722657|t=2021. Timing and dosage may be the key in the realisation of hydroxychloroquine + azithromycin treatment benefit in Covid-19 elderly patients.|pdf=|usr=}}
{{tp|p=33731132|t=2021. How COVID-19 lockdown and reopening affected daily steps: evidence based on 164,630 person-days of prospectively collected data from Shanghai, China.|pdf=|usr=}}
{{tp|p=33607132|t=2021. Underscoring the immense potential of chitosan in fighting a wide spectrum of viruses: A plausible molecule against SARS-CoV-2?|pdf=|usr=}}
{{tp|p=33794238|t=2021. A review on antiviral and immunomodulatory polysaccharides from Indian medicinal plants, which may be beneficial to COVID-19 infected patients.|pdf=|usr=}}
{{tp|p=33766591|t=2021. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase.|pdf=|usr=}}
{{tp|p=33385461|t=2021. Development of new vaccine target against SARS-CoV2 using envelope (E) protein: An evolutionary, molecular modeling and docking based study.|pdf=|usr=}}
{{tp|p=33716131|t=2021. Exploitation of polyphenols and proteins using nanoencapsulation for anti-viral and brain boosting properties - Evoking a synergistic strategy to combat COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33421473|t=2021. Denovo designing, retro-combinatorial synthesis, and molecular dynamics analysis identify novel antiviral VTRM1.1 against RNA-dependent RNA polymerase of SARS CoV2 virus.|pdf=|usr=}}
{{tp|p=33548314|t=2021. Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33548321|t=2021. Targeting C-terminal Helical bundle of NCOVID19 Envelope (E) protein.|pdf=|usr=}}
{{tp|p=33767597|t=2021. Evaluation and characterization of HSPA5 (GRP78) expression profiles in normal individuals and cancer patients with COVID-19.|pdf=|usr=}}
{{tp|p=33390829|t=2021. Current advances in the development of SARS-CoV-2 vaccines.|pdf=|usr=}}
{{tp|p=33447763|t=2020. Cardiovascular medications and regulation of COVID-19 receptors expression.|pdf=|usr=}}
{{tp|p=33751323|t=2021. Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases.|pdf=|usr=}}
{{tp|p=33555131|t=2021. The association between micronutrient and hemogram values and prognostic factors in COVID-19 patients: A single-center experience from Turkey.|pdf=|usr=}}
{{tp|p=33550688|t=2021. Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab.|pdf=|usr=}}
{{tp|p=33650165|t=2021. Androgens and women: COVID-19 outcomes in women with acne vulgaris, polycystic ovarian syndrome, and hirsutism.|pdf=|usr=}}
{{tp|p=33419015|t=2021. Is It Time for Sports and Health in the Era of Covid-19 Pandemic?|pdf=|usr=}}
{{tp|p=33668304|t=2021. Cardiac Rehabilitation Based on the Walking Test and Telerehabilitation Improved Cardiorespiratory Fitness in People Diagnosed with Coronary Heart Disease during the COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33668262|t=2021. A Pandemic within the Pandemic? Physical Activity Levels Substantially Decreased in Countries Affected by COVID-19.|pdf=|usr=}}
{{tp|p=33576451|t=2021. Pineal hormone melatonin as an adjuvant treatment for COVID19 (Review).|pdf=|usr=}}
{{tp|p=33576441|t=2021. Determining available strategies for prevention and therapy: Exploring COVID19 from the perspective of ACE2 (Review).|pdf=|usr=}}
{{tp|p=33537824|t=2021. Potential immunomodulatory effects of vitamin D in the prevention of severe coronavirus disease 2019: An ally for Latin America (Review).|pdf=|usr=}}
{{tp|p=33573283|t=2021. Pseudo-Dipeptide Bearing alpha,alpha-Difluoromethyl Ketone Moiety as Electrophilic Warhead with Activity against Coronaviruses.|pdf=|usr=}}
{{tp|p=33530554|t=2021. Mediterranean Diet for the Prevention of Gestational Diabetes in the Covid-19 Era: Implications of Il-6 In Diabesity.|pdf=|usr=}}
{{tp|p=33572480|t=2021. Human Milk Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers.|pdf=|usr=}}
{{tp|p=33572274|t=2021. Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics.|pdf=|usr=}}
{{tp|p=33557278|t=2021. Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33557253|t=2021. Predicting Potential SARS-COV-2 Drugs-In Depth Drug Database Screening Using Deep Neural Network Framework SSnet, Classical Virtual Screening and Docking.|pdf=|usr=}}
{{tp|p=33671104|t=2021. Nutraceuticals in the Prevention of Viral Infections, including COVID-19, among the Pediatric Population: A Review of the Literature.|pdf=|usr=}}
{{tp|p=33669738|t=2021. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33671463|t=2021. Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19.|pdf=|usr=}}
{{tp|p=33669456|t=2021. Adjunctive Nutraceutical Therapies for COVID-19.|pdf=|usr=}}
{{tp|p=33669167|t=2021. Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?|pdf=|usr=}}
{{tp|p=33671877|t=2021. Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library.|pdf=|usr=}}
{{tp|p=33668523|t=2021. Bioactive Alkaloids from Genus Aspergillus: Mechanistic Interpretation of Their Antimicrobial and Potential SARS-CoV-2 Inhibitory Activity Using Molecular Modelling.|pdf=|usr=}}
{{tp|p=33673372|t=2021. Platelet Lysate Nebulization Protocol for the Treatment of COVID-19 and Its Sequels: Proof of Concept and Scientific Rationale.|pdf=|usr=}}
{{tp|p=33670304|t=2021. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.|pdf=|usr=}}
{{tp|p=33688191|t=2021. New Acaciin-Loaded Self-Assembled Nanofibers as M(Pro) Inhibitors Against BCV as a Surrogate Model for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33746660|t=2021. In-Silico Drug Designing of Spike Receptor with Its ACE2 Receptor and Nsp10/Nsp16 MTase Complex Against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33781885|t=2021. BRD4 targeting nanotherapy prevents lipopolysaccharide induced acute respiratory distress syndrome.|pdf=|usr=}}
{{tp|p=33540028|t=2021. Self-injectable extended release formulation of Remdesivir (SelfExRem): A potential formulation alternative for COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33484917|t=2021. Visualizing the spatial localization of ciclesonide and its metabolites in rat lungs after inhalation of 1-mum aerosol of ciclesonide by desorption electrospray ionization-time of flight mass spectrometry imaging.|pdf=|usr=}}
{{tp|p=33785968|t=2021. Distance based and bond additive topological indices of certain repurposed antiviral drug compounds tested for treating COVID-19.|pdf=|usr=}}
{{tp|p=33612855|t=2020. Topological indices and QSPR/QSAR analysis of some antiviral drugs being investigated for the treatment of COVID-19 patients.|pdf=|usr=}}
{{tp|p=33677049|t=2021. Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia: A Randomized Double-Blind Study.|pdf=|usr=}}
{{tp|p=33677050|t=2021. COVID-19 Vaccine-Induced Radiation Recall Phenomenon.|pdf=|usr=}}
{{tp|p=33722770|t=2021. Low Doses of Radiation Increase the Immunosuppressive Profile of Lung Macrophages During Viral Infection and Pneumonia.|pdf=|usr=}}
{{tp|p=33688993|t=2021. Potential role for interferon gamma in the treatment of recurrent ventilator-acquired pneumonia in patients with COVID-19: a hypothesis.|pdf=|usr=}}
{{tp|p=33694056|t=2021. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply.|pdf=|usr=}}
{{tp|p=33547620|t=2021. Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients.|pdf=|usr=}}
{{tp|p=33598871|t=2021. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment.|pdf=|usr=}}
{{tp|p=33687691|t=2021. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine.|pdf=|usr=}}
{{tp|p=33635496|t=2021. Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug-drug interactions-reply.|pdf=|usr=}}
{{tp|p=33583886|t=2021. Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient.|pdf=|usr=}}
{{tp|p=33580823|t=2021. Allergische Reaktionen auf COVID-19-Impfstoffe - Evidenz und praxisorientiertes Vorgehen.|pdf=|usr=}}
{{tp|p=33560450|t=2021. Impfstoffentwicklung zur Pravention von COVID-19 - Teil 2.|pdf=|usr=}}
{{tp|p=33788135|t=2021. Vigilance regarding immune thrombocytopenic purpura after COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33710481|t=2021. COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view.|pdf=|usr=}}
{{tp|p=33598881|t=2021. The role of taurine derivatives in the putative therapy of COVID-19-induced inflammation.|pdf=|usr=}}
{{tp|p=33639626|t=2021. Mechanisms of COVID-19 Entry into the Cell: Potential Therapeutic Approaches Based on Virus Entry Inhibition in COVID-19 Patients with Underlying Diseases.|pdf=|usr=}}
{{tp|p=33639625|t=2021. Relationship between Bacillus Calmette Guerin Vaccination Policy and Coronavirus Disease-2019 (COVID-19) Incidence.|pdf=|usr=}}
{{tp|p=33787513|t=2021. Does prior immunization with measles, mumps, and rubella vaccines contribute to the antibody response to COVID-19 antigens?|pdf=|usr=}}
{{tp|p=33603991|t=2020. The efficacy of remdesivir in coronavirus disease 2019 (COVID-19): a systematic review.|pdf=|usr=}}
{{tp|p=33680028|t=2020. Approaches for the Treatment of SARS-CoV-2 Infection: A Pharmacologic View and Literature Review.|pdf=|usr=}}
{{tp|p=33708724|t=2020. Selected Micronutrients: An Option to Boost Immunity against COVID-19 and Prevent Adverse Pregnancy Outcomes in Pregnant Women: A Narrative Review.|pdf=|usr=}}
{{tp|p=33708723|t=2020. Convalescent Plasma in the Treatment of Severe COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=33681723|t=2021. Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19.|pdf=|usr=}}
{{tp|p=33665567|t=2021. A computational framework of host-based drug repositioning for broad-spectrum antivirals against RNA viruses.|pdf=|usr=}}
{{tp|p=33585804|t=2021. Transcriptomic profiling of SARS-CoV-2 infected human cell lines identifies HSP90 as target for COVID-19 therapy.|pdf=|usr=}}
{{tp|p=33817567|t=2021. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment.|pdf=|usr=}}
{{tp|p=33748696|t=2021. Learning from HIV-1 to predict the immunogenicity of T cell epitopes in SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33723528|t=2021. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation.|pdf=|usr=}}
{{tp|p=33734623|t=2021. Peripheral Facial Nerve Palsy Following BNT162b2 (COVID-19) Vaccination.|pdf=|usr=}}
{{tp|p=33639998|t=2021. Breastfeeding and COVID-19 vaccination: position statement of the Italian scientific societies.|pdf=|usr=}}
{{tp|p=33588905|t=2021. Could nutritional supplements act as therapeutic adjuvants in COVID-19?|pdf=|usr=}}

{{tp|p=33764850|t=2021. Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?|pdf=|usr=}}
{{tp|p=33651911|t=2021. Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders.|pdf=|usr=}}
{{tp|p=33647634|t=2021. Older adults' activity destinations before and during COVID-19 restrictions: From a variety of activities to mostly physical exercise close to home.|pdf=|usr=}}
{{tp|p=33623809|t=2021. Characteristics of the First 102 Severe COVID-19 Cases Treated With Convalescent Plasma or Tocilizumab or Both in Al-Nahdha Hospital, Oman.|pdf=|usr=}}
{{tp|p=33651967|t=2021. beta-glucans: wide-spectrum immune-balancing food-supplement-based enteric (beta-WIFE) vaccine adjuvant approach to COVID-19.|pdf=|usr=}}
{{tp|p=33577374|t=2021. Immunotherapies and immunomodulatory approaches in clinical trials - a mini review.|pdf=|usr=}}
{{tp|p=33606594|t=2021. Phylodynamic analysis in the understanding of the current COVID-19 pandemic and its utility in vaccine and antiviral design and assessment.|pdf=|usr=}}
{{tp|p=33536584|t=2021. Estrogen receptors are linked to angiotensin-converting enzyme 2 (ACE2), ADAM metallopeptidase domain 17 (ADAM-17), and transmembrane protease serine 2 (TMPRSS2) expression in the human atrium: insights into COVID-19.|pdf=|usr=}}
{{tp|p=33596958|t=2021. Unanticipated efficacy of SARS-CoV-2 vaccination in older adults.|pdf=|usr=}}
{{tp|p=33728100|t=2021. COVID-19 Antiviral and Treatment Candidates: Current Status.|pdf=|usr=}}
{{tp|p=33728098|t=2021. Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33728097|t=2021. Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages.|pdf=|usr=}}
{{tp|p=33631118|t=2021. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs.|pdf=|usr=}}
{{tp|p=33557591|t=2021. Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma.|pdf=|usr=}}
{{tp|p=33753964|t=2021. Wild Sambucus nigra L. from north-east edge of the species range: A valuable germplasm with inhibitory capacity against SARS-CoV2 S-protein RBD and hACE2 binding in vitro.|pdf=|usr=}}
{{tp|p=33714413|t=2021. HCQ prophylaxis in COVID-19 did not show any QTc prolongation in Healthcare workers.|pdf=|usr=}}
{{tp|p=33814589|t=2021. Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study.|pdf=|usr=}}
{{tp|p=33814753|t=2021. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review.|pdf=|usr=}}
{{tp|p=33551585|t=2021. Association of Vitamin D Status with COVID-19 Infection and Mortality in the Asia Pacific region: A Cross-Sectional Study.|pdf=|usr=}}
{{tp|p=33613002|t=2021. Trace Elements as Immunoregulators in SARS-CoV-2 and Other Viral Infections.|pdf=|usr=}}
{{tp|p=33623187|t=2020. Prospects of Vaccine against COVID-19.|pdf=|usr=}}
{{tp|p=33790504|t=2021. Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33790498|t=2021. Tocilizumab in COVID-19: Is the Temptation Worthwhile?|pdf=|usr=}}
{{tp|p=33707911|t=2021. Painful Blisters of Left Hand Following Extravasation of Remdesivir Infusion in COVID-19.|pdf=|usr=}}
{{tp|p=33746378|t=2021. Efficacy and Safety of Convalescent Plasma for COVID-19: A Systematic Review and Meta-analysis.|pdf=|usr=}}
{{tp|p=33781656|t=2021. The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 -a systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33533733|t=2021. Use of convalescent plasma for COVID-19 in India: A review & practical guidelines.|pdf=|usr=}}
{{tp|p=33595460|t=2021. Vitamin D supplementation in diabetic retinopathy in the era of COVID-19.|pdf=|usr=}}
{{tp|p=33614469|t=2021. Otorhinolaryngological Manifestations and Its Management in COVID 19 Patients.|pdf=|usr=}}
{{tp|p=33666200|t=2020. Efficacy and safety of steroid therapy in COVID-19: A rapid systematic review and Meta-analysis.|pdf=|usr=}}
{{tp|p=33666199|t=2020. Antiviral effect of amiodarone and its possible role in COVID-19: An appraisal.|pdf=|usr=}}
{{tp|p=33641858|t=2021. A review: Epidemiology, pathogenesis and prospect in developing vaccines for novel Coronavirus (COVID-19).|pdf=|usr=}}
{{tp|p=33641831|t=2021. BCG vaccination induced protection from COVID-19.|pdf=|usr=}}
{{tp|p=33706819|t=2021. Extensive environmental contamination and prolonged severe acute respiratory coronavirus-2 (SARS CoV-2) viability in immunosuppressed recent heart transplant recipients with clinical and virologic benefit with remdesivir.|pdf=|usr=}}
{{tp|p=33642866|t=2021. Inhibition of ACE2 Expression by Ascorbic Acid Alone and its Combinations with Other Natural Compounds.|pdf=|usr=}}
{{tp|p=33620019|t=2021. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.|pdf=|usr=}}
{{tp|p=33748805|t=2021. Mosaic vaccination schedule: An unexpected card to play against SARS-CoV-2?|pdf=|usr=}}
{{tp|p=33681861|t=2021. COVID-19 vaccines: Frequently asked questions and updated answers.|pdf=|usr=}}
{{tp|p=33585830|t=2021. BCG vaccination and COVID-19: Was flattening the curve just an illusion?|pdf=|usr=}}
{{tp|p=33731163|t=2021. Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial.|pdf=|usr=}}
{{tp|p=33726861|t=2021. Human coronaviruses and therapeutic drug discovery.|pdf=|usr=}}
{{tp|p=33532909|t=2021. Computational and Experimental Studies Reveal That Thymoquinone Blocks the Entry of Coronaviruses Into In Vitro Cells.|pdf=|usr=}}
{{tp|p=33738764|t=2021. Evaluating Clinical Efficacy of Antiviral Therapy for COVID-19: A Surrogate Endpoint Approach.|pdf=|usr=}}
{{tp|p=33790587|t=2021. BCG Vaccine-Induced Trained Immunity and COVID-19: Protective or Bystander?|pdf=|usr=}}
{{tp|p=33774178|t=2021. Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach.|pdf=|usr=}}
{{tp|p=33704465|t=2021. Barriers to Administering Vaccines in Inflammatory Bowel Disease Centers.|pdf=|usr=}}
{{tp|p=33740066|t=2021. Association of alpha-1-antitrypsin deficiency with vitamin D status: who is most at risk of getting severe COVID-19?|pdf=|usr=}}
{{tp|p=33608746|t=2021. Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection.|pdf=|usr=}}
{{tp|p=33751358|t=2021. A Dual Target-Directed Single Domain-Based Fusion Protein Against Interleukin-6 Receptor Decelerate Experimental Arthritis Progression Via Modulating JNK Expression.|pdf=|usr=}}
{{tp|p=33715284|t=2021. COVID-19-vaccinated plasma treatment for COVID-19 patients?|pdf=|usr=}}
{{tp|p=33649734|t=2021. Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations.|pdf=|usr=}}
{{tp|p=33623816|t=2021. Evaluation of drug repositioning by molecular docking of pharmaceutical resources available in the Brazilian healthcare system against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33594342|t=2021. Identification of potential antivirals against SARS-CoV-2 using virtual screening method.|pdf=|usr=}}
{{tp|p=33553571|t=2021. The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus.|pdf=|usr=}}
{{tp|p=33531865|t=2021. Aurintricarboxylic acid and its metal ion complexes in comparative virtual screening versus Lopinavir and Hydroxychloroquine in fighting COVID-19 pandemic: Synthesis and characterization.|pdf=|usr=}}
{{tp|p=33589845|t=2021. Are vanadium complexes druggable against the main protease M(pro) of SARS-CoV-2? - A computational approach.|pdf=|usr=}}